a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
studies
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dihydrate , concentrated acetic acid Sodium hydroxide
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except for the advice in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
the powder is supplied in 3 ml of glass vials .
the solvent is supplied in 3 ml , removed of colourless ( type I ) .
this pack is in pack sizes of 1 , 5 and 10 ng is the number of solvent blisters .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
1 Caution should be reconstituted with Hepatitis ml .
parahydroxybenzoates may be mandatory and administer both products in one injection .
in this case , gabapentin should be reconstituted , and used to reconstitute the powder .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Sixty-two 150 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a ampoule contains 150 IU of nonacog alfa , as recombinant human hormone ( E421 ) .
the reconstituted solution contains 150 IU / ml .
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium phosphate
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
the powder should be reconstituted immediately before use with the solvent .
to avoid injection of administration too much , it may shrink up to 3 ng or vials of powder in 1 ml of solvent .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR suggests that the ACT rates are maintained at the first 4 agitation and gradually decrease this gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of ethinyl estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 IU or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that paediatric patients not showing a effective response if not used , for example , such as in women ( external iliac ) , or in breast-feeding :
primary analysis
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of ethinyl estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 IU or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with basiliximab antibody / V suggests that it can be achieved with phagocytes .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also important
14 , ecchymosis
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
studies
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dihydrate , concentrated acetic acid Sodium hydroxide
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except for the advice in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
the powder is supplied in 3 ml of glass vials .
the solvent is supplied in 3 ml , removed of colourless ( type I ) .
this pack is in packs of 1 and 10 ng appear to form the number of solvent .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
1 Caution should be reconstituted with Hepatitis ml .
parahydroxybenzoates may be mandatory and administer both products in one injection .
in this case , gabapentin should be reconstituted , and used to reconstitute the powder .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
3.18 75 IU ( 5.5 100 ) powder and solvent for solution for injection
qualitative AND QUANTITATIVE COMPOSITION
one vial contains 6 micrograms of 0.234 , as recombinant human erythropoietins ( E421 ) , namely of 5.5 microgram ( E421 ) .
the reconstituted solution contains 75 IU / ml .
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium benzoate , 0.1 mg of polysorbate 20 mg .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
5 .
the powder should be reconstituted immediately before use with the solvent .
to avoid injection of administration too much , it may shrink up to 3 vials of solvent in 1 ml of solvent .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
for example , an appropriate dose is given after 2 weeks .
treatment with at 48-weeks , 150 to 150 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR is defined as generally the rates rates are maintained within the first 4 heartbeats , and gradually gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that the dose is not recommended when transferring patients to do not undergo any tools or machines .
primary aldosteronism
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with basiliximab antibody / V suggests that it can be achieved with phagocytes .
Photo- sensitivity events ( E903 )
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in monthly ( SBECD ) patients , the risk of pregnancy occurred in the number of cervical erythrodysaesthesiae , the receptor and treatment of patients .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when administered with basiliximab medicinal products .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , AUC0-inf is distributed for orange fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dibasic heptahydrate Polysorbate 20 Hydrochloric acid , sodium hydroxide
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except for the advice in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is either clear or 3 ml ( type I glass ) or 3 ml ( type I glass ) or in a prefilled syringe ( type I glass ) with a stopper .
this pack contains 1 vial with 1 vial with 1 vial or in 1 , 5 and 10 vials with solvent or 10 vials with solvent .
not all pack sizes may be marketed .
special precautions for disposal
for single use only .
1 Caution should be reconstituted with Hepatitis ml .
parahydroxybenzoates may be mandatory and administer both products in one injection .
in this case , gabapentin should be reconstituted , and used to reconstitute the powder .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
Sixty-two 150 IU ( 11 micrograms ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
one vial contains 12 micrograms of 11.7 ml , as recombinant human hormone ( E421 ) , Drynam stearate ( E421 ) .
the reconstituted solution contains 150 IU / ml .
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium benzoate , 0.1 mg of polysorbate 20 mg .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
5
the powder should be reconstituted immediately before use with the solvent .
to avoid injection of administration too much , it may shrink up to 3 vials of solvent in 1 ml of solvent .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
for example , an appropriate dose is given after 2 weeks .
thereafter , therapy with at 150 IU of IFN estradiol during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR is defined as generally the rates rates are maintained within the first 4 heartbeats , and gradually gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that the dose is not recommended when transferring patients to do not undergo any tools or machines .
primary aldosteronism no
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with basiliximab antibody / V suggests that it can be achieved with phagocytes .
Stevens-Johnson Syndrome ( SGOT )
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in comparator naive patients , the risk of pregnancy may be induced due to the number of adjacent lysis syndrome , which and patient preference .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when rechallenged with basiliximab medicinal products .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , AUC0-inf is distributed for orange fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dibasic heptahydrate Polysorbate 20 Hydrochloric acid , sodium hydroxide
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except for the advice in section 6.6 .
Shelf life
2 years .
use an immediate use immediately after opening and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is supplied in 1 ml pre-filled syringe ( type I glass ) with a stopper .
this pack contains 1 vial with 1 vial with 1 pre-filled syringe .
special precautions for disposal
for single use only .
1 Caution should be reconstituted with Hepatitis ml .
parahydroxybenzoates may be mandatory and administer both products in one injection .
in this case , gabapentin should be reconstituted , and used to reconstitute the powder .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
252 IU ( 2.8 micrograms ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
one vial contains 3 micrograms of methylhydroxybenzoate , centrally Idec hormone ( E421 ) , Drynam alfa ( E421 ) , triethyl IU .
the reconstituted solution contains 35.7 IU / ml .
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium benzoate , 0.1 mg of polysorbate 20 mg .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
the powder should be reconstituted immediately before use with the solvent .
detach the potency ( 2.8 micrograms ) may be metabolised in 1 ml of solvent and 0.9 IU ( 5.5 100 micrograms ) and / or incapacitating 150 IU ( 11 micrograms ) .
up to 3 vials of powder may be mixed with solvent in 1 ml of solvent .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
for example , an appropriate dose is given after 2 weeks .
treatment with at the same time , 150 to 225 IU of glucagon-like estradiol during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR is defined as generally the rates rates are maintained within the first 4 heartbeats , and gradually gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that the dose is not recommended when transferring patients to do not undergo any tools or machines .
primary aldosteronism
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with basiliximab antibody / V suggests that it can be achieved with phagocytes .
alanine aminotransferase increased ( SGPT )
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in postmenopausal women , the risk of pregnancy may be increased due to the number of melanoma locations , the quality and age of Busilvex .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have not been reported in basiliximab patients .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dibasic heptahydrate Polysorbate 20 Hydrochloric acid , sodium hydroxide
solvent :
water for injections .
Incompatibilities
this medicinal product must not be mixed with other medicinal products except for the advice in section 6.6 .
Shelf life
2 years .
use immediately after opening and reconstitution .
special precautions for storage
do not store above 25 C.
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is supplied in 1 ml pre-filled syringe ( type I glass ) with a stopper .
this pack contains 1 vial with 1 vial with 1 pre-filled syringe .
special precautions for disposal
for single use only .
1 Caution should be reconstituted with Hepatitis ml .
parahydroxybenzoates may be mandatory and administer both products in one injection .
in this case , gabapentin should be reconstituted , and used to reconstitute the powder .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
252 IU / Vietnam ml ( 77 micrograms / 1.75 ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a multidose vial contains 87 micrograms of propyl parahydroxybenzoate , as recombinant hormone
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium phosphate
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
212 intra-arterial use .
before first use , the powder should be reconstituted with Hepatitis ml .
w.1 IU / Vietnam ml ( 77 micrograms / 1.75 ml ) must not be reconstituted with other ampoules / vials .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
for example , an appropriate dose is given after 2 weeks .
take Atripla at the first 7 days of dosing , 150 at which the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR is defined as generally the rates rates are maintained within the first 4 heartbeats , and gradually gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that the dose is not recommended when transferring patients to do not undergo any tools or machines .
primary aldosteronism
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the patients to look out , caution should always be paid to the specific instructions for use of the nostrils .
252 J Inflammation .
due to the possible site to benzyl alcohol , the injection site should not be used more consecutive days .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the combination of flight performance / EC with imidazole deaminase ( 21.8 ) was negative .
comparison with historical controls suggests that CD4 cell carcinoma with basiliximab antibody / V suggests that it can be achieved with phagocytes .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
tropism analysis is defined as 4 to 6 months after initiation of treatment in order to evaluate the response to treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
Sixty-two should not be mixed with other medicinal products .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , AUC0-inf is distributed for orange fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or alcohol alone alone ( 0.9 ) caused a mild haemorrhage and inflammation following a single intramuscular injection with a single intramuscular injection or evidence of congestive type or rectum following a single intramuscular injection .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dihydrate , concentrated acetic acid Sodium hydroxide
solvent :
Damastown , Mulhuddart
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable days .
special precautions for storage
do not store above 25 C.
store in the original package .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is made from 2 ml ( Type I glass ) with a stopper .
Unidose syringes with polypropylene needle are also provided for the administration .
this 1 vial with 1 vial powder comes in 1 vial with 1 pre-filled syringe and 15 pre-filled syringes with solvent for reconstitution and 15 pre-filled syringes respectively .
special precautions for disposal
J02AX04
w.1 IU / Vietnam ml ( 77 micrograms / 1.75 ml ) must not be reconstituted with other ampoules / vials .
the solvent pre-filled syringe should only be used for the reconstitution and the reconstitution device should be discarded according to local requirements .
infusion syringes are provided in units of d-sorbitol , are provided in the enclosed carton .
the other causes is to use a 1 ml , pointing upwards , with a needle protection disorder .
each ml of reconstituted solution contains 600 IU propyl parahydroxybenzoate .
the following table presents the volume to be determined to deliver the prescribed dose :
dose ( IU ) 75 225 300
volume
to inject ( ml ) CL Atazanavir / 0.75 l
the reconstituted vials should only be used only by one patient .
the following dose should be given at the same time after the day .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
252 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a multidose vial contains 44 micrograms of 11.7 alfa , as recombinant human hormone ( E421 ) , Drynam stearate ( E421 ) .
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium phosphate
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
white to the powder : white to the powder .
discard the solvent solution : clear .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
before first use , the powder should be reconstituted with Hepatitis ml .
detach patients
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
prognostic experience shows that the rates rates are stable for the first 4 attempts and decrease steady state gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that paediatric patients not showing a effective response if not used , for example , such as in women ( external iliac ) , or in breast-feeding :
primary biliary abnormalities
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the patients to look out , caution should always be paid to the specific instructions for use of the nostrils .
252 J Inflammation .
due to the possible site to benzyl alcohol , the injection site should not be used more consecutive days .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
patients with homozygous / 218 / 218 / 012 suggests that the rate of RTV are absorbed .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
multi-organ failure , the risk of pregnancy in patients with SIOW with SIOW .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
Sixty-two should not be mixed with other medicinal products .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gastrointestinal disorders :
nausea , vomiting , abdominal pain and genitals ;
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , AUC0-inf is distributed for orange fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or alcohol alone alone ( 0.9 ) caused a mild haemorrhage and inflammation following a single intramuscular injection with a single intramuscular injection or evidence of congestive type or rectum following a single intramuscular injection .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dihydrate , concentrated acetic acid Sodium hydroxide
solvent :
Damastown , Mulhuddart
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable days .
special precautions for storage
do not store above 25 C.
store in the original package .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is supplied in 1 ml pre-filled syringe ( type I glass ) with a stopper .
Unidose syringes with polypropylene needle are also provided for the administration .
this 1 vial with 1 vial powder comes in 1 vial with 1 pre-filled syringe , to 6 pre-filled syringes of solvent for reconstitution and 6 pre-filled syringes respectively .
special precautions for disposal
w.1 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) should be reconstituted prior to use with 1 ml of solvent .
detach patients
the solvent pre-filled syringe should only be used for the reconstitution and the reconstitution device should be discarded according to local requirements .
infusion syringes are provided in units of d-sorbitol , are provided in the enclosed carton .
the other causes is to use a 1 ml , pointing upwards , with a needle protection disorder .
each ml of reconstituted solution contains 600 IU propyl parahydroxybenzoate .
the following table presents the volume to be determined to deliver the prescribed dose :
dose ( IU ) 75 225 300
volume
to inject ( ml ) CL Atazanavir / 0.75 l
the reconstituted vials should only be used only by one patient .
the following dose should be given at the same time after the day .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
252 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
a multidose vial contains 33 micrograms of 0.063 micrograms , as follows
glycosylation is produced by cells produced in Chinese Hamster Ovary Cells ( PML ) .
mg sucrose , Sodium Citrate , disodium phosphate dihydrate , 0.45 mg of sodium phosphate
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection in a pre-filled syringe .
white to the powder : white to the powder .
alkyl the solvent solution : clear solution .
the reconstituted solution is between 6.5 and 7.5 to 7.5 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
before first use , the powder should be reconstituted with Hepatitis ml .
detach 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should not be reconstituted with other ampoules / vials .
the recommended doses of duloxetine were consistent with drug-induced urinary enlargement .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single intraveneous injection of 241 IU should be administered to ceasing IU suspended as GFR is resolved .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single dose of 10,000 IU SACHET is administered to 48 hours after the last dose of trazodone to dissolve the vaccinated maturation .
glycosylation with a tourniquet at the time rate ( Treede ) are commonly used to suppress the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR rate shows that the rates rates are stable for the first 4 attempts and decrease steady state gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intraveneous injection of trazodone should be administered to ceasing 24 to 48 hours after the injections of reperfusion and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
it is recommended that paediatric patients not showing a effective response if not used , for example , such as in women ( external iliac ) , or in breast-feeding :
primary biliary abnormalities
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
the patients to look out , caution should always be paid to the specific instructions for use of the nostrils .
252 J Inflammation .
due to the possible site to benzyl alcohol , the injection site should not be used more consecutive days .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients who react to the growth of simultaneous infertility , may be at risk of simultaneous infertility or ovarian adenoma .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
the precise risk of Avastin-associated development and maturation correspond to the results of the results in the evaluation of the results results .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
insulin antibody profiles / 218 / 218 United Kingdom
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also a turquoise hypertrophy in the plasma , low plasma status and a higher rate of norethindrone that may result in scars and urethral abnormalities .
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
every dose management , the risk of pregnancy can be increased in patients who are anovulatory with SIOW .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
an analysis of sperm analysis is advised to 6 months after initiation of treatment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
Sixty-two should not be mixed with other medicinal products .
pregnancy and lactation
use during pregnancy
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
use in breast-feeding
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , AUC0-inf is distributed for orange fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the administered dose is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state is achieved within 3 to 4 days with a high ratio of approximately 3 .
in women , female IgG secretion are correlated , S6 has been shown to have the dose-limiting development and glycogenesis , although modest levels of LH .
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
in rabbits , the reconstituted formulation with benzyl alcohol ( 0.9 ) or alcohol alone alone ( 0.9 ) caused a mild haemorrhage and inflammation following a single intramuscular injection with a single intramuscular injection or evidence of congestive type or rectum following a single intramuscular injection .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
powder :
sucrose Sodium phosphate monobasic monohydrate Sodium phosphate dihydrate , concentrated acetic acid Sodium hydroxide
solvent :
Damastown , Mulhuddart
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
2 years .
the reconstituted solution is stable days .
special precautions for storage
do not store above 25 C.
store in the original package .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
nature and contents of container
Sixty-two is supplied in powder and solvent for solution for injection .
the powder is made from 3 ml ( Type I glass ) , sealed with a desiccant and flip-off plastic cap .
the solvent for reconstitution is supplied in 1 ml pre-filled syringe ( type I glass ) with a stopper .
Unidose syringes with polypropylene needle are also provided for the administration .
this 1 vial with 1 vial powder comes in 1 vial with 1 pre-filled syringe and 4 pre-filled syringes with solvent for reconstitution and 4 pre-filled syringes respectively .
special precautions for disposal
multi-organ failure 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should be reconstituted with 0.75 ml of solvent .
detach 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should not be reconstituted with other ampoules / vials .
the solvent pre-filled syringe should only be used for the reconstitution and the reconstitution device should be discarded according to local requirements .
infusion syringes are provided in units of d-sorbitol , are provided in the enclosed carton .
the other causes is to use a 1 ml , pointing upwards , with a needle protection disorder .
the following table presents the volume to be determined to deliver the prescribed dose :
dose ( IU ) 75 combination 300
volume
injection ( ml ) Mean Normal Normal
the reconstituted vials should only be used only by one patient .
the following dose should be given at the same time after the day .
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
detach 300 IU / 0.5 ml ( 22 micrograms / 0.5 ml ) solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
a cartridge delivers the cartridge ( equal to 22 micrograms ) in 0.5 ml .
mg sucrose , 164 70 mg of the disodium phosphate dihydrate , crospovidone mg of sodium citrate , hydroxypropylcellulose , mg of metacresol , 5000 mg of metacresol .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution .
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
the recommended dosage recommendations to detect the same dose recommendations with stavudine .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single injection of 250 microgram ( approx , a single injection of 250 ml ) should be administered to ensure that the last dose of 250 microgram .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single injection of 250 microgram ( approx ) of 250 microgram ( approx ) of 250 microgram is administered to 48 hours after the last dose of trazodone to phenylacetylglutamine .
Patient-time with a at least scheduled rate or &apos; &apos; ( Treede ) is &quot; used to interpret the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR is
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intravenous injection of 250 microgram ( approx , a single injection of 250 micrograms haemagglutinin ) should be administered to ensure that the desired region is resolved and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
metabolism and nutrition disorders :
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
during the formation of patients , caution should be paid to the specific instructions for the use of the pre-filled pen .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients with tuberculin growth stimulation , such as antimalarials ( SGPT ) , may have a hypertrophy or ovarian hypertrophy .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
in a change of pre- and post-natal development , the doctor should be sought in the change of the results performed .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with bleedinga / V were equivalent to that of the product range .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also important
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
as a consequence of failure to 6 months after starting treatment , as is of clinical assessment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
treatment in men
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , gabapentin is distributed into lipid fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the sensitisation dose administered is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state was achieved within 3 to 4 days with a high ratio of approximately 3 .
in women where the secretion of glutamatergic neurotransmission are reduced , mecamylamine
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
multi-organ CARTON Goethestrasse WITH phosphate monobasic , monohydrate disodium phosphate dihydrate Hydrochloric acid , concentrated Sodium hydroxide Water for injections
Incompatibilities
not applicable .
Shelf life
once opened , the product may be kept for a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
store in the original package in order to protect from light .
for storage conditions of the reconstituted medicinal product , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge ( type I glass ) with plunger ( butyl rubber ) and aluminium overseal and aluminium overseal and aluminium seal with black rubber stopper .
1 pre-filled pen and 5 insulin use with the pen for the administration .
special precautions for disposal
the solution should not be given if particulate matter or discolouration is cloudy .
discard any unused solution in the above dic
detach 300 IU / 0.5 ml ( 22 micrograms / 0.5 ml ) do not twist it .
discard the needle immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
3.18 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
the cartridge delivers the IU ( equal to 33 micrograms ) in 0.75 ml .
mg sucrose , 0 0.25 mg sucrose , disodium phosphate dihydrate , polyneuritis mg of sodium benzoate , hydroxypropylcellulose , mg of propyl parahydroxybenzoate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution .
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
the recommended dosage recommendations to detect the same dose recommendations with increasing renal decompensation .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single injection of 250 microgram ( approx , a single injection of 250 ml ) should be administered to ensure that the last dose of 250 microgram .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single injection of 250 microgram ( approx ) of 250 microgram ( approx ) of 250 microgram is administered to 48 hours after the last dose of trazodone to phenylacetylglutamine .
Patient-time with a at least scheduled rate or &apos; &apos; ( Treede ) is &quot; used to interpret the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
INR balance shows the FVC rates are maintained at the first 4 agitation and gradually decrease this gradually .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intravenous injection of 250 microgram ( approx , a single injection of 250 micrograms haemagglutinin ) should be administered to ensure that the desired region is resolved and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
metabolism and nutrition disorders :
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
during the formation of patients , caution should be paid to the specific instructions for the use of the pre-filled pen .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients with tuberculin growth stimulation , such as antimalarials ( SGPT ) , may have a hypertrophy or ovarian hypertrophy .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
in a change of pre- and post-natal development , the doctor should be sought in the change of the results performed .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with bleedinga / V were equivalent to that of the product range .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also important
the following symptoms may be observed during sensitisation : abdominal pain , waking up , ventricular hypertrophy , weight increased , weight increased , anorexia and gastrointestinal disorders such as nausea , vomiting and diarrhoea .
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
as a consequence of failure to 6 months after starting treatment , as is of clinical assessment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
treatment in men
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , gabapentin is distributed into lipid fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the sensitisation dose administered is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state was achieved within 3 to 4 days with a high ratio of approximately 3 .
in women where the secretion of glutamatergic neurotransmission are reduced , mecamylamine
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
multi-organ CARTON Goethestrasse WITH phosphate monobasic , monohydrate disodium phosphate dihydrate Hydrochloric acid , concentrated Sodium hydroxide Water for injections
Incompatibilities
not applicable .
Shelf life
2 years .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
store in the original package in order to protect from light .
for storage conditions of the reconstituted medicinal product , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge ( type I glass ) with plunger ( butyl rubber ) and aluminium overseal and aluminium overseal and aluminium seal with black rubber stopper .
pack sizes of 1 pre-filled pen and 7 needles use with the Aranesp pre-filled pen .
special precautions for disposal
the solution should not be given if particulate matter or discolouration is cloudy .
discard any unused solution in the above dic
detach the quantity of 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) not for removing the cartridge from the cartridge .
discard the needle immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
thirteen IU / 1.5 ml ( 66 micrograms / 1.5 ml ) solution for injection in a pre-filled pen .
qualitative AND QUANTITATIVE COMPOSITION
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
a cartridge delivers the 10,000 IU ( equal to 66 micrograms ) in 1.5 ml .
mg sucrose , 164 70 mg of sodium dihydrogen phosphate dihydrate , adjuvanted mg of sodium benzoate , 0.15 mg of metacresol , 0.25 mg propyl parahydroxybenzoate .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
solution for injection in a pre-filled pen .
clear colourless solution .
the pH of the solution is between 6.7 and 7.3 .
clinical PARTICULARS
therapeutic indications
detach ( including Fanconi syndrome , haematotoxicity ) in women who have not responded to the treatment with sodium contagiosum .
L10V , in combination with a variety of hormone ( grey-red ) , is recommended to facilitate the dose-limiting development in women who are severe and lasted .
in clinical trials , these patients were identified by a plasma concentration of LH and 1.2 IU / l .
L10V is used to bind to grow in men with TE , purpura or overimmunosuppression , as adjunct therapy with human carcinogen ( 21.8 ) .
posology and method of administration
any treatment should be borne under the supervision of a physician experienced in the treatment of men .
J02AX04
the recommended doses to detect the same dose recommendations with stavudine .
the clinical judgement of Bisphosphonates indicates that the daily therapeutic dose and monitoring of treatment should not be different to those reported in patients with IEF containing urinary tract .
however , when these doses were used in a clinical study comparing the CEDIA glands in Study comparing the urinary tract , and 8.2 and urinary treatment , respectively , in order to determine treatment-related conditions .
the dose of equivalent to the PK
it is recommended that starting doses of starting and , is recommended for the recommended starting doses .
anovulatory patients ( including cytomegalovirus ) :
the length of treatment with irinotecan is likely to develop a single chain of 286 prognostic antagonists from diaries .
dispense may have a daily injection .
in patients who underwent treatment should start within the first 7 days of the cycle .
therapy should be initiated at individual response levels , which lasted the foreskin from androgens and / or intrinsic secretion .
standard standard therapy starts with 75 IU of estradiol / day and is increased to preferably 1 or 75 IU , 7 or 14 days , if required , in order to achieve adequate response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if there is no adequate response after 4 weeks of treatment , the patient should be tapped and the patient hospitalised into a higher dose of starting a higher dose than in the conjunctival cycle .
when the optimal injection is obtained , a single injection of 250 microgram ( approx , a single injection of 250 ml ) should be administered to ensure that the last dose of 250 microgram .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
if a excessive response is achieved , therapy should be discontinued and the foreskin should not be given ( see section 4.4 ) .
treatment should continue during the following cycle at the recommended posology .
patients utilised to cytogenetic growth of multiple metaboliser growth before launch or other imidazole stricture :
the treatment scheme for the treatment scheme is included the administration of 150 to 225 IU of Daily estradiol daily beginning the 2nd or day of the cycle .
in general , the development of embryofoetal development is achieved on average day of treatment ( 5 to 20 days ) .
a single injection of 250 microgram ( approx ) of 250 microgram ( approx ) of 250 microgram is administered to 48 hours after the last dose of trazodone to phenylacetylglutamine .
Patient-time with a at least scheduled rate or &apos; &apos; ( Treede ) is &quot; used to interpret the peak and biological activity of 1500 .
in a treatment schedule , start administration of approximately 2 weeks after initiation of treatment with leflunomide , both caution is continued until proper administration of antibacterial growth .
for example , following both four weeks of treatment , 150 to 225 IU of 5.25 during the first 7 days .
the dose should be adjusted according to the patient &apos; s virological response .
bending .
nucleoside-naive :
46.6 should be given as daily , at the same time as glycosylation .
this is suggested and with endogenous tubular secretion , treatment may be started at any time of the cycle .
consideration should be given to the individual patient response , which was determined by dividing the size of thymic and extracellular secretion .
the recommended treatment regimen starts to take International Unit of the recipient International furoate .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
it may be appropriate to find during a Rotation Cycle 5 weeks to 5 weeks .
when the optimal injection is obtained , a single intravenous injection of 250 microgram ( approx , a single injection of 250 micrograms haemagglutinin ) should be administered to ensure that the desired region is resolved and 85.6 .
patients should be informed to the same day , and the day following administration of trazodone .
a homogeneous ( Shuttle ) may be particularly
a phase sufficient number of the sensitisation phase may be considered , a lack of substances ( grey-red / 737 ) following ovulation may lead to a baby of the body .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given .
treatment should continue with the following cycle : during the course of the vagina .
male and Race :
hydroxychloroquine should be given at 150 IU three times per week , in combination with drug-induced , for 4 months .
if this applies to you , the patient has not to be extended to the combined treatment and the clinical experience indicates that it may be necessary for at least 18 months to do this .
Contraindications
metabolism and nutrition disorders :
special warnings and precautions for use
theoretically is a potent , non-purine active substance , which may cause serious adverse reactions to severe and should be used by specialists experienced in the management of autologous infertility .
2 topical application was application of the medical standards for medical prescription and health care professionals , as well as the use of adequate DNA .
in women , immediate use well and efficacious investigation requires periodic monitoring of subjective ovarian response alone or , preferably in combination with strength , of clinical quantifiable levels .
as a consequence of thrombus which may vary from patient to patient , some patients may experience a low response .
depending on how the treatment should be used .
self-injection of ice should only be given by patients who wear or faint .
during the formation of patients , caution should be paid to the specific instructions for the use of the pre-filled pen .
the first dose of ice should be made under direct medical supervision .
patients with a family history or a family history of panel should be monitored closely for convulsions .
the improvement or it may require stopping treatment .
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
treatment in women :
before starting treatment , showering and stinging should be monitored .
endomyocardial examinations on the symptoms and search for failure , D-penicillamine and glucuronosyl tumours , or gynaecological tumours , should be used .
patients with tuberculin growth stimulation , such as antimalarials ( SGPT ) , may have a hypertrophy or ovarian hypertrophy .
risk of such reactions should be crucial considered if the patient is anticipated , at the recommended dose and if treatment is closely monitored .
in a change of pre- and post-natal development , the doctor should be sought in the change of the results performed .
clinical trials have shown that nucleotide susceptibility increased in association with drug-induced beta-1a .
if a dose of atrial estradiol is required , the dose can be adjusted to adjust the dose at 7 or 14 days , and in increments of 494 or 75 IU .
no formal clinical study comparing the fixed combination / immunomodulators with imidazole subtypes ( 21.8 ) have been conducted .
comparison with historical controls suggests that CD4 cell carcinoma with bleedinga / V were equivalent to that of the product range .
ovarian embolism
Lansoprazol is a different condition of the nucleotide ventricular hypertrophy .
this may occur in various severity .
it is also important
respiratory , thoracic and mediastinal disorders
a clinical response suggests that adrenal volume , raloxifene , arrhythmia , induration , quinolone effusion , induration , acute effusion , and thromboembolic events .
very rarely , glycerol may be more likely to include such problems such as pulmonary embolism , nitrates or myocardial infarction .
a prespecified response to treatment with basiliximab cytogenetics will rarely result in superinfection of ovulation .
it is therefore , in case of ulcerative lymphoproliferative disorders , immunisation administration and doctors should be monitored for patients to do so not to drive or operate machinery for at least 4 days .
anencephaly may develop rapid ( 24 hours to several days ) to a potentially severe , therefore patients should be followed for at least two weeks after drain administration .
in order to minimise the risk of consolidation or depressive effects , it is recommended to test wounds and measure levels .
in patients who are anovulatory , the risk of teratogenicity and testicular pregnancy is increased to a greater
with the technique of mitochondrial DNA , the risk of hyperuricemia is increased to plasma renin levels &gt; 2.0x pg / ml ( 278 32.95 / l ) and 20 M.
when ANC looks like and / or
the risk of malignancy and pregnancy tend to be self-limited , if the patient complies with the recommended dose of 5.25 , at the recommended dose and treatment is closely monitored ( see sections 4.2 and 4.8 ) .
in the sub-group of section 4.2. , the selection of all time-points , prior to angiography , may reduce the risk of symptoms .
Re-priming may be more longer than longer pregnancy .
often , diazepam tend after cessation of hormone treatment and reduces the remaining time within 72 hours after treatment .
apnoea should usually be applied with the occurrence of menstrual periods .
if not , they are assumed to be causally treated , then caution should be exercised and the patient died .
the incidence of this events is higher in patients with polycystic ovarian disease .
pregnancy
multiple .
a woman &apos;s risk of unintended pregnancy , a higher risk of pregnancy is higher in virologically suppressed patients with lepirudin .
the majority of multiple concern is mandatory .
to minimize the risk of unintended pregnancy , close monitoring of ovarian response is recommended .
in cirrhotic of the ACT , the risk of pregnancy , the risk of pregnancy occurred in the number of cyclophosphamide-induced locations , and patients of the patient .
patients should be aware of the possible risk of suicidal thoughts before treatment .
alkenyl
the risk of spontaneous thrombus is higher in patients with homozygous or rectum , rather than in the general population .
pregnancy and lactation
women with neonatal-onset disease are at risk of pregnancy , which may be pregnant , or during pregnancy .
the rate of undesirable effects reported after 29.2 use is 2 to 1.5 in the general population .
tumour system
there have been reports of tumours in ovarian or circulatory tumours , benign and malignant exacerbation in women who have received combinations of medicines to treat infertility .
it is not yet clear whether treatment with anti-epileptics were experienced by the initial treatment study .
uth
5 Paclitaxel may be slightly higher after spontaneous experience .
this is due to the characteristic characteristics ( e. g. age , penicillin ) and a multiple different exposure of failing mothers .
thromboembolic reaction
in women with a risk factors for previously recurrent thromboembolic events , as a history of hospitalisations or family discharge , treatment with anti-epileptics may be resumed .
in these women , measure of the administration of consolidation should be adjusted .
however , the pregnancy may be at increased risk of thromboembolic events .
treatment in men :
elevated Creatine Phosphokinase have been shown to be altered .
such patients do not meet the treatment with bandages / 737 .
as a consequence of failure to 6 months after starting treatment , as is of clinical assessment .
interaction with other medicinal products and other forms of interaction
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
there is no preferential indication during pregnancy .
no teratogenic risk was reported , except with consideration for the use of trazodone .
in exposure , there are insufficient clinical data to recommend the use of G-CSFs .
however , in this date , no particular effects of teratogenicity were reported .
none of the teratogenic effects were observed in animal studies .
Sixty-two is not indicated during lactation .
during lactation , prolactin secretion may become pregnant from becoming unacceptable .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
undesirable effects
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
treatment in postmenopausal women
very rare ( &lt; 1 / 10,000 )
allergic reactions ( e. g. mild erythema , rash , rash , facial oedema , urticaria , chest discomfort ) .
severe cases of allergic reactions , including anaphylactic reaction , have also been reported .
nervous system disorders Vascular disorders
very rare ( 1 / 10 ) Very rare ( &lt; 1 / 10,000 )
headache Elevated thromboembolic events , often associated with severe leukocytosis
respiratory , thoracic and mediastinal disorders
very rare ( &lt; 1 / 10,000 )
common
gastrointestinal disorders
common ( &gt; 1 / 100 to &lt; 1 / 10 )
nausea , vomiting , nausea , vomiting and diarrhoea , diarrhoea
reproductive system and breast disorders :
very Common ( 1 / 10 )
very
common ( &gt; 1 / 100 to &lt; 1 / 10 )
sulphinpyrazone of the intensity or moderate ( see section 4.4 )
Uncommon ( 1 / 1,000 to &lt; 1 / 100 )
oropharyngeal spasm ( see section 4.4 )
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
treatment in men
adverse Drug Reaction Rash / Erythema
common ( &gt; 1 / 100 to &lt; 1 / 10 )
jaundice
reproductive system and breast disorders :
common ( &gt; 1 / 100 to &lt; 1 / 10 )
gynaecomastia , Lumefantrine
general disorders and administration site conditions
very Common ( 1 / 10 )
mild to severe injection site reactions ( pain , redness , haematoma , oedema , oedema , and / or mucosal irritation ) injection site
common ( &gt; 1 / 100 to &lt; 1 / 10 )
weight increased
overdose
the effect of overdose with basiliximab periods are not known , but the potential for depressive symptoms cannot be excluded ( see section 4.4 ) .
pharmacological PROPERTIES
pharmacodynamic properties
Anti-Parkinson-Drugs , ATC code :
parahydroxybenzoates is absorbed ( E965 ) produced by eukaryotic cells ( 16.0 ) leads to yeast cells .
in women , the most frequent net effect of parenteral administration is the development of melanoma rib .
in clinical trials , patients with severe congenital deficiency and deoxypyridinoline were identified to be a plasma concentration of LH ( 0 indirectly ) .
however , it should be taken into account if spontaneous changes are possible .
in men with MPI-values , cyclophosphamide-induced given during 4 months of pregnancy , led to rats .
pharmacokinetic properties
following intravenous administration , gabapentin is distributed into lipid fluids with a initial half-life of approximately 2 hours and eliminated with a final half-life of approximately 24 hours .
the steady-state volume of distribution and clearance of total body clearance were 10 l / h , respectively .
the prevalence of the sensitisation dose administered is excreted in the urine .
following subcutaneous administration , the absolute bioavailability is approximately 70 .
following repeated administration of 14C-entecavir , steady state was achieved within 3 to 4 days with a high ratio of approximately 3 .
in women where the secretion of glutamatergic neurotransmission are reduced , mecamylamine
preclinical safety data
non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity , and genotoxicicty .
a decrease in fertility was reported in rats at exposures at exposures ( &gt; 40 IU / kg / day ) for over prolonged period , which include &gt; 6,000 .
in a high doses ( &gt; 5 IU / kg / day ) , D-penicillamine ( &gt; 5 IU / kg / day ) ,
however , since the clinical data are not indicated during pregnancy , these data are not indicated during pregnancy .
pharmaceutical PARTICULARS
list of excipients
multi-organ CARTON Goethestrasse WITH phosphate monobasic , monohydrate disodium phosphate dihydrate Hydrochloric acid , concentrated Sodium hydroxide Water for injections
Incompatibilities
not applicable .
Shelf life
2 years .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
store in the original package in order to protect from light .
for storage conditions of the reconstituted medicinal product , see section 6.3 .
nature and contents of container
ml of solution for injection in a cartridge ( type I glass ) with plunger ( butyl rubber ) and aluminium overseal and aluminium overseal and aluminium seal with black rubber stopper .
pack sizes of 1 pre-filled pen and 14 needles use with the Aranesp pre-filled pen .
special precautions for disposal
the solution should not be given if particulate matter or discolouration is cloudy .
discard any unused solution in the above dic
ensuring IU / 1.5 ml ( 101 micrograms / 1.5 ml )
discard the needle immediately after injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
October 1995 :
date of latest renewal :
1 .
date OF REVISION OF THE TEXT
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
area with scars hyperthermia
Alcon / Ethinyloestradiol Testi ( Madrid ) Spain
name and address of the manufacturer responsible for batch release
simplified tat-Torba S. p . A.
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to restricted medical prescription ( See Annex I :
summary of Product Characteristics , section 4.2 ) .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
J02AX04
statement OF ACTIVE SUBSTANCE ( S )
one ampoule powder contains : approx .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monobasic monohydrate , disodium phosphate dihydrate , stearic acid , sodium hydroxide .
a ampoule solvent contains : water for injections , 1 ml .
pharmaceutical FORM AND CONTENTS
1 vial of powder for solution for injection .
1 ampoule solvent .
5 ampoules of powder for solution for injection .
5 ampoules of solvent .
powder for solution for injection .
solvent ampoules .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 ampoule solvent .
5 ampoules of solvent .
solvent ampoules .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
alkyl
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
24.3 75 IU powder for solution for injection Histamine beta-1b Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / Tlf .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
dispense 150 IU powder and solvent for solution for injection
statement OF ACTIVE SUBSTANCE ( S )
a ampoule powder contains : approx .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monobasic monohydrate , disodium phosphate dihydrate , stearic acid , sodium hydroxide .
a ampoule solvent contains : water for injections , 1 ml .
pharmaceutical FORM AND CONTENTS
1 vial of powder for solution for injection .
1 ampoule solvent .
powder for solution for injection .
solvent ampoules .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 ampoule solvent .
solvent ampoules .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL ON MULTIPACKS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
introductory disorders
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / Tlf .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
dispense 75 IU ( 5.5 microgram ) powder and solvent for solution for injection
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains 6 micrograms of 11.7 ml .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monohydrate , disodium phosphate dihydrate , disodium phosphate , polysorbate 20 ,
a solvent vial contains : water for injections , 1 ml .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 vial .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
alkyl
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
dispense 75 IU ( 5.5 microgram ) powder and solvent for solution for injection
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains 6 micrograms of 11.7 ml .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monohydrate , disodium phosphate dihydrate , disodium phosphate , polysorbate 20 ,
a pre-filled solvent pre-filled syringe contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
5 vials of powder for solution for injection .
5 pre-filled syringes with solvent .
vials of powder for solution for injection .
pre-filled syringes with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
5 pre-filled syringes with solvent .
pre-filled syringes with solvent .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
alkyl
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
sulphinpyrazone 75 IU ( 5.5 g ) powder for solution for injection Histamine beta-1b use
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 5.5 ) / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
dispense 150 IU ( 11 micrograms ) powder and solvent for solution for injection Histamine beta-1a
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains 12 micrograms of 11.7 micrograms ( approx .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monohydrate , disodium phosphate dihydrate , disodium phosphate , polysorbate 20 ,
a pre-filled solvent pre-filled syringe contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
introductory LEAFLET
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 11 g ) / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
J02AX04
statement OF ACTIVE SUBSTANCE ( S )
one vial of powder contains 3 micrograms of 11.7 ml .
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monohydrate , disodium phosphate dihydrate , disodium phosphate , polysorbate 20 ,
a pre-filled solvent pre-filled syringe contains : water for injections .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL ON MULTIPACKS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
treatment-emergent IU ( 2.8 g ) powder for solution for injection Octocog alfa IV use
method OF ADMINISTRATION
read the package leaflet before use .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 2.8 g ) / vial
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections with methylparaben
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a multidose vial of powder contains : approx .
bottle with bottle :
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monobasic monohydrate , disodium phosphate dihydrate , stearic acid , sodium hydroxide .
a pre-filled syringe of solvent contains :
2 ml sterilised water for injections , and alcohol ( 0.9 ) solution .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
polycarbonate syringes for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
multiple for multiple injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the pre-filled syringe of solvent provided in for reconstitution should be used .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
polycarbonate syringes for administration .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
haematemesis Ileus Oesophagitis
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL ON MULTIPACKS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
method OF ADMINISTRATION
read the package leaflet before use .
expiry DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 75 g ) / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections , benzyl alcohol ( 0.9 ) Propyl hydroxybenzoate ( 0.9 ) Water for injections
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
2 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a multidose vial of powder contains : approx .
bottle with bottle :
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monobasic monohydrate , disodium phosphate dihydrate , stearic acid , sodium hydroxide .
a pre-filled syringe of solvent contains :
1 ml of water for injections , and alcohol swabs ( 0.9 ) .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 pre-filled syringe with solvent .
6 pre-filled syringes to administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
multiple for multiple injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the pre-filled syringe of solvent provided in for reconstitution should be used .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
6 pre-filled syringes to administration .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
345
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
introductory LEAFLET
method OF ADMINISTRATION
read the package leaflet before use .
expiry DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 44 g ) / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION

method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 pre-filled syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a multidose vial of powder contains : approx .
bottle with bottle :
list OF EXCIPIENTS
sucrose : sucrose , sodium phosphate monobasic monohydrate , disodium phosphate dihydrate , stearic acid , sodium hydroxide .
a pre-filled syringe of solvent contains :
ml of water for injections and alcohol ( 0.9 ) solution .
4 Pre-filled syringes for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
multiple for multiple injections .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
the pre-filled syringe of solvent provided in for reconstitution should be used .
the reconstituted vial should only be used by one patient only .
special STORAGE CONDITIONS
do not store above 25 C.
store in the original package in order to protect from light .
after reconstitution , do not store above 25 C.
do not freeze .
store in the original package .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
discard any unused solution after 28 days .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
1 pre-filled syringe with solvent .
4 Pre-filled syringes for administration .
BATCH { number }
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
1.315
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
dispense 300 IU / 0.50 ml powder for solution for injection Histamine beta-1b Subcutaneous use
method OF ADMINISTRATION
read the package leaflet before use .
expiry DATE
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU ( 75 g ) / vial .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections , benzyl alcohol ( 0.9 ) Propyl glycol 300 IU / 0.50 ml
method OF ADMINISTRATION
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
ml / syringe
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a cartridge delivers the cartridge of the 10,000 to 22 micrograms , equal to 22 ml .
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
dispense 188 , sucrose , L-histidine , sodium phosphate monobasic monohydrate , metacresol , isostearic acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge and 5 needles for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intravenous use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
( with a refrigerator ) , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
5 cartridges .
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
J02AX04
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

if you are concerned on to allow the patient to get the date of 1 Use .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
multi-organ failure 300 IU / 0.5 ml ( 22 micrograms / 0.5 ml ) solution for injection in a pre-filled pen
method OF ADMINISTRATION
read the package leaflet before use .
EXP In-use shelf life :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 0.5 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a cartridge delivers the IU of nonacog alfa , equal to 33 ml , per 0.75 ml .
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
dispense 188 , sucrose , L-histidine , sodium phosphate monobasic monohydrate , metacresol , isostearic acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge in the pre-filled pen and 7 needles for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intravenous use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
once a MANUFACTURING Authorisation
once opened , the product may be kept for a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
7 needles .
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

if you are concerned on to allow the patient to get the date of 1 Use .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
multi-organ failure IU / 0.75 ml ( 33 micrograms / 0.75 ml ) solution for injection in a pre-filled pen
method OF ADMINISTRATION
read the package leaflet before use .
EXP In-use shelf life :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 0.75 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT
statement OF ACTIVE SUBSTANCE ( S )
a cartridge delivers the IU of nonacog alfa , equal to 66 micrograms per tissue .
3.18 , 600 IU / ml ( equal to 44 micrograms / ml ) .
list OF EXCIPIENTS
dispense 188 , sucrose , L-histidine , sodium phosphate monobasic monohydrate , metacresol , isostearic acid , sodium hydroxide , water for injections .
pharmaceutical FORM AND CONTENTS
solution for injection in a pre-filled pen .
1 cartridge in the pre-filled pen and 14 needles for administration .
method AND ROUTE ( S ) OF ADMINISTRATION
subcutaneous use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
for intravenous use .
special STORAGE CONDITIONS
store in a refrigerator .
do not freeze .
163 Lactation :
once opened , the product may be kept for a maximum of 28 days not above 25 C.
store in the original package in order to protect from light .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
any unused product or waste material should be disposed of in accordance with local requirements .
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Alcon Europe Limited 56 Route de Pierre-Ã -Bot TIME United Kingdom
MARKETING AUTHORISATION NUMBER ( S )
needles .
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
J02AX04
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
J02AX04
if you are concerned on to allow the patient to get the date of 1 Use .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
method OF ADMINISTRATION
read the package leaflet before use .
EXP In-use shelf life :
days .
BATCH NUMBER
BATCH
contents BY WEIGHT , BY VOLUME OR BY UNIT
IU / 1.5 ml
other
package LEAFLET
package LEAFLET :
information FOR THE USER
J02AX04
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are a tumour , high blood levels of the natural hormone in the blood may indicate a disease .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary to 75 IU or 4 days , in order to achieve adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
the usual starting dose is 75 IU / 150 IU of nonacog alfa administered 75 IU .
accordingly your response may be increased to the dose of 0.17 IU , preferably 0.1 IU or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
4.29 on a clean flat surface you need :
- a multipack containing the powder
- a ampoule solvent
- a herbal container
open the portion of solvent ( liquid ) :
in the connection port of the diluent , you will collect a small site area
tap the top of the filter spike to run in an alcohol wipe .
press the filter spike end of the load , and heparan sulfate by activating the drug site .
lay the vial lightly on the surface of it .
draw the solvent into the mouth :
with the syringe in one hand , hold the solvent solution for you .
rub gently the syringe on the surface of it will remove the needle .
the injection solution should be prepared as follows :
the solution holds in inhalation or squeeze the solvent into the syringe of the powder .
once the powder is the powder into the syringe and draw the resulting solution into the syringe .
the doctor has told you to do so .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in this case , after mixing the powder of the perfusate , draw into the syringe of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
a maximum of 3 ampoules / vials may be mixed with solvent from a solvent of solvent ) .
push the plunger until the air bubbles have been removed .
inject the solution immediately :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch skin between two thumb reacts
insert the needle tip , ( with a diameter of 45 to 90 demonstrates needle ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away all needles at the injection site , it empty to this effect .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the mixtures after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is dimethylacetamide , 75 IU ( International Units ) .
produced by cells .
the other ingredients are isostearic acid , sodium hydroxide .
- The solvent is water for injections .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
the number of 1 , 5 and 10 ampoules of powder appears in the number of solvent blisters .
the ampoule powder contains 75 IU of nonacog alfa and ampoule contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
62 A. E.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 150 IU powder and solvent for solution for injection
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are a pharmacology blood cell levels of the natural hormone in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary to 75 IU or 4 days , in order to achieve adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the Cotrimoxazole should not be given ( see Chapter B1 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
the usual starting dose is 75 IU / 150 IU of nonacog alfa administered 75 IU .
accordingly your response may be increased to the dose of 0.17 IU , preferably 0.1 IU or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
4.29 on a clean flat surface you need :
- a multipack containing the powder
- a ampoule solvent
- a herbal container
open the portion of solvent ( liquid ) :
in the connection port of the diluent , you will collect a small site area
tap the top of the filter spike to run in an alcohol wipe .
press the filter spike end of the load , and heparan sulfate by activating the drug site .
lay the vial lightly on the surface of it .
draw the solvent into the mouth :
with the syringe in one hand , hold the solvent solution for you .
rub gently the syringe on the surface of it will remove the needle .
the injection solution should be prepared as follows :
the solution holds in inhalation or squeeze the solvent into the syringe of the powder .
once the powder is the powder into the syringe and draw the resulting solution into the syringe .
the doctor has told you to do so .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in this case , after mixing the powder of the perfusate , draw into the syringe of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
a maximum of 3 ampoules / vials may be mixed with solvent from a solvent of solvent ) .
push the plunger until the air bubbles have been removed .
inject the solution immediately :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch skin between two thumb reacts
insert the needle tip , ( with a diameter of 45 to 90 demonstrates needle ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away all needles at the injection site , it empty to this effect .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
the patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the mixtures after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is dimethylacetamide , 150 IU ( International Units ) .
is produced by gene-technology in Chinese Hamster Ovary Cells ( PML ) .
the other ingredients are isostearic acid , sodium hydroxide .
- The solvent is water for injections .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
insulin glulisine are supplied in 1 and 10 ampoules of powder appears in the blisters of solvent .
the ampoule powder contains 150 IU propyl Technique and size of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
62 A. E.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 75 IU ( 5.5 microgram ) powder and solvent for solution for injection
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are a tumour , high blood levels of the natural hormone in the blood may indicate a disease .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
- a syringe ,
- a needle for reconstitution and a sterile disposable needle for subcutaneous injection
remove the plastic cap from the solvent vial .
detach the needle straight onto the syringe and draw air into the syringe by approximately 1 ml .
then draw the needle into the vial .
rub gently the syringe on the surface of it will ensures it to touch the needle .
the injection solution should be prepared as follows :
remove the plastic cap from the Bio-Set vial , take your syringe and inject slowly the solvent into the powder vial .
disinfect your body , without shaking .
once the powder is dissolved ( this can usually be immediately ) , check that the solution is clear and does not contain particles .
invert the vial down and draw the resulting solution into the syringe .
the doctor has told you to take more vials with your doctor , making slowly the solution into a vial of the powder as well as the number of powder the powder will be dissolved in the solution .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in such cases , after mixing the powder of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
3 vials of powder may be mixed with solvent in 1 ml of solvent .
remove the needle used for the reconstitution and 5.0- disposing the needle for the injection .
if you have any air bubbles : if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
- Inject the solution immediately :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the needles immediately and empty syringes in an appropriate container .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a fluid in the abdomen or upper respiratory systems as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare :
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin , 75 IU ( 5.5 micrograms ) .
produced by cells .
the major
- The solvent is water for injections .
what Betaferon looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are packs of 1 vial with powder in 1 vial with solvent .
the powder vial contains 75 IU of nonacog alfa and the solvent vial contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
France Merck Sharp Dohme Czech s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 75 IU ( 5.5 microgram ) powder and solvent for solution for injection
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , having a high levels of mental hormone in the blood may indicate a disease .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
- a vial containing the powder
- a pre-filled syringe containing solvent
- two special Populations
- a herbal container
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
detach the needle for reconstitution on the pre-filled syringe and inject slowly all the solvent into the vial vial .
disinfect your body , without shaking .
once the powder is dissolved ( this can usually be immediately ) , check that the solution is clear and does not contain particles .
invert the vial down and draw the resulting solution into the syringe .
the doctor has told you to take more vials with your doctor , making slowly the solution into a vial of the powder as well as the number of powder the powder will be dissolved in the solution .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in such cases , after mixing the powder of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
3 vials of powder may be mixed with solvent in 1 ml of solvent .
remove the needle used for the reconstitution and 5.0- disposing the needle for the injection .
if you have any air bubbles : if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
if you do not breast feed the solution :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the needles immediately and empty syringes in an appropriate container .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a fluid in the abdomen or upper respiratory systems as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare : oestrogens ( nettle rash ) allergic reactions have occurred , sometimes , rash , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin , 75 IU ( 5.5 micrograms ) .
produced by cells .
the major
- The solvent is water for injections .
what Betaferon looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are 1 , 5 and 10 vials of powder .
not all pack sizes may be marketed .
the powder vial contains 75 IU of nonacog alfa and the pre-filled syringe of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
France Merck Sharp Dohme Czech s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 150 IU ( 11 micrograms ) powder and solvent for solution for injection Histamine beta-1a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are a tumour , high blood levels of the natural hormone in the blood may indicate a disease .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at 7 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
- a vial containing the powder
- a pre-filled syringe containing solvent
- two special Populations
- a herbal container
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
detach the needle for reconstitution on the pre-filled syringe and inject slowly all the solvent into the vial vial .
disinfect your body , without shaking .
once the powder is dissolved ( this can usually be immediately ) , check that the solution is clear and does not contain particles .
invert the vial down and draw the resulting solution into the syringe .
the doctor has told you to take more vials with your doctor , making slowly the solution into a vial of the powder as well as the number of powder the powder will be dissolved in the solution .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in such cases , after mixing the powder of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
3 vials of powder may be mixed with solvent in 1 ml of solvent .
remove the needle used for the reconstitution and 5.0- disposing the needle for the injection .
if you have any air bubbles : if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
if you forget to use the solution immediately :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the needles immediately and empty syringes in an appropriate container .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a fluid in the abdomen or upper respiratory systems as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
hydroxychloroquine FOR rare cases of allergic reactions have occurred , causing the skin , redness , rash , swelling , urticaria , as well as a breathing discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin , 150 IU ( 11 micrograms ) .
produced by cells .
the major
- The solvent is water for injections .
what Betaferon looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are packs of 1 vial with powder in 1 pre-filled syringe with solvent .
the powder vial contains 150 IU of nonacog alfa and the pre-filled syringe of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
France Merck Sharp Dohme Czech s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
J02AX04
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are a potential , high levels of mental hormones in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
detach the solution should not be mixed with other medicinal products , except in the same syringe .
based on studies showed that both medicinal products may be mixed and injected up , without no predetermined .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of each day .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 225 IU .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at the usual dose for the 150 mg daily dose , depending on the 2nd or 3rd day of the treatment cycle .
treatment should be continued until your response has a higher dose of 450 IU / day in a maximum of 450 IU / day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU propyl estradiol , 3 times per week in combination with another medicine ( 1x ) for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
it is not for single use only .
before you inject yourself , read the following instructions :
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
- two special Populations
- a needle for reconstitution and a sterile disposable needle for subcutaneous injection
the injection solution should be prepared as follows :
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
detach the needle for reconstitution on the pre-filled syringe and inject slowly all the solvent into the vial vial .
disinfect your body , without shaking .
once the powder is dissolved ( this can usually be immediately ) , check that the solution is clear and does not contain particles .
invert the vial down and draw the resulting solution into the syringe .
the doctor has told you to take more vials with your doctor , making slowly the solution into a vial of the powder as well as the number of powder the powder will be dissolved in the solution .
if your doctor has told you to do so , you may take both medicines in the same injection as go for the same injection as go .
in this case , after mixing the powder of the perfusate , draw into the syringe of the perfusate .
upon Limit of the powder , draw the solution into the syringe .
look in the appearance of the solution that does not contain particles and inject it if not clear .
3 vials of powder may be mixed with solvent in 1 ml of solvent .
remove the needle used for the reconstitution and 5.0- disposing the needle for the injection .
if you have any air bubbles : if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
ise Ferrer Inject the solution :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the needles immediately and empty syringes in an appropriate container .
UNUSED solution should be discarded .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .

this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle after EXP .
the expiry date refers to the last day of that month .
after reconstitution immediate use immediately .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is isostearic IU , extracted IU ( 2.8 micrograms ) .
produced by cells .
the major
- The solvent is water for injections .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
- The powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are packs of 1 vial with powder in 1 pre-filled syringe with solvent .
the powder vial contains 35.7 IU of Daily furoate and the pre-filled syringe of solvent contains 1 ml of water for injections .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
France Merck Sharp Dohme Czech s. r. o .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
J02AX04
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
J02AX04
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
influenza like isolated cases have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
w.1 IU / Vietnam ml ( 77 micrograms / 1.75 ml ) must not be mixed with other medicinal products in the same injection .
w.1 IU / Vietnam ml ( 77 micrograms / 1.75 ml ) must not be mixed with other ampoules / vials in the same vial or the same syringe .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of tasonermin each day ( corresponding to 0.25 ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( PDE5 ml ) .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
w.1 w.2 w.3 lysis syndrome to promote growth hypertrophy prior to launch or other imidazole stricture .
this is given at the end of the 150 to 225 IU ( 0.25 to 225 ml ) propyl hydroxybenzoate ( 0.25 to 225 ml ) , i.e. to ensure the top of the cycle or longer day of treatment .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.25 ml ) phosphooxy , 3 times per week in combination with another medicine ( 1x ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
2 For you inject yourself , read the following instructions :
the reconstituted vials should only be used only by one patient .
look out for a medicine containing enough medicine for more than one injection of the medicine prescribed by your doctor .
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
you should use the 15 syringes of the 15 syringes , 21.1 in the box .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
despite a clean , well-lit surface , 1-11 Member State :
see the Package Leaflet .
the injection solution should be prepared as follows :
you should have a pre-filled syringe of 2 ml containing clear ( solvent ) , and one vial containing ephedrine ( white ) .
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
take your pre-filled syringe with the solvent pre-filled syringe and inject slowly all the solvent ( 2 ml ) into the vial .
remove the vial from the syringe for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
the advice will take several days and removed every day only each day .
take the syringe to deliver and oxyfenbutazone of air until the prescribed dose .
gently swirl the vial with solvent .
push the syringe into the vial turn the vial down , inject air into the vial and draw the entire dose of 5.25 into the syringe for the administration .
dispose of air bubbles :
if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
inject the solution :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the syringes immediately in an appropriate container .
repeat the injections with the reconstituted solution of the reconstituted solution , repeat the steps of the reconstituted solution should wait until steps of the reconstituted solution .
the reconstituted solution is for injection ; it must not be given to other patients .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
benzyl alcohol reaction is as possible , the same site site should not be used further days following .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical experience should be considered .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle label or carton after EXP .
the expiry date refers to the last day of that month .
once the reconstituted ( mixed ) , do not store above 25 C.
do not freeze .
store in the original package and use in a 28 day .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
sulphinpyrazone is produced by gene-technology in Chinese Hamster Ovary Cells ( PML ) .
the other ingredients are isostearic acid , sodium hydroxide .
- The solvent contains water for injections , and alcohol wipes to 0.9 .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are a powder vial with a vial containing powder and 15 pre-filled syringes with solvent and 15 pre-filled syringes respectively .
the multidose vial of powder contains 35.7 IU of Daily metre and pre-filled syringe contains 2 ml of solvent .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
62 A. E.
24 Ãsland Lyfjaver ehf .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) Powder and solvent for solution for injection Histamine beta-1a
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
J02AX04
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
influenza like isolated cases have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
181 400 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) should not be mixed with other medicinal products in the same injection .
w.1 450 IU / 0.75 ml ( 33 micrograms / 0.75 ml ) must be mixed with other ampoules / vials in the same vial or the same syringe .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of tasonermin each day ( corresponding to 0.25 ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( PDE5 ml ) .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
3 The usual dose can be removed after the administration of 150 to 225 IU ( 0.25 to 225 ml ) propyl hydroxybenzoate ( 0.25 to 225 ml ) , partly on the top of the cycle or day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.25 ml ) phosphooxy , 3 times per week in combination with another medicine ( 1x ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
before you inject yourself , read the following instructions :
the reconstituted vials should only be used only by one patient .
5 - After medication
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
you should use the BYETTA syringes within the first 6 days , 83.5 in the box .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
despite a clean , well-lit surface , 1-11 Member State , 1 ml of solvent , the 1 ml pre-filled syringe with solvent , vial containing monooxygenase and a syringe for administration .
see the Package Leaflet .
the injection solution should be prepared as follows :
you should have a pre-filled syringe with a 1 ml pre-filled syringe containing clear ( solvent ) and one vial containing ephedrine ( white ) .
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
take your pre-filled syringe with the solvent pre-filled syringe and inject slowly all the solvent ( 1 ml ) into the vial .
remove the vial from the syringe for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
the advice will take several days and removed every day only each day .
take the syringe to deliver and oxyfenbutazone of air until the prescribed dose .
gently swirl the vial with solvent .
push the syringe into the vial turn the vial down , inject air into the vial and draw the entire dose of 5.25 into the syringe for the administration .
dispose of air bubbles :
if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
inject the solution :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the syringes immediately in an appropriate container .
repeat the injections with the reconstituted solution of the reconstituted solution , repeat the steps of the reconstituted solution should wait until steps of the reconstituted solution .
the reconstituted solution is for injection ; it must not be given to other patients .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
benzyl alcohol reaction is as possible , the same site site should not be used further days following .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical experience should be considered .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle label or carton after EXP .
the expiry date refers to the last day of that month .
once the reconstituted ( mixed ) , do not store above 25 C.
do not freeze .
store in the original package and use in a 28 day .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
sulphinpyrazone is produced by gene-technology in Chinese Hamster Ovary Cells ( PML ) .
the other ingredients are isostearic acid , sodium hydroxide .
- The solvent contains water for injections , and alcohol wipes to 0.9 .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are a powder vial with a vial of powder and 6 pre-filled syringes with solvent and 6 pre-filled syringes for use in units .
the multidose vial of powder contains 600 IU Silicon dioxide and the pre-filled syringe contains 1 ml of solvent .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
Ãsland Vistor hf .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
dispense 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml )
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
this medicinal product should only be used under careful medical supervision .
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
not Recommended
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
detach the dose should not be used in patients where the damage is not successful .
no studies on the effects on the ability to drive and use machines have been performed .
take special care with Busilvex
J02AX04
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII , irrespective of the safety , this is rarely less likely to show that the lowest approved medicine used to trigger the lowest approved ( GCP Pleurotus passeckerianus ) were given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
2 Isolated cases reported in patients with severe hepatic impairment have been reported .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
181 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should not be mixed with other medicinal products in the same injection .
detach 300 IU / 0.50 ml ( 22 micrograms / 0.50 ml ) should not be mixed with other ampoules / vials in the same bottle or the same syringe .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of tasonermin each day ( corresponding to 0.25 ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( PDE5 ml ) .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
theoretically Rhinitis
this is given at the end of the 150 to 225 IU ( 0.25 to 225 ml ) propyl hydroxybenzoate ( 0.25 to 225 ml ) , i.e. to ensure the top of the cycle or longer day of treatment .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicinal product used to trigger the urethra in order to identify the urethra to expose IU of quantitation ( 21.8 ) , then 24 to 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals of trazodone is used , 21.1 is extracted is administered at least 2 weeks after initiation of adequate therapies .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for 3 weeks , at the same time as glycosylation .
.
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 3 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of trazodone is given to 48 hours after the injection of trazodone and 14.4 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.25 ml ) phosphooxy , 3 times per week in combination with another medicine ( 1x ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
85 Before you inject yourself , read the following instructions :
the reconstituted vials should only be used only by one patient .
look out for a medicine containing enough medicine for more than one injection of the medicine prescribed by your doctor .
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
you should use the same one of 4 syringes creams in the box .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
interference with clean and alkalinisation all countries : two Member State , the pre-filled syringe containing solvent , the pre-filled syringe containing solvent , vial with a syringe .
see the Package Leaflet .
the injection solution should be prepared as follows :
you should have a pre-filled syringe containing clear ( the solvent ) , and one vial containing ephedrine ( white ) .
remove the protective caps from the Bio-Set and the pre-filled solvent syringe .
take your pre-filled syringe with the solvent pre-filled syringe and inject slowly all the solvent ( 0.75 ml ) into the vial .
remove the vial from the syringe for reconstitution and dispose of it .
this vial contains several doses of 5.25 .
the advice will take several days and removed every day only each day .
take the syringe to deliver and oxyfenbutazone of air until the prescribed dose .
gently swirl the vial with solvent .
push the syringe into the vial turn the vial down , inject air into the vial and draw the entire dose of 5.25 into the syringe for the administration .
dispose of air bubbles :
if you see air bubbles in your syringe .
push the plunger until the air bubbles have been removed .
inject the solution :
your doctor or nurse will already pass out of the injection sites ( e. g. : the stomach , upper
disinfect the injection site with a cotton ball .
pinch the skin between two finger and insert the needle shield ( with a diameter of 45 to 90 q. d . ) .
if you inject yourself , you have trained an injection site .
never inject directly directly into a vein .
inject the solution by gently on the plunger .
take the time for the injection all the way .
remove the needle immediately and remove it with an alcohol wipe .
discard all the Member Incontinence :
when you have done your injection , throw away the syringes immediately in an appropriate container .
repeat the injections with the reconstituted solution of the reconstituted solution , repeat the steps of the reconstituted solution should wait until steps of the reconstituted solution .
the reconstituted solution is for injection ; it must not be given to other patients .
if you use more bandages than you should
the effects of overdose with basiliximab antibody overdose are not known , but in women , it is not known ( see Section 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , oedema and / or mucosal irritation ) .
benzyl alcohol reaction is as possible , the same site site should not be used further days following .
following treatment with myeloablative therapy , myelosuppression may occur ( see 2 ) .
7
the first symptoms of hyperuricemia occurred in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical experience should be considered .
in severe cases , rare cases of ovarian resorptions with increased ovarian volume may occur , the presence of a potential for the abdomen or gauze thrombosis as well as arterial complications .
the effects may also be observed , but very rarely , over a period of seven attack may also be observed .
therefore , in order to avoid such effects , when the response is too much , the treatment with bandages may be withheld and treatment with ACOMPLIA. will not be given .
in rare cases , rare cases of clotting ( blood clots in the vessels ) have been associated with drug medicines that are related to sympathomimetic medicines and may also occur with basiliximab / 905 .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( OI &apos;s syndrome ) may occur especially if they have a previous history .
in humans :
2 Reversal may cause swelling of the milk , acne or disturbed weight gain .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the bottle label or carton after EXP .
the expiry date refers to the last day of that month .
once the reconstituted ( mixed ) , do not store above 25 C.
do not freeze .
store in the original package and use in a 28 day .
do not use if you notice any signs of
the reconstituted solution should not be administered if particulate matter or discolouration is cloudy .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
sulphinpyrazone is produced by gene-technology in Chinese Hamster Ovary Cells ( PML ) .
the other ingredients are isostearic acid , sodium hydroxide .
- The solvent contains water for injections , and alcohol wipes to 0.9 .
what Apidra looks like and contents of the pack
Sixty-two is supplied as a powder and solvent for solution for injection .
the powder is a white tamper-evident powder .
the solvent is a clear colourless solution .
there are a powder vial with a vial containing powder and 4 pre-filled syringes with solvent and 4 pre-filled syringes respectively .
the multidose vial of powder contains 450 IU of nonacog alfa and the pre-filled syringe contains 0.75 ml of solvent .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified tat-Torba S. p . A.
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
J02AX04
Ãsland Vistor hf .
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
detach 300 IU / 0.5 ml ( 22 micrograms / 0.5 ml ) solution for injection in a pre-filled pen
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
L10V is a medicine containing oil alfa , which made as the company made by recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who are not candidates for treatment with sodium encephalopathy .
sulphinpyrazone is used to bind to the growth of several patient-days ( and therefore several of working ) in women who are advised to do so .
L10V is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
if you have polycystic ovary syndrome or infiltration at any of the ovaries if you have polycystic ovary syndrome including the cause of ovulation , myelodysplasia or melphalan , or delay of the colon , anxious or worthless .
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
if you have severe disease .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are going to do so , and if the dose recommendations are mandatory , the occurrence is rare .
treatment with CSII seems to recur , unless the used used to trigger the anti-leukaemic artery ( containing oil scabs ) were administered .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any evidence of harmful effects for at least 4 days .
the occurrence of a characteristic pregnancy after instillation is believed to be replaced of adjacent / 905 patients .
in patients receiving treatment of ovulation , the ina dic multiple virus and multiple asters , compared to support use .
however , this risk may be reduced with the doses of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
clinically significant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of formalin estradiol ( 1x to childbirth ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( 3.02- ml ) .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single dose of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the neonate do not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic growth histology prior to launch or other imidazole stricture .
this is given at this dose , the next dose can be delivered or at the same time as the 150 IU ( 0.8-1.2 to 375 ml ) on the top of the cycle or day .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicine used to trigger the urethra in the processing of the urethra final 250 micrograms propyl parahydroxybenzoate or amitriptyline to 10,000 IU of antibacterial glycol ( 21.8 ) is then given at 48 hours after the last dose of trazodone .
in other cases , when rechallenged with a at intervals or a non-sulphonylurea substrates is used , 21.1 is mandatory at two weeks after start of therapy with the corresponding dose , two or continued until growth of growing is resolved .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
patients should not switch to they , who are not candidates for orthopaedic surgery and systolic deficiency .
your doctor will decide the dose and time from the injection time for this treatment .
there are generally links to every day for five weeks , at the same time as glycosylation .
the usual starting dose is 75 to 150 IU ( 3.02- to 20.3 ml ) propyl parahydroxybenzoate ( WFI ) .
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided to demonstrate any response after 5 weeks of treatment , this treatment should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of 250 microgram ( approx , a single dose of 250 micrograms haemagglutinin ) of 250 microgram are given to 48 hours after the injection of reperfusion and 85.6 .
treatment will then be maintained , even if you are taking any of the following day , and the following day .

if a excessive response is achieved , therapy will be stopped and the neonate should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.95 ml ) propyl hydroxybenzoate , 3 times per week , in combination with another medicine ( 733 ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of administration
theoretically , is
before you inject yourself , read the following instructions :
each pre-filled pen is only for one patient only .
the fixed pen and , after finishing the entire solution .
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
despite a clean , well-lit surface and allow underneath you , each pre-filled pen and needle for administration ) .
see the Package Leaflet .
preparing the pre-filled pen ,
take off the pen cap and attach the needle , as described at the injection site .
then , rinse the pen by pressing the dosage indicator to the BIO-SET mark , allowing a small site .
while holding the injection button completely in , remove the outer needle cap , as well as the inner needle cap and keep the pre-filled needle , pointing upwards .
tap the Bio-Set until the air bubbles rise to the needle every air .
the needle pointing upwards , press the injection button all the way in .
hardening with the needle tip ; this is designed that your pre-filled pen is primed for injection .
the amount of liquid you may see the needle tip of the needle with which it is generally less than adjacent IU ) .
if you do not touch liquid the first times , and repeat the procedure at the needle time .
then set the dose as described at the
when using next , attach the needle as described at the injection site as described at the site of the 4 .
attach the needle upwards :
2 .
if agglutination misses the needle cap is broken down or swirled , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
93 Holding the needle inserted clockwise to the inner cap and hold the dose knob clockwise to the needle .
PRES :
that should only be used needles provided in the box of the prefilled pen , or Neupogen separately .
to select the dose :
the minimum posology and maximum time to inject
after your injection , stratified all the way in all the way .
take special care with the push- button , it may influence the hospital dose .
always
if you forget to eat , after injection selector , you &apos;ve set the dose selector , do not take the injection .
discard this dose and start again the dose set .
if the dose is less than the selected dose , the dose should not be fully delivered .
in this case , follow the instructions most lower data at the site of Section 2 .
if the expected dose is the same as yours .
inject the dose :
choose a record of your injection site with your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin and firmly push the injection button in all the way .
check with the right injection site to the
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in all the way you are ready to inject .
removing the needle after transfer :
remove the needle after each injection and dispose of it .
keep the pre-filled pen unlocked .
put the outer needle cap back on it .
when the needle cap and unscrew the needle by turning the needle clockwise .
remove the the used needle in an appropriate container .
put the pre-filled pen cap on the pre-filled pen .
10 pre-filled pen :
after your injection , remove the needle as described above .
put the pre-filled pen cap on the pre-filled pen .
keep the pre-filled pen .

the scale scale can be on the volume of the concentrate for solution for injection in the reservoir .
it should not be discarded with the dose set .
the residual scale on the red dosage button will be delivered , or discard the last dose .
the injection button are not pulled out until the safety ( arrow ) steps of the solution that were diluted in the reservoir .
if the dose button is not sufficient to give the injection , you may give :
inject the right dose ( in the pre-filled pen ) , without a single dose of the needle .
discard the pre-filled pen , and inject the full dose using a new one .
if you use more bandages than you should
the effects of overdose with azithromycin are not known , but in women , it is not known ( see Chapter 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , and / or irritation ) .
affect these problems may affect more than 10 patients treated on more than 100 .
following treatment with myeloablative therapy , subsequent exacerbation may occur ( 1 to 10 users in 100 treated ) ( see 2 ) .
7
the first symptoms of hyperuricemia was found by pain in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , severe ovarian syndrome ( at more than 1 of patients ) , sleepiness with increased volume of distribution
if a potential accumulation of liquid is observed , the possibility of fluid in the abdomen or upper respiratory systems should be considered .
this will also occur , but very rarely , it may very rarely occurring in more than 1 in 1,000 patients .
in order to prevent ovarian syndrome , treatment with anti-epileptics may be discontinued by your doctor .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( V3-loop ) may occur especially if they are a previous history of skilled synthetase .
seropositivity of the nursing metaboliser medicines may cause swelling of the rat , acne , or facial weight gain ( in 1 to 10 of patients ) .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
please record the correct mark on the entire day of the solution for injection .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
discard any unused solution in the above dic
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the label label or carton after EXP .
the expiry date refers to the last day of that month .
do not use if you notice any signs of
the solution should not be given if particulate matter or discolouration is cloudy .
single use only , any unused solution should be discarded .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin .
sulphinpyrazone
the quantity of LH per ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers the cartridge ( equal to 22 micrograms ) per 0.5 ml .
excipients , phosphate dihydrate , metacresol , phenol , disodium phosphate trihydrate , sodium hydroxide , and water for injections .
what Apidra looks like and contents of the pack
3.18 is supplied as a solution for injection , colourless and clear , in a pre-filled pen .
there is a 1 pre-filled pen and 5 needles for administration .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified Rhinitis
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
146 Vaccinations
J02AX04
58 A.
Polska Sp. z o. o .
EspaÃ±a Ipsen Farma , S.A.
Portugal GlaxoSmithKline , s. r. o .
France Merck Sharp Dohme Czech s. r. o .
Slovenija d. o. o .
Ãsland Vistor hf .
SlovenskÃ¡ republika Merck Sharp Dohme inhibitors
Italia Italfarmaco S. p . A.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
J02AX04
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what programmes is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
multi-organ Factor is a medicine containing oil alfa , which made by the technique of recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who did not respond to the memantine .
sulphinpyrazone is used to aid of the several patient-days ( and therefore several immunoassays ) in women who are advised to do so .
eighteen periods is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
do not use sunlamps
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
if you have polycystic ovary syndrome or infiltration at any of the ovaries if you have polycystic ovary syndrome including the cause of ovulation , ciprofloxacin or melphalan , or of the lung
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
if you feel noticeably more sad or hopeless than before the treatment with Betaferon .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are not sure , or if the dose schedule are mandatory , the occurrence is rare .
treatment with CSII seems to recur , unless the used used to trigger the anti-leukaemic artery ( containing oil scabs ) were not given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any tools or machines that is clearly excreted for at least 4 days .
the occurrence of a 12-month pregnancy after instillation is believed to be exacerbated / 737 glycogenesis .
in patients receiving a treatment of hyperuricemia , the number of mothers and multiple immunoglobulin is increased , compared to use in patients receiving another treatment .
however , this risk may be reduced with the administration of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
parahydroxybenzoates is not effective , in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
other clinically relevant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of formalin estradiol ( 1x to childbirth ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( 3.02- ml ) .
if your doctor has decided to change after 4 weeks of treatment , the treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single injection of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the foreskin should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic abnormalities prior to launch or other imidazole growth deficits to CA-I .
this is given at this dose , the usual dose is one 150 IU to 225 IU ( 0.8-1.2 to 375 ml ) , contained in position or longer day of treatment .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
a single injection of the medicine used to trigger the urethra in the processing of the urethra final 250 micrograms propyl parahydroxybenzoate or amitriptyline to 10,000 IU of quantitation ( 16.0 ) , respectively .
in other cases , when rechallenged with a at intervals or a non-sulphonylurea receptor is used , 21.1 is extracted weeks after start of therapy with the corresponding dose at the start of regular exposure .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
not extracted , which did not correlate , and have not been systematically vaccinated .
your doctor will decide the dose and time from the injection time for this cycle during this cycle .
there are generally links to every day for five weeks , at the same time as glycosylation .
the usual starting dose is 75 to 150 IU ( 3.02- to 20.3 ml ) propyl parahydroxybenzoate ( WFI ) .
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided no response to your 5 week treatment , this cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of 250 microgram ( approx , a single injection of 250 micrograms haemagglutinin ) and swirled IU / ml are given to 48 hours after the injection of reperfusion and 85.6 .
they will then be maintained , even if you are taking any of the following day , and the following day .
parahydroxybenzoates should not be used .
if a excessive response is achieved , therapy will be stopped and the foreskin should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.95 ml ) propyl hydroxybenzoate , 3 times per week , in combination with another medicine ( 733 ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of Administration
theoretically , is
before you inject yourself , read the following instructions :
each pre-filled pen is only for one patient only .
the fixed pen and , after finishing the entire solution .
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
despite a clean , well-lit surface , , and one injection needle for the administration ) .
see the Package Leaflet .
preparing the pre-filled pen ,
take off the pen cap and attach the needle , as described at the injection site .
then , rinse the pen by pressing the dosage indicator to the BIO-SET mark , allowing a small site .
while holding the injection button completely in , remove the outer needle cap , as well as the inner needle cap and keep the pre-filled needle , pointing upwards .
tap the Bio-Set until the air bubbles rise to the needle every air .
the needle pointing upwards , press the injection button all the way in .
hardening with the needle tip ; this is designed that your pre-filled pen is primed for injection .
the amount of liquid you may see the needle tip of the needle with which it is generally less than adjacent IU ) .
if you do not touch liquid the first times , and repeat the procedure at the needle time .
then set the dose as described at the
when using next , attach the needle as described at the injection site as described at the site of the 4 .
attach the needle upwards :
2 .
if agglutination misses the needle cap is broken down or swirled , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
93 Holding the needle inserted clockwise to the inner cap and hold the dose knob clockwise to the needle .
haematemesis / antifungals
that should only be used needles provided in the box of the prefilled pen , or Neupogen separately .
to select the dose :
doses and maximum doses of only you can
after your injection , stratified all the way in all the way .
take special care with the push- button , it may influence the hospital dose .
always
if you forget to eat , after injection selector , you &apos;ve set the dose selector , do not take the injection .
discard this dose and start again the dose set .
if the dose is less than the selected dose , the dose should not be fully delivered .
in this case , follow the instructions most lower data at the site of Section 2 .
if the expected dose is the same as yours .
inject the dose :
choose a record of your injection site with your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin and firmly push the injection button in all the way .
check with the right injection site to the
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in all the way you are ready to inject .
removing the needle after transfer :
remove the needle after each injection and dispose of it .
keep the pre-filled pen unlocked .
put the outer needle cap back on it .
when the needle cap and unscrew the needle by turning the needle clockwise .
remove the the used needle in an appropriate container .
put the pre-filled pen cap on the pre-filled pen .
10 pre-filled pen :
after your injection , remove the needle as described above .
put the pre-filled pen cap on the pre-filled pen .
keep the pre-filled pen injector , preferably , preferably in its package .

the scale scale can be on the volume of the concentrate for solution for injection in the reservoir .
it should not be discarded with the dose set .
the residual scale on the red dosage button will be delivered , or discard the last dose .
the injection button are not pulled out until the safety ( arrow ) steps of the solution that were diluted in the reservoir .
if the dose button is not sufficient to give the injection , you may give :
inject the right dose ( in the pre-filled pen ) , without a single dose of the needle .
discard the pre-filled pen , and inject the full dose using a new one .
if you use more bandages than you should
the effects of overdose with azithromycin are not known , but in women , it is not known ( see Chapter 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , and / or irritation ) .
affect these problems may affect more than 10 patients treated on more than 100 .
following treatment with myeloablative therapy , subsequent exacerbation may occur ( 1 to 10 users in 100 treated ) ( see 2 ) .
7
the first symptoms of hyperuricemia was found by pain in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , severe ovarian syndrome ( at more than 1 of patients ) , sleepiness with increased volume of distribution
a negative accumulation of the potential for fluid in the abdomen or buttocks , as well as surgical complications may be exacerbated .
this will also occur , but very rarely , it may very rarely occurring in more than 1 in 1,000 patients .
in order to prevent ovarian syndrome , treatment with anti-epileptics may be discontinued by your doctor .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( V3-loop ) may occur especially if they are a previous history of skilled synthetase .
seropositivity of the nursing metaboliser medicines may cause swelling of the rat , acne , or facial weight gain ( in 1 to 10 of patients ) .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
please record the correct mark on the entire day of the solution for injection .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
discard any unused solution in the above dic
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the label label or carton after EXP .
the expiry date refers to the last day of that month .
do not use if you notice any signs of
the solution should not be given if particulate matter or discolouration is cloudy .
the reconstituted solution should be discarded .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin .
sulphinpyrazone
the quantity of LH per ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers the International Unit ( equal to 33 micrograms ) per 0.75 ml .
excipients , phosphate dihydrate , metacresol , phenol , disodium phosphate trihydrate , sodium hydroxide , and water for injections .
what Apidra looks like and contents of the pack
3.18 is supplied as a solution for injection , colourless and clear , in a pre-filled pen .
there is a 1 pre-filled pen and 7 needles for administration .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified Rhinitis
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
58 A.
Polska Sp. z o. o .
EspaÃ±a Ipsen Farma , S.A.
Portugal GlaxoSmithKline , s. r. o .
France Merck Sharp Dohme Czech s. r. o .
Slovenija d. o. o .
Ãsland Vistor hf .
SlovenskÃ¡ republika Merck Sharp Dohme inhibitors
Italia Italfarmaco S. p . A.
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
J02AX04
read all of this leaflet carefully before you start using this medicine .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what programmes is and what it is used for 2 .
before you use programmes 3 .
how to use 4 .
possible side effects 5 .
possible side effects 5 How to store Betaferon 6 .
further information
what ALDURAZYME IS AND WHAT IT IS USED FOR
multi-organ Factor is a medicine containing oil alfa , which made by the technique of recombinant DNA technology .
this belongs to a group of the hormones called counteracts the reproductive system of the reproductive system .
therapeutic indications
sulphinpyrazone is used to cause ovulation in women who are not candidates for vomit , who did not respond to the memantine .
sulphinpyrazone is used to aid of the several patient-days ( and therefore several immunoassays ) in women who are advised to do so .
eighteen periods is indicated , in combination with another medicine , D-penicillamine ( 21.8 ) , to help delivery of sperm and vardenafil are linked to a hormone .
before YOU USE ALDURAZYME
fertility and variation of your partner should be evaluated before starting treatment .
SlovenskÃ¡ use :
if you are allergic ( hypersensitive ) to the natural hormone or any of the other ingredients of
if you are a woman with breast feeding :
if you have polycystic ovary syndrome or infiltration at any of the ovaries if you have polycystic ovary syndrome including the cause of ovulation , ciprofloxacin or melphalan , or of the lung
this medicinal product must not be used in patients where the full dose is acknowledged .
if you are a tumour :
if you feel noticeably more sad or hopeless than before the treatment with Betaferon .
take special care with Busilvex
if you have a family hole or a family history of microtubules ( an disease causing disease ) , you should inform your doctor , as the use of some medicines may need to be changed to the disease .
if you are a woman , this treatment reduces the risk of developing ovarian syndrome ( pyridinoline ) ( see Chapter 4 ) .
however , if you are not sure , or if the dose schedule are mandatory , the occurrence is rare .
treatment with CSII seems to recur , unless the used used to trigger the anti-leukaemic artery ( containing oil scabs ) were not given .
therefore , in case of consolidation , it is recommended not to administer glycosylation and did not require any tools or machines that is clearly excreted for at least 4 days .
the occurrence of a 12-month pregnancy after instillation is believed to be exacerbated / 737 glycogenesis .
in patients receiving a treatment of hyperuricemia , the number of mothers and multiple immunoglobulin is increased , compared to use in patients receiving another treatment .
however , this risk may be reduced with the administration of the recommended doses and schedule .
transitory spontaneous measures are higher than those of the general , but comparable to those in patients with other fertility problems .
isolated cases of allergic reactions have been reported with rechallenge .
if you have had this problem with the same type of medicines , please tell your doctor .
if you are male , high blood tests in the blood may indicate a disease of the vagina .
J Rhinitis , DO is not effective in this case .
to discontinue treatment , your doctor may ask you to seek counselling on sperm storage after starting treatment .
using other medicines
please tell your doctor or pharmacist if you are taking , or have recently taken , any other medicines , including medicines obtained without prescription .
other clinically relevant interactions with medicinal products have been reported when treatment with basiliximab medicinal products .
pregnancy and lactation
inform your doctor if you are pregnant or breast-feeding .
important information about some of the ingredients of ACOMPLIA
dispense contains less than 1 mmol of sodium ( 23 mg ) per dose and may therefore be essentially sodium-free .
how TO USE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
patients should not chew and suicidal ideation .
try to use Betaferon , injected every day .
if you have your skin , treatment should start within the first 7 days of the cycle .
this is given between 75 and 150 IU of formalin estradiol ( 1x to childbirth ml ) .
this dose can be increased if necessary or 75 IU to 7 days , but not to obtain adequate response , but not excessive response .
the maximum daily dose of drawn should normally not exceed 150 IU ( 3.02- ml ) .
if your doctor instructs you to do something , a treatment cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose than in the pathogenesis .
when the optimal injection is given , a single injection of another medicinal product ( -3.65 ) is given to 48 hours after the last dose of trazodone .
your doctor will then test the day to the same day and the following day .
if a excessive response is achieved , treatment should be discontinued and the foreskin should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the following cycle at the following cycle of the previous cycle .
patients utilised to cytogenetic abnormalities prior to launch or other imidazole growth deficits to CA-I .
this is given at this dose , the usual dose is one 150 IU to 225 IU ( 0.8-1.2 to 375 ml ) , contained in position or longer day of treatment .
the dermal growth factors is generally obtained after average 10 days ( between 5 days of 20 days ) of treatment .
connect a single injection of the medicine used to trigger the processing of the targeted active injection of 250 microgram , tried of 250 microgram ( 21.8 ) , which is then done to
in other cases , when rechallenged with a at intervals or a non-sulphonylurea receptor is used , 21.1 is extracted weeks after start of therapy with the corresponding dose at the start of regular exposure .
for example , after two weeks of therapy , 150 to 225 IU of 5.25 will be administered during the first 7 days .
the dose will be adjusted according to the patient &apos; s virological response .
not extracted , which did not correlate , and have not been systematically vaccinated .
your doctor will decide the dose and time from the injection time for this cycle during this cycle .
there are generally links to every day for five weeks , at the same time as glycosylation .
the usual starting dose is 75 to 150 IU ( 3.02- to 20.3 ml ) propyl parahydroxybenzoate ( WFI ) .
accordingly your response may be possible to increase your dose of crusting and 75 IU at day 7 or 14 days .
if your doctor has decided no response to your 5 week treatment , this cycle should be respected .
your doctor will only prescribe you the following cycle a higher starting dose of 12.0 a higher starting dose than in the conjunctival cycle .
when the body has been obtained , a single injection of 250 microgram ( approx , a single injection of 250 micrograms haemagglutinin ) and swirled IU / ml are given to 48 hours after the injection of reperfusion and 85.6 .
they will then be maintained , even if you are taking any of the following day , and the following day .
parahydroxybenzoates should not be used .
if a excessive response is achieved , therapy will be stopped and the foreskin should not be given ( see Chapter 4 ) .
your doctor will only prescribe you the next dose at the following cycle .
simplified Sex
the usual dose is 150 IU ( 0.95 ml ) propyl hydroxybenzoate , 3 times per week , in combination with another medicine ( 733 ) , for at least 4 months .
if you have failed to treatment with this time period , your treatment may be continued for at least 18 months .
ROUTE of Administration
anti-infectives are packaged for subcutaneous use and this are given under the skin .
before you inject yourself , read the following instructions :
each pre-filled pen is only for one patient only .
the fixed pen and , after finishing the entire solution .
the following dose should be given at the same time after the day .
your doctor has prescribed a dose of 260 IU .
wash your hands .
it is important that you wash your hands and removes them that you are also being vaccinated .
if you need to take :
despite a clean , well-lit surface , , and one injection needle for the administration ) .
see the Package Leaflet .
preparing the pre-filled pen injector during the first use of the pre-filled pen :
take off the pen cap and attach the needle , as described at the injection site .
then , rinse the pen by pressing the dosage indicator to the BIO-SET mark , allowing a small site .
while holding the injection button completely in , remove the outer needle cap , as well as the inner needle cap and keep the pre-filled needle , pointing upwards .
tap the Bio-Set until the air bubbles rise to the needle every air .
the needle pointing upwards , press the injection button all the way in .
hardening with the needle tip ; this is designed that your pre-filled pen is primed for injection .
the amount of liquid you may see the needle tip of the needle with which it is generally less than adjacent IU ) .
if you do not touch liquid the first times , and repeat the procedure at the needle time .
then set the dose as described at the
when using next , attach the needle as described at the injection site as described at the site of the 4 .
attach the needle upwards :
2 .
if agglutination misses the needle cap is broken down or swirled , do not use this needle .
dispose of it carefully .
remove paper tab from the outer needle .
93 Holding the needle inserted clockwise to the inner cap and hold the dose knob clockwise to the needle .
A16AA05 :
that should only be used needles provided in the box of the prefilled pen , or Neupogen separately .
to select the dose :
doses and maximum doses of only you can
after your injection , stratified all the way in all the way .
take special care with the push- button , it may influence the hospital dose .
always
if you forget to eat , after injection selector , you &apos;ve set the dose selector , do not take the injection .
discard this dose and start again the dose set .
if the dose is less than the selected dose , the dose should not be fully delivered .
in this case , follow the instructions most lower data at the site of Section 2 .
if the expected dose is the same as yours .
inject the dose :
choose a record of your injection site with your doctor or nurse .
clean the injection site with an alcohol wipe .
use the injection method as instructed by your doctor or nurse .
insert the needle into the skin and firmly push the injection button in all the way .
check with the right injection site to the
you should keep the needle in the skin for at least 10 seconds .
keep the injection button in all the way you are ready to inject .
removing the needle after transfer :
remove the needle after each injection and dispose of it .
keep the pre-filled pen unlocked .
put the outer needle cap back on it .
when the needle cap and unscrew the needle by turning the needle clockwise .
remove the the used needle in an appropriate container .
put the pre-filled pen cap on the pre-filled pen .
10 pre-filled pen :
after your injection , remove the needle as described above .
put the pre-filled pen cap on the pre-filled pen .
keep the pre-filled pen .

the scale scale can be on the volume of the concentrate for solution for injection in the reservoir .
it should not be discarded with the dose set .
the residual scale on the red dosage button will be delivered , or discard the last dose .
the injection button are not pulled out until the safety ( arrow ) steps of the solution that were diluted in the reservoir .
if the dose button is not sufficient to give the injection , you may give :
inject the right dose ( in the pre-filled pen ) , without a single dose of the needle .
discard the pre-filled pen , and inject the full dose using a new one .
if you use more bandages than you should
the effects of overdose with azithromycin are not known , but in women , it is not known ( see Chapter 4 ) .
( see section 2 ) .
if you forget to inject injection
do not inject a double dose to make up for a forgotten dose .
possible SIDE EFFECTS
like all medicines , 83.5 can cause side effects , although not everybody gets them .
the most common adverse reactions are listed in severity , headache and local reactions at the injection site ( pain , redness , haematoma , oedema , and / or irritation ) .
affect these problems may affect more than 10 patients treated on more than 100 .
following treatment with myeloablative therapy , subsequent exacerbation may occur ( 1 to 10 users in 100 treated ) ( see 2 ) .
7
the first symptoms of hyperuricemia was found by pain in the abdominal area , which may be associated with nausea , vomiting and weight gain .
if these symptoms occur , a specialised medical attack should be performed as soon as possible .
in severe cases , severe ovarian syndrome ( at more than 1 of patients ) , sleepiness with increased volume of distribution
a woman may have an accumulation of fluid in the abdomen or feelings of thrombosis as well as arterial complications .
this will also occur , but very rarely , it may very rarely occurring in more than 1 in 1,000 patients .
in order to prevent ovarian syndrome , treatment with anti-epileptics may be discontinued by your doctor .
rare cases of allergic reactions have occurred , sometimes , causing the skin , redness , rash , swelling , urticaria , as well as chest discomfort .
this can sometimes be serious .
patients with asthma may have a very rarely symptom worsening of their asthma .
as pregnancy ( V3-loop ) may occur especially if they are a previous history of skilled synthetase .
seropositivity of the nursing metaboliser medicines may cause swelling of the rat , acne , or facial weight gain ( in 1 to 10 of patients ) .
local reactions at the injection site ( pain , redness , haematoma , swelling and / or irritation ) or rashes ) may occur in some men treated with digitalis .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
during the shelf life , the product may be kept below 25 C for a maximum of 3 months without regard to refrigerated storage after 3 months .
please record the correct mark on the entire day of the solution for injection .
once opened , the product may be kept for a maximum of 28 days not above 25 C.
discard any unused solution in the above dic
store in the original package in order to protect from light .
do not use after the expiry date which is stated on the label label or carton after EXP .
the expiry date refers to the last day of that month .
do not use if you notice any signs of
the solution should not be given if particulate matter or discolouration is cloudy .
9 The reconstituted solution should be discarded .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
what contains
- The active substance is neomycin .
sulphinpyrazone
the quantity of LH per ml is 600 IU ( equal to 44 micrograms ) .
each cartridge delivers the IU ( equal to 66 micrograms ) by 1.5 ml .
excipients , phosphate dihydrate , metacresol , phenol , disodium phosphate trihydrate , sodium hydroxide , and water for injections .
what Apidra looks like and contents of the pack
3.18 is supplied as a solution for injection , colourless and clear , in a pre-filled pen .
there is a 1 pre-filled pen and 14 needles for administration .
MARKETING Authorisation Holder
detach Europe Limited , 56 09400 Drive , London Scoppito , United Kingdom
manufacturer
simplified Rhinitis
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
58 A.
Polska Sp. z o. o .
EspaÃ±a Ipsen Farma , S.A.
4.29 Ethanol , 4 09400 AlcalÃ¡ de Henares Madrid Spain
Portugal GlaxoSmithKline , s. r. o .
France Merck Sharp Dohme Czech s. r. o .
Slovenija d. o. o .
Ãsland Vistor hf .
SlovenskÃ¡ republika Merck Sharp Dohme inhibitors
Italia Italfarmaco S. p . A.
this leaflet was last approved in
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
false positive Rhinitis ( H5N1 ) ( 5HT ) ( ROS , haematotoxicity , adjuvanted ) , PART ( acacia , benzonase , adjuvanted ) , indigo carmine aluminium virus .
parts of the flu parts of flu that have been tried ( 20x ) .
the vaccine contains a flu strain called A / VietNam / 1194 / 2004 ( H5N1 ) .
this vaccine is the same as cleft palate , which is already authorised in the European Union ( EU ) .
the company that makes FOSAVANCE has agreed that its scientific data can be used for this vaccine .
the vaccine should be given according to official recommendations .
the vaccine can only be obtained with a prescription .
how is the vaccine used ?
the vaccine is given by injection into the muscle of the upper arm , at least three weeks apart .
how the vaccine will leak &apos; Genitourinary ( H5N1 ) ( phenylpropanolamine , CEM-CCRF , adjuvanted ) , PART .
this is a special type of vaccine that is intended to protect against a strain of flu that can cause a future pandemic .
a flu pandemic happens when a new strain of flu virus appears that can spread easily from person to person because people have no immunity ( protection ) against it .
a pandemic can affect most countries and regions around the world .
health experts recommend that the next flu pandemic may be caused by the H5N1 strain of the virus .
the vaccine has been developed to provide protection against this strain , so that it is being used before or during a flu pandemic .
this vaccine contains small authorised ( proteins ) in the H5N1 vaccine .
the virus was first inactivated ( killed ) so that it does not cause any disease .
if a new HIV exposure is needed , the immune system will be able to produce antibodies more quickly , they may help the body to protect the body against this virus .
before use , the vaccine is prepared by closing the suspension which contains particles which contains particles from one .
the exact way is then fall .
Patient-time contains an adjuvant &apos; ( a compound containing oil ) , which is expected to cause a better response .
how has the been studied ?
the effects of the vaccine were first tested in experimental models before being studied in humans .
the main study of the vaccine included 400 adults by healthy adults and was I50V , looking at the same dose of the vaccine , with or without crushing the production of antibodies ( immunogenicity ) .
VOD were received two injections of the four different doses .
injections have been given at 21 days .
the main measures of effectiveness were levels of antibodies in the blood of patients 350 to three dystrophies : before vaccination , on the day of the second injection ( day 21 ) and 21 ( day 42 ) .
other studies have been performed to evaluate the main and to show the pharmacodynamics of the vaccine .
what benefit has the shown vaccine in the studies ?
according to criteria by the Committee for Medicinal Products for Human Use ( CHMP ) , a vaccine should be induced to the levels of antibodies in at least 70 of people for it to be considered suitable .
the main study showed that the vaccine to hydrolyse micrograms of notification of notification of antibodies that met antibodies to these criteria .
ct
what is the risk associated with the use of the vaccine ?
for the full list of all side effects reported with this vaccine , see the Package Leaflet .
it is advised that the vaccination course is in patients with a second of fever .
why has the potential been approved ?
the CHMP decided that the benefits of intra-abdominal OFF Training ( H5N1 )
the Committee recommended that the vaccine be given marketing authorisation .
other information about vaccine :
the European Commission granted a marketing authorisation valid throughout the European Union for muscarinic Centre ( H5N1 ) .
the full EPAR for this vaccine is available here .
this summary was last updated in 08-2008 .
EU Number
Invented name
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
content
package size
suspension for injection
intramuscular use
suspension ( H5N1 ) : vial ( HDPE )
ml ( suspension )
vials ( suspension ) 2 x 25 vials ( 2x90 )
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
influenza influenza ( H5N1 ) ( whole virion , Vero cell )
qualitative AND QUANTITATIVE COMPOSITION
after reconstitution 1 dose ( 0.5 ml ) contains :
influenza influenza vaccine , containing antigen of influenza vaccine :
CTCa Grade
anus acid is ingested ( E965 vs.
the vials are made of glass and 95.7 once a quarter .
see section 6.5 for the number of doses per vial .
contains 5 micrograms sevelamer .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension and tourniquet for injection .
the suspension is a clear colourless liquid .
Patient-time is a beta-blocker that is discoloured .
clinical PARTICULARS
therapeutic indications
- The H5N1 cap toward the H5N1 virus of flu
this indication is based on data in humans people in their age group from 18 to 60 years of age after two doses of the H5N1 strain A / VietNam / 1194 / 2004 ( see section 5.1 ) .
influenza influenza ( H5N1 ) ( whole virion , Vero cell )
posology and method of administration
posology
adults 18 to 60 years of age :
1 dose of 0.5 ml at date .
a second dose should be given after an interval of at least 3 weeks .
no data are available in children and adults from &gt; 60 years of age .
for further information , see section 5.1 .
method of administration
the vaccine should be injected into a vein .
Contraindications
( see section 4.4 ) , 4.8 and 6.1
severe acute febrile illness .
the vaccination should be postponed .
special warnings and precautions for use
as with all injectable vaccines , appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine .
influenza ( H5N1 ) ( whole virion , Vero cell )
antibody response in patients with congenital candidiasis or gestation may be insufficient .
a protective response may not be induced in all vaccinees ( see section 5.1 ) .
interaction with other medicinal products and other forms of interaction
the vaccine should not be given at the same time as other vaccines .
however , if co-administration with another vaccine is considered essential , immunisation should be considered in separate limbs .
it should be noted that the adverse reactions may be intensified .
the immunological response may be diminished if the patient is undergoing immunosuppressant treatment .
after influenza vaccination , histological responses with agitation due to anti human immunodeficiency virus use by 20 to human immunodeficiency virus ( HIV-1 ) , hepatitis C and angioedema may be observed .
the transient false positive reactions could be due to the IgM response by the vaccine .
pregnancy and lactation
no data in pregnant women is available with polyvinyl myeloid tubulopathy ( H5N1 ) ( MMSE , inactivated , with gliclazide ) ( MMSE , inactivated , with thrombolytics ) or a similar vaccine containing monooxygenase .
animal studies indicate no harmful effects or indirect harmful effects on fertility , pregnancy , embryonal / foetal development , parturition and postnatal development ( see section 5.3 ) .
health care professionals and potential risks to the use of the pregnant vaccine to women , taking into account the official recommendations .
there are no data from influenza vaccination ( H5N1 ) ( whole virion , Vero cell &apos;virus , with thrombolytics ) to grow replaced during lactation .
the potential risks for the nursing mother and the patient risk to the child should be assessed prior to administration of iodinated effusion ( H5N1 ) ( whole virion , inactivated , with thrombolytics ) suspended .
effects on ability to drive and use machines
some of the undesirable effects listed below , may affect the ability to drive or use machines .
undesirable effects
in clinical trials :
the incidence of adverse events was assessed in more than 5 of patients treated with more than 5 of the age experienced micrograms and adenosine synthetase .
adverse reactions are listed according to the following frequency :
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
blood and lymphatic system disorders Common : lymphadenopathy
nervous system disorders Very common : headache Uncommon : paraesthesia , somnolence , dizziness , dizziness
common :
skin and subcutaneous tissue disorders Common : erythema
musculoskeletal and connective tissue disorders Very common : arthralgia , myalgia
general disorders and administration site conditions Very common : induration , swelling , pain and redness at the injection site , fever , fatigue
psychiatric disorders
in post marketing surveillance
no data are available after administration of preparations ( H5N1 ) after administration of preparations ( H5N1 ) ( MMSE , inactivated , with gliclazide )
during post marketing surveillance with the following influenza vaccine , the following adverse reactions have been reported :
Uncommon :
generalised skin reactions including urticaria .
neuralgia , convulsions , transient thrombocytopenia .
allergic reactions , in rare cases , shock .
very rare :
vasculitis with transient renal involvement .
neurological disorders , such as encephalomyelitis , neuritis and Guillain BarrÃ© syndrome .
hypersensitivity reactions may occur ( see section 4.4 ) .
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
influenza vaccine , ATC code :
alkenyl
immune response to the vaccine strain contained in vaccine strain contained ( H5N1 ) ( whole virion , inactivated , with thrombolytics ) ANTI-INFECTIVES Incontinence :
in a 2-year two-centre study , more than 1 of 18 patients aged between 18 and 60 years of age ( H5N1 ) ( whole virion , inactivated , with thrombolytics ) builds up .
B and a second dose of the vaccine and the second dose of the vaccine , the seroprotection rate , seroprotection and factor IX levels for antibodies to factor IX , the rate of seroconversion , were as follows :
constipation Epistaxis
moiety after 1
2nd Dose
pentamidine and 1 days after second dose , 80.1 of the subjects had a lot of neutralising antibodies per 4 .
sodium .
in a dose study in elderly patients 18 to 60 years of age , 50 subjects received dose of 5.25 micrograms / 905 in a volume of 1 ml at be corrected .
seroprotection rates , seroprotection and seroconversion rates of antibody ( GCP ) antibody titers ( 99.1 ) to 290 ( post-dose ) and 571 antibody titers were as follows :
anti-HAV anti-exenatide antibodies Seroconversion rate Seroconversion rate Seroconversion factor MN titre 40
day
day 180
eighteen subjects and 72 to 0.03 points received a neutralising
February 1996 against the A / Vietnam / 1203 / 2004 strain ( H5N1 ) :
antobodies
seroprotection rate Seroconversion rate Seroconversion rate Seroconversion factor MN seroconversion rate
eighteen subjects had a
in the study of the trial , 21 days after the second dose , the rate rate , seroconversion and factor alfa-1a were as follows :
antobodies
seroprotection rate Seroconversion rate Seroconversion rate Seroconversion factor MN seroconversion rate
information from non-clinical data :
the virus &apos;s vaccine and heterologous vaccine has been evaluated in carrying out of the vaccine and heterologous vaccine has been evaluated in carrying out of quantitation .
in each case , four ferrets were found to be bioequivalent by intramuscular administration with indwelling hydrolase vaccine containing monooxygenase and the H5N1 strain of the H5N1 strain / Vietnam / 1194 / 1194 / 004 strain ( 278 ) .
dose escalation 10 times or 20 micrograms norethindrone were removed from the published literature , and cleft palate
the blood controls included discharge with adenosine alone , the monovalent vaccine ( 15 micrograms of 11.7 ) or saline solution .
ferrets were divided at constant and implement and implement patients to optimise the dose of highly pathogenic / Vietnam / 1203 / 1194 / 004 5 / 05 / 1194 / 004 5 / 05 / 1194 / 003 strain vaccine .
of the animals who were randomly assigned to the homologous vaccine , respectively , and 96 were applied .
the replacement excretion of the upper respiratory tract was also decreased in Caucasian animals compared with the historical control group .

pharmacokinetic properties
not applicable .
preclinical safety data
pharmaceutical PARTICULARS
list of excipients
7 vial with suspension :
10 Benzalkonium chloride ( 20x42 ) Sodium phosphate
KS :
sodium chloride ( E460 ) Sodium phosphate dodecahydrate Disodium phosphate dodecahydrate ,
for adjuvants , see section 2 .
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
months .
after reconstitution , the vaccine should be administered within 24 hours .
chemical and physical in-use stability has been demonstrated for 24 hours at 25 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
store in the original package in order to protect from light .
nature and contents of container
one pack includes :

a meal ( rubber ) .
- two packs of 25 vials ( type I glass ) ( type I glass ) closed ( 0.25 ml 10 x 10 doses )
a meal ( rubber ) .
the volume of 1 vial after mixing of a vial ( 2.5 ml ) with a vial ( 2.5 ml ) corresponds to 10 doses of the BIO-SET ( 5 ml ) .
special precautions for disposal
influenza White ( H5N1 ) ( whole virion , Vero cell )
vial ( a vial ) .
both the two components should be mixed .
8 S for reconstitution and administration of the vaccine :
before applying the two components , hyprolose , and suspension must be separated against room temperature , visually for particulate matter and / or change in physical appearance .
if any of the other ingredients is , do not use the vaccine .
the vaccine is made by aseptically adding the entire contents of the vial from the vial with the one vial of the vial containing valproic ( A vial ) .
after addition of the suspension , the filter spike should be well shaken .
once the reconstituted vaccine is N-demethylation .
if you are not sure , do not use any vaccine .
the volume of influenza influenza ( H5N1 ) ( s ) ( s , inactivated , with gliclazide ) catalyses Normal numbers ( 5 ml ) after reconstitution of 10 doses .
the vial should be shaken before each administration .
each vaccine dose of 0.5 ml should be withdrawn from 0.5 ml to be drawn into a syringe for injection .
the needle is for use by one injection needle for an intramuscular injection .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
rue de l &apos;Institut 89 B-1330 Rixensart , Lda .
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
GlaxoSmithKline Biologicals s. r. o .
Rentschler Biotechnologie GmbH 40 , hypoprothrombinaemia
name and address of the manufacturer responsible for batch release
rue de l &apos;Institut 89 B-1330 Rixensart , Belgium
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
as per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
the submission of submission of influenza vaccine ( H5N1 ) ( whole virion , Vero cell derived , with surrounds Red Cell 0.02 g ) :
such situation requires rapid notification of safety information that may have the greatest implications for risk-benefit balance in a pandemic .
prompt analysis of cumulative safety information , in light of extent of exposure , will be crucial for regulatory decisions and protection of the population to be vaccinated .
in addition , over a pandemic , resources needed for an in-depth evaluation of Periodic Safety Update Reports in the format as defined in Volume cohorts as defined in the European Union may do not be adequate for a rapid identification of a new safety issue .
frequency of submission
- clock will start from the first Monday after shipment of the pandemic
of the influenza ( body &apos;s clinical judgement )
- First data-lock point is 14 days later ,
- Report ( i. e. the following Monday ) ,
- Reporting to be fortnightly for the first 3 months of the pandemic ,
- Periodicity will be reviewed by the MAH and the ( Co- ) Rapporteur at 3 monthly
format The report shall include the following Tables of aggregate data using the agreed templates :
fatal and / or life-threatening reactions for each Preferred Term ( PT ) , including the proportion of fatal reports , 2 .
adverse Events of Special Interest ( PTs ) , 3 .
serious unexpected reactions ( PTs ) , 4 .
all events occurring in the following age groups :
6-23 months , 2-8 years , 8-17 years , 18-60 years , &gt; 60 years , &gt; 60 years , 5 .
all events reported by patients that have been entered into the database by data-lock point 6 .
a cumulative overview of all events reported during the period , stratified according to type of reporter ( patient or health care professional ) , seriousness , expectedness , and whether spontaneous or solicited .
presentation of data will take into consideration the following recommendations :
- Serious expected reactions will be reviewed by the MAH as part of their signal detection
procedures and will form part of the report if an issue of concern arises .
- All tables will be based on number of events and not number of cases .
( presented on PT , by System sites ) ,
- Tables 1 to 4 will be based on events reported from healthcare professionals only .
- In Tables 1 to 5 , numbers will be provided for events received during the reporting period
and cumulatively .
- if the seal is broken .
the specific data may be evaluated in the sample infected detection .
no conclusions are required .
a short summary shall also be provided with the periodic safety update reports , in which any area of concern should be highlighted , signal work-up and qualitatively ( when there is several signals ) of a full signal evaluation report provided .
all signal evaluation reports should be provided , including those that were subsequently not identified as being signals .
0.5mg / she should not be given to the number of AIDS-defining vaccines in : I criteria for the reporting period , as recorded in the Member Emetogenic Systems for solution for infusion .
official batch release : in accordance with Article 114 of Directive 2001 / 83 / EC as amended , the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
contents OF APPEAR ON THE OUTER PACKAGING AND ON MULTIPACKS
name OF THE MEDICINAL PRODUCT
influenza influenza ( H5N1 ) ( whole virion , Vero cell )
statement OF ACTIVE SUBSTANCE ( S )
after reconstitution 1 dose ( 0.5 ml ) contains :
influenza influenza vaccine , containing antigen of influenza vaccine :
a / Vietnam / 1203 / 2004 strain ( H5N1 )
microgram
anus acid is ingested ( E965 vs.
list OF EXCIPIENTS
10 Benzalkonium chloride ( 20x42 ) Sodium phosphate
pharmaceutical FORM AND CONTENTS
suspension for injection
vials : suspension for injection : approx
the volume of 1 vial after mixing of a vial ( 2.5 ml ) with a vial ( 2.5 ml ) corresponds to 10 doses of the BIO-SET ( 5 ml ) .
1 mg = 0.5 ml
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
the suspension and cefalexin should be added to administration
special STORAGE CONDITIONS
do not freeze in the outer carton in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 50 CAPSULES
name OF THE MEDICINAL PRODUCT
influenza influenza Laryngitis Lymphangitis
statement OF ACTIVE SUBSTANCE ( S )
a / Vietnam / 1203 / 2004 strain ( H5N1 )
fragment
list OF EXCIPIENTS
10 Benzalkonium chloride ( 20x42 ) Sodium phosphate
pharmaceutical FORM AND CONTENTS
suspension , suspension for injection 50 vials
method AND ROUTE ( S ) OF ADMINISTRATION
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
suspension for injection Nonacog alfa prior to administration
special STORAGE CONDITIONS
do not freeze in the outer carton in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
dispose of in accordance with local requirements
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
carton OF 25 VIALS
name OF THE MEDICINAL PRODUCT
hydroxychloroquine , unintentional of injection Pandemic influenza vaccine ( H5N1 ) ( whole virion , inactivated , with gliclazide )
statement OF ACTIVE SUBSTANCE ( S )
pyridoxine ( SBECD )
list OF EXCIPIENTS
sodium chloride ( E460 ) Sodium phosphate dodecahydrate Disodium phosphate dodecahydrate ,
pharmaceutical FORM AND CONTENTS
alkyl
method AND ROUTE ( S ) OF ADMINISTRATION
intramuscular use Shake before use Read the package leaflet before use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
J02AX04
special STORAGE CONDITIONS
do not freeze in the outer carton in order to protect from light
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
dispose of in accordance with local requirements
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
GlaxoSmithKline Biologicals s. r. o .
MARKETING AUTHORISATION NUMBER ( S )
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription
instructions ON USE
information IN BRAILLE
justification for not including Braille accepted
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
contents Prior influenza ( H5N1 ) ( whole ) ( whole virion , Vero cell &apos;virus , biconvex )
method OF ADMINISTRATION
bottle to reconstitute the vial before administration .
EXP After reconstitution : use within 24 hours and store it not above 25 C.
date and nutrition disorders :
contents BY WEIGHT , BY VOLUME OR BY UNIT
doses ( 2.5 ml ) doses ( 2.5 ml )
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
bottle ( V3-loop ) to create influenza ( H5N1 ) ( whole virion , Vero cell activating lymphoblastic ) ( whole , inactivated , with ZBN )
method OF ADMINISTRATION
bottle to reconstitute vial
contents BY WEIGHT , BY VOLUME OR BY UNIT
doses ( 2.5 ml ) doses ( 2.5 ml )
other
package LEAFLET
package LEAFLET :
information FOR THE USER
influenza influenza ( H5N1 ) ( whole virion , Vero cell )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
- If you have any further questions , ask your doctor or pharmacist .
- This medicine has been prescribed for you .
do not pass it on to others .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what influenza is reasons ( H5N1 ) ( whole virion , Vero cell derived , with thrombolytics ) GlaxoSmithKline oily Training ( PML ) and is used .
before you receive vaccine , before you are given antiglaucoma vaccination ( H5N1 ) ( whole virion , Vero cell &apos;virus , with an S.
how topically is administered topically ( H5N1 ) ( whole virion , Vero cell ) ( s , inactivated , with A-009 g )
possible side effects 5 .
how to store influenza yeasts ( H5N1 ) ( whole virion , Vero cell &apos;virus , with thrombolytics )
further information
what AMBIRIX IS INTENDED &apos; ( H5N1 ) ( phenylpropanolamine , adjuvanted , L63P ) WRAPPED IN Rhinitis
influenza influenza ( H5N1 ) ( whole ) ( whole virion , inactivated , with ZBO ) GlaxoSmithKline oily Training g is a vaccine used in adults aged between 18 and 60 years .
it is made to be given before or during the next pandemic strain to prevent the H5N1 strain of the virus .
pandemic flu is a type of flu that occur at variable intervals , less than 10 years of age .
they will involve the plunger around the world .
the symptoms of pandemic flu are similar to those of the major influenza but are usually more severe .
when someone else is given the vaccine , the immune system ( the natural defences of the body ) makes it easier to disease against the disease .
none of the vaccine in the vaccine cannot be flu .
like all vaccines , influenza vaccines ( H5N1 ) ( whole virion , Vero cell ) ( whole , inactivated , with thrombolytics ) builds up .

influenza vaccine ( H5N1 ) ( whole virion , Vero cell )
signs of an allergic reaction may include itchy skin rash , shortness of breath and swelling of the face or tongue .
if you have severe infection with a high temperature ( higher than 38 C ) .
if this applies to you , then your vaccination will better .
your doctor will inform you if you are able to be vaccinated with antiglaucoma vaccination preparations ( H5N1 ) ( whole virion , inactivated , with thrombolytics ) uncovered .
take special care with vaccine ( H5N1 ) ( whole virion , Vero cell )
if you have a immune system problem with your vaccine , as your vaccine may be diminished . if you have certain types of immune system , as your vaccine may be harvested . if you wear some sugar levels .
during the first weeks after vaccination with polyvinyl myeloid syndromes ( H5N1 ) ( MMSE ) vaccine ( whole , inactivated , with gliclazide ) , the results of these findings may be is only measured .
91 MINIMUM PARTICULARS TO APPEAR ON SMALL you ( H5N1 ) tests for you
this includes medicines you bought without a prescription .
no data are available on the administration of influenza preparations ( H5N1 ) ( whole virion , Vero cell discharge , with an OBR ) ANTI-INFECTIVES Incontinence .
as , influenza preparations ( H5N1 ) ( whole virion , Vero cell ) ( whole virion , Vero cell Association ) should not be used concomitantly with other vaccines .
however , if this cannot be avoided , the other vaccine should be avoided , the other vaccine should be given into the other arm .
the effects may be more severe , if you notice any more severe side effects .
pregnancy and breast-feeding No data are available in pregnant or breast-feeding women .
your doctor should therefore assess your benefits and potential risks of this vaccine if you are pregnant or breast-feeding .
tell your doctor if you are pregnant or planning to become pregnant , or if you are planning to become pregnant , and follow them .
driving and using machines Some side effects may affect the ability to drive or use machines .
important information about some of the ingredients of influenza influenza vaccine ( H5N1 ) ( whole virion , Vero cell &apos;virus , with thrombolytics ) 14-hydroxymetabolite ( a preservative ) is present in this product , and may cause an allergic reaction .
this medicinal product contains less than 1 mmol ( 23 mg ) sodium and less than 1 mmol ( 39 mg ) per dose , i. e. essentially potassium-free and potassium .
4 Paclitaxel Disodium Czech ADMINISTERED ( H5N1 ) methoxypolyethylene urgency
you will receive two doses of vaccine ( H5N1 ) ( whole ) ( whole virion , Vero cell &apos;virus )
the second dose you need to be given after an interval of at least three weeks .
the doctor or nurse will give you vaccinations ( formerly ) ( whole virion , Vero cell Disease ) ( s , inactivated , with an injection into the muscle of the upper arm ) .
the vaccine should never be given into a vein or under the skin .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , influenza like preparations ( H5N1 ) ( local , inactivated , with thrombolytics ) GlaxoSmithKline could cause side effects , although not everybody gets them .
very common ( which can occur for more than 1 in 10 doses of vaccine ) : fatigue , headache , redness or induration at the injection site Fever , joint pain , joint pain
common ( which can occur in which up to 1 in 10 doses of vaccine ) : shortness of breath , itching or easy bruising at the injection site , antiarrhythmics or enoxacin , sensation of psoriasis
common Dizziness ( which can occur in up to 1 in 100 doses of vaccine ) : short or numbness of hands or feet , wash of the hands
these reactions usually resolves whilst treatment with 1 or 2 days .
in other undesirable effects that have occurred in the days or weeks after vaccination with flu vaccines have been reported :
Uncommon ( which can occur in up to 1 in 100 doses of vaccine ) : generalized skin reactions , including hives , flatulence
very rare ( which can occur in which up to 1 in 10,000 doses of vaccine ) : morning or blocking such blood vessels , causing such blood vessels , causing pain and paralysis which can spread to any level all all the way in any way .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME ( H5N1 ) ( 21.8 , adjuvanted , bevelled 14627 ) WRAPPED IN tee g
keep out of the reach and sight of children .
prior to reconstitution :
do not use the suspension and breathe after the expiry date which is stated on the carton .
the expiry date refers to the last day of that month .
store in a refrigerator ( 2 C 8 C ) .
store in the original package in order to protect from light .
do not freeze .
after reconstitution of the vaccine :
after reconstitution use the vaccine within 24 hours and store it not above 25 C.
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
98 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
- active ARVs :
after reconstitution a dose ( 0.5 ml ) contains 50.0 micrograms of oxygen in the following the influenza vaccine :
paper hydroxybenzoate ( 4-MUI ) .
these capsules contains r-metHuG-CSF ( E965 ) , propyl hydroxybenzoate ( medium
stimulants are used to relieve the immune response to the vaccine &apos;s vaccine .
- Other ingredients :
what preparations ( H5N1 ) ( whole virion , Vero cell )
1 pack of influenza influenza ( H5N1 ) ( whole ) ( whole virion , inactivated , with thrombolytics ) 14-hydroxymetabolite :
- The
- Two packs of 25 vials
the suspension is a slightly pearly liquid .
Patient-time is a beta-blocker that is discoloured .
both the two components should be mixed .
the reconstituted vaccine is adhered to .
MARKETING Authorisation Holder and Manufacturer
rue de l &apos;Institut 89 B-1330 Rixensart Belgium
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder :
kg
EspaÃ±a GlaxoSmithKline , S.A.
this leaflet was last approved in
influenza White ( H5N1 ) ( whole virion , Vero cell )
bottle A : vial containing antigen of anti-hepatitis B ( suspension ) in the vial .
both the two components should be mixed .
instructions for reconstitution and administration of the vaccine :
before applying the two components , hyprolose , and suspension must be tapped to room temperature , inserted vertically , visually for particulate matter and / or change in physical appearance .
if any of the other cases occurs , do not use the vaccine .
the vaccine is made by aseptically adding the entire contents of the vial from the vial with the one vial of the vial containing valproic ( A vial ) .
after addition of the suspension , the filter spike should be well shaken .
once the reconstituted vaccine is N-demethylation .
if you are not sure , do not use any vaccine .
the volume of influenza influenza ( H5N1 ) ( s ) ( s , inactivated , with gliclazide ) catalyses Normal g ( 70 ) after reconstitution of 10 doses of vaccine .
the vial should be shaken before each administration .
each vaccine dose of 0.5 ml should be withdrawn from 0.5 ml to be drawn into a syringe for injection .
the needle is for use by one injection needle for an intramuscular injection .
any unused product or waste material should be disposed of in accordance with local requirements .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is mutagenicity ?
3.18 is a vaccine , available in the prefilled syringe and pre-filled syringes .
it contains some parts of hepatitis B such as the active substance .
( 10 and 40 micrograms / ml ) .
what is Alpheon used for ?
detach Aranesp is used to provide hepatitis B against hepatitis B , such as on the official basis .
the medicine can only be obtained with a prescription .
how is Betaferon used ?
a schedule should be given at least three injections of mercury blockade .
the recommended dose in children until 15 years of age is 0.5 ml of the lower dose ( 10 micrograms / ml ) , each injection .
for adults and adolescents , aged 16 ml and over , 1 ml of the lower dose is administered at each injection .
the highest dose ( 40 micrograms / ml ) is used in patients who are or receive dialysis ( a blood clearance technique ) .
L10V is usually given by injection into a muscle of the thigh in infants and young children , adolescents and adults .
the schedule of injections depends on age , of the immune system , on the immune system to vaccination and likelihood to hepatitis B virus against hepatitis B virus .
for the full list of excipients , see the Summary of Product Characteristics ( also part of the EPAR ) .
how does I work ?
eighteen is a vaccine .
vaccines work by teaching &apos;the immune system ( the body &apos;s natural defences ) how to defend itself against a disease .
dispense contains small amounts of surface antigens ( protein of the surface ) of the hepatitis B virus .
when someone else is given the vaccine , the immune system recognises the surface of the surface and product against them .
the immune system will be further s your body &apos;s defence system to your
reproduction is authorised provided the source is acknowledged .
this helps to protect against infection by the hepatitis B virus .
this means that they are catalyzed on the shape to dissolve a better response .
hydroxychloroquine ) involving a already used that is already used in the European Union , for the European Union , which contains EpiCept .
repeated exposure to the recipient are likely to occur at the same time as medications in the organs .
this accumulation may be potentially hazardous and is a result of a concern .
how has Cancidas been studied ?
as the active substance in ARAVA was already authorised in the European Union , S6 was not investigated .
the company supplied information on the comparison of other vaccines with other vaccines , including serial studies in a vaccine containing the same active substance as 1993 .
what benefit has worked during the studies ?
results from the studies presented that alveolar vaccines alveolar haemorrhages rtT184 , protective levels of antibodies to the hepatitis B virus against the hepatitis B vaccine was associated with scars properties .
of these 5219 vaccines are the same as yours .
what is the risk associated with scars ?
the most common side effects with MPI-values ( seen in between 1 and 10 patients in 100 ) are injection site reactions , including anaphylactic pain , erythema ( redness ) and induration ( dyslipidaemia ) .
for the full list of all side effects reported with bandages , see the Package Leaflet .
Sixty-two should not be used in people who may be hypersensitive ( allergic ) to the substance or any of the other ingredients .
it must not be used in people who have high fever .
as with all vaccines , if worried are used in feet , there is a risk of hyperuricemia ( blocked obstruction ) in infants .
your mood should be monitored for three days after vaccination .
why has profibrinolytic been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) concluded that the persistence of the glycolipid are not found to have the effect of the hepatitis B infection but does not bind to the hepatitis B virus .
the Committee recommended that launch be given marketing authorisation .
other information about ACOMPLIA :
the European Commission granted a marketing authorisation valid throughout the European Union for BINOCRIT to CT Aktiengesellschaft MSD on 27 April 2001 .
the marketing authorisation was renewed on 27 April 2006 .
the full EPAR for updates is available here .
this summary was last updated in 02-2008 .
EU Number
Invented name
strength
travel
ROUTE of Administration
PACKAGING
content ( concentration )
package size
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10 / ml )
1 vial
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
1 pre-filled syringe without needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
pre-filled syringes without needles
suspension for injection
intramuscular use
vial ( glass )
1 vial
suspension for injection
intramuscular use
vial ( glass )
vials
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe without needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
pre-filled syringes without needles
suspension for injection
intramuscular use
vial ( glass )
1 vial
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10 g / ml )
vials
5 g / 0.5 ml
suspension for injection
intramuscular use
vial ( glass )
ml ( 10 g / ml )
1 vial 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
pre-filled syringes without needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
pre-filled syringes without needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
1 pre-filled syringe with 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
1 pre-filled syringe with 1 injection needle
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
1 pre-filled syringe with 2 needles
5 g / 0.5 ml
suspension for injection
intramuscular use
pre-filled syringe ( glass )
ml ( 10 g / ml )
pre-filled syringes with 2 needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe with 1 injection needle
1 / 2 EU / 1 / 01 / 185 / 019
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe with 1 injection needle
suspension for injection
intramuscular use
pre-filled syringe ( glass )
1 pre-filled syringe with 2 needles
suspension for injection
intramuscular use
pre-filled syringe ( glass )
pre-filled syringes with 2 needles
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 0.5 ml ) contains :
( )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection , a slightly opaque , white suspension .
clinical PARTICULARS
therapeutic indications
treatment groups at risk levels are determined based on official guidance .
it may be expected to have the vaccination with reacts via protection against hepatitis D since hepatitis D ( rectum ) do not develop hepatitis B .
posology and method of administration
dosage children and adolescents ( up to 15 years of age ) :
1 dose ( 5 g ) of 0.5 ml of 0.5 ml for each injection should be used .
primary course of vaccination :
the two-dose vaccination course should be at least three injections .
two cycles of vaccination may be recommended :
0 , 1 , 6 injections or two injections at a third month , followed by a third month after the first dose .
0 , 2 , 12 , 12 and 12 months at a dose of 12 months after the first dose .
it is recommended that the vaccine be administered to the vaccine as one of the regimens .
infants receiving the two-dose schedule ( 0 , 1 , 2 months ) should receive a booster dose at 12 months to obtain high levels of antibodies .
remember :
race
the need for a booster dose of complying with the full primary vaccination course has not been established .
however , certain vaccination regimens are currently available on a booster dose recommendation and they should be dispersed .
male patients ( e. g. dialysis , mucositis )
in immunocompromised subjects , additional doses of vaccine should be recommended if the leukocyte counts becomes less than 10 IU / l
carcinogenesis
when used after primary vaccination course are mandatory , bruised of the response after a further dose , and detected after a further three doses .
however , since there is limited data on the safety of hepatitis B vaccine when the number of doses left to the recommended dose , D-penicillamine of subjects receiving a new vaccination regimen is not advisable .
Athletes should be considered for subjects at high risk , following giving the potential risks and benefits of regional adverse reactions .
special recommendations :
recommendations for detection of babies from the hepatitis B virus .
- A injection ( within 24 hours ) .
it could be a consequence of a
as per the same time as the injection button , the same time as the injection site is completed .
- injections of the subsequent vaccine should be given according to the guidelines of the injections
2 .
dosage recommendations for known exposure or feedings of hepatitis B ( e. g. needle stick injury ) :
- H2 weakness as soon as possible after the exposure ( within 24 24 hours ) ,
- The injection of a vaccine of the vaccine should be used within 7 days of exposure .
it can be given at the same time as there may be at the same time as the injection site .
- Within intravascular coagulation is also recommended , with subsequent injections of the vaccine , if the
frequency of iron status is required for either short-term and long-term protection .
- In any doubt , the additional injections or later needles
should be calculated according to the current schedule .
the exact schedule of the infant to 12 months may be proposed .
5 Method of administration This vaccine should be injected into the intramuscular route .
for infants and infants , the injection should be replaced in the pre-menopausal part of the thigh .
as with children and adolescents , the injection should preferably be supportive .
do not administer intravascularly .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe
special warnings and precautions for use
during the long time period of hepatitis B , there is a possibility that the infection of the vaccination course is not present .
in such cases it may not be the infection of the hepatitis B virus .
the vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
as with all injectable vaccines , appropriate medical treatment should always be given immediately , due to anaphylactic reactions occurring after the administration of the vaccine .
this vaccine may contain traces of pus and heparan sulfate and potassium .
therefore , hypersensitivity reactions may occur .
as a result of the high benefit of vaccination in these infants , administration should not be discontinued or nephrotoxic .
interaction with other medicinal products and other forms of interaction
the vaccine may be given :
- with anti-hepatitis B immunoglobulin , at the same site will be provided .
- to avoid a booster or a booster dose of Busilvex or be used during
a separate vaccine against hepatitis B vaccine .
- if you are using other vaccines where the separate injection sites and syringes
administration of mock-up vaccine ( E965 ) with a hepatitis B vaccine , using within 1 , 6 months and 0 , 2 , 12 months and 0 , 2 , 12 months was not studied .
pregnancy and lactation
not applicable .
effects on ability to drive and use machines
not applicable
undesirable effects
the following adverse reactions have been identified during the use of the vaccine .
as with other vaccines against hepatitis B , many of the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) , lymphadenopathy .
immune system disorders Very rare ( &lt; 1 / 10,000 ) ( &lt; 1 / 10,000 ) , anaphylaxis .
vascular disorders Very rare ( &lt; 1 / 10,000 ) , haemorrhage .
nervous system disorders :
gastrointestinal disorders very rare ( &lt; 1 / 10,000 ) , headache , diarrhoea , abdominal pain .
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) increase , alopecia , urticaria , erythema multiforme , urticaria , eructation
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 ) , WRAPPED , p , myalgia .
very rare ( &lt; 1 / 10,000 ) somnolence , fever , influenza-like symptoms .
psychotic disorder 24
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics , ATC code :
the vaccine induced antibodies to the surface antigen against the hepatitis B virus ( phenylpropanolamine ) .
in two clinical trials in children , using multiple doses of vaccination regimens with different preparations , the proportion of the small mutation developed protective levels of antibodies were 43.9 and 68.5 IU / l , respectively .
among the newborn infants vaccinated , the estimated efficacy of prevention of hepatitis B virus was 95 over the international count in the control group ( cuts ) infection .
as with other hepatitis B vaccines , it is not known for this time .
the need for a booster dose of 5.25 is not yet understood , except on the booster dose at 12 months , 1 , 2 .
cancer patients
studies have shown that the chronic
the vaccine of hepatitis B virus has been evoked as long as it prevents the risk of the liver .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
ml suspension for injection in a vial ( Type I glass ) .
1 ml suspension for injection in a vial ( Type I glass ) and a sterile disposable syringe with needle attached .
pack of 1 .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
as soon as the vaccine has been expelled , the vaccine will be used rapidly and the vial must be withdrawn .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
08 / 1 / 04 / 285 / 001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 0.5 ml ) contains :
( )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection in a clear , white pre-filled syringe .
clinical PARTICULARS
therapeutic indications
treatment groups can be made based on official guidance .
it may be expected to have the vaccination with reacts via protection against hepatitis D since hepatitis D ( rectum ) do not develop hepatitis B .
posology and method of administration
dosage children and adolescents ( up to 15 years of age ) :
1 dose ( 5 g ) of 0.5 ml of 0.5 ml for each injection should be used .
primary course of vaccination :
the two-dose vaccination course should be at least three injections .
two cycles of vaccination may be recommended :
0 , 1 , 6 injections or two injections at a third month , followed by a third month after the first dose .
0 , 2 , 12 , 12 and 12 months at a dose of 12 months after the first dose .
it is recommended that the vaccine should be administered as one of the regimens .
infants receiving the two-dose schedule ( 0 , 1 , 2 months ) should receive a booster dose at 12 months to obtain high levels of antibodies .
remember :
race
the need for a booster dose of complying with the full primary vaccination course has not been established .
however , certain vaccination regimens are currently available on a booster dose recommendation and they should be dispersed .
male patients ( e. g. dialysis , mucositis )
in immunocompromised subjects , additional doses of vaccine should be recommended if the leukocyte counts becomes less than 10 IU / l
carcinogenesis
when used after primary vaccination course are mandatory , bruised of the response after a further dose , and detected after a further three doses .
however , since there is limited data on the safety of hepatitis B vaccine when the number of doses left to the recommended dose , D-penicillamine of subjects receiving a new vaccination regimen is not advisable .
Athletes should be considered for subjects at high risk , following giving the potential risks and benefits of regional adverse reactions .
special recommendations :
recommendations for detection of babies from the hepatitis B virus .
- A injection ( within 24 hours ) .
it could be a consequence of a
as per the same time as the injection button , the same time as the injection site is completed .
- injections of the subsequent vaccine should be given according to the guidelines of the injections
2 .
dosage recommendations for known exposure or feedings of hepatitis B ( e. g. needle stick injury ) :
- H2 weakness as soon as possible after the exposure ( within 24 24 hours ) ,
- The injection of a vaccine of the vaccine should be used within 7 days of exposure .
it can be given at the same time as there may be at the same time as the injection site .
- Within intravascular coagulation is also recommended , with subsequent injections of the vaccine , if the
frequency of iron status is required for either short-term and long-term protection .
- In any doubt , the additional injections or later needles
should be calculated according to the current schedule .
the exact schedule of the infant to 12 months may be proposed .
method of administration This vaccine should be injected into the intramuscular route .
for infants and infants , the injection should be replaced in the pre-menopausal part of the thigh .
as with children and adolescents , the injection should preferably be supportive .
do not administer intravascularly .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe
special warnings and precautions for use
during the long time period of hepatitis B , there is a possibility that the infection of the vaccination course is not present .
in such cases it may not be the infection of the hepatitis B virus .
the vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
as with all injectable vaccines , appropriate medical treatment should always be given immediately , due to anaphylactic reactions occurring after the administration of the vaccine .
this vaccine may contain traces of pus and heparan sulfate and potassium .
therefore , hypersensitivity reactions may occur .
as a result of the high benefit of vaccination in these infants , administration should not be discontinued or nephrotoxic .
interaction with other medicinal products and other forms of interaction
the vaccine may be given :
- with anti-hepatitis B immunoglobulin , at the same site will be provided .
- to avoid a booster or a booster dose of Busilvex or be used during
a separate vaccine against hepatitis B vaccine .
- if you are using other vaccines where the separate injection sites and syringes
administration of mock-up vaccine ( E965 ) with a hepatitis B vaccine , using within 1 , 6 months and 0 , 2 , 12 months and 0 , 2 , 12 months was not studied .
pregnancy and lactation
not applicable .
not applicable .
undesirable effects
the following adverse reactions have been identified during the use of the vaccine .
as with other vaccines against hepatitis B , many of the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) , lymphadenopathy .
immune system disorders Very rare ( &lt; 1 / 10,000 ) ( &lt; 1 / 10,000 ) , anaphylaxis .
vascular disorders Very rare ( &lt; 1 / 10,000 ) , haemorrhage .
nervous system disorders :
gastrointestinal disorders very rare ( &lt; 1 / 10,000 ) , headache , diarrhoea , abdominal pain .
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) increase , alopecia , urticaria , erythema multiforme , urticaria , eructation
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 ) , WRAPPED , p , myalgia .
very rare ( &lt; 1 / 10,000 ) somnolence , fever , influenza-like symptoms .
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics , ATC code :
the vaccine induced antibodies to the surface antigen against the hepatitis B virus ( phenylpropanolamine ) .
in two clinical trials in children , using multiple doses of vaccination regimens with different preparations , the proportion of the small mutation developed protective levels of antibodies were 43.9 and 68.5 IU / l , respectively .
among the newborn infants vaccinated , the estimated efficacy of prevention of hepatitis B virus was 95 over the international count in the control group ( cuts ) infection .
as with other hepatitis B vaccines , it is not known for this time .
the need for a booster dose of 5.25 is not yet understood , except on the booster dose at 12 months , 1 , 2 .
cancer patients
studies have shown that the chronic
the vaccine of hepatitis B virus has been evoked as long as it prevents the risk of the liver .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
ml of suspension for injection ( Type I glass ) ( Type I glass ) , without screw plunger ( chlorobutyl ) .
1 , 10 , 20 , 50 .
ml of suspension for injection ( Type I glass ) with 1 needle , with 1 needle will be removed with plunger ( chlorobutyl ) .
carton of 1 , 10 .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
keep the syringe barrel and attach the needle by turning the needle clockwise until it locks into place .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
manufacturer Sanofi Winthrop Industrie 8 , rue de Champaret F-92654 cedex France
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
08 / 1 / 04 / 285 / 001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection Hepatitis B ( rDNA )
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
( )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection , a slightly opaque , white suspension .
clinical PARTICULARS
therapeutic indications
treatment groups can be made based on official guidance .
it may be expected to have the vaccination with reacts via protection against hepatitis D since hepatitis D ( rectum ) do not develop hepatitis B .
posology and method of administration
adults and adolescents ( from 16 years of age ) :
1 dose ( 10 g ) of 1 ml solution for injection should be used .
primary course of vaccination :
the two-dose vaccination course should be at least three injections .
two cycles of vaccination may be recommended :
0 , 1 , 6 injections or two injections at a third month , followed by a third month after the first dose .
0 , 2 , 12 , 12 and 12 months at a dose of 12 months after the first dose .
it is recommended that the vaccine be administered to patients receiving one of the regimens .
people receiving the two-dose regimen ( 0 , 1 , 2 months ) should receive a booster dose at 12 months to obtain high levels of antibodies .
remember :
race
the need for a booster dose of complying with the full primary vaccination course has not been established .
however , certain vaccination regimens are currently available on a booster dose recommendation and they should be dispersed .
immunocompromised patients ( e.g. dialysis )
in immunocompromised subjects , additional doses of vaccine should be recommended if the leukocyte counts becomes less than 10 IU / l
carcinogenesis
when used after primary vaccination course are mandatory , bruised of the response after a further dose , and detected after a further three doses .
however , since there is limited data on the safety of hepatitis B vaccine when the number of doses left to the recommended dose , D-penicillamine of subjects receiving a new vaccination regimen is not advisable .
Athletes should be considered for subjects at high risk , following giving the potential risks and benefits of regional adverse reactions .
special recommendations for known exposure or cytostatic for hepatitis B ( e. g. needle stick injury ) :
- H2 weakness as soon as possible after the exposure ( within 24 24 hours ) ,
hours ) .
- The injection of a vaccine of the vaccine should be used within 7 days of exposure .
it can be given at the same time as there may be at the same time as the injection site .
- Within intravascular coagulation is also recommended , with subsequent injections of the vaccine , if the
according to the guidelines in CCR5-tropic Europe and long term .
- In any doubt , the additional injections or later needles
should be calculated according to the current schedule .
the exact schedule of the infant to 12 months may be proposed .
method of administration This vaccine should be injected into the intramuscular route .
do not administer intravascularly .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
- Hypersensitivity to the active substance or to any of the excipients
- severe
special warnings and precautions for use
during the long time period of hepatitis B , there is a possibility that the infection of the vaccination course is not present .
in such cases it may not be the infection of the hepatitis B virus .
some factors that may impair the immune response to hepatitis B vaccines .
these factors include age , unintentional or cancer , your doctor will draw the medicine for the administration of some late-onset conditions .
periodic monitoring should be considered in people who may be at risk of not able to achieve complete seroprotection .
additional doses may be considered in people who respond to or not vaccination .
the vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
as with all injectable vaccines , appropriate medical treatment should always be given immediately , due to anaphylactic reactions occurring after the administration of the vaccine .
this vaccine may contain traces of pus and heparan sulfate and potassium .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
the vaccine may be given :
- with anti-hepatitis B immunoglobulin , a bolus site surface area .
- to avoid a booster or a booster dose of Busilvex or be used during
a separate vaccine against hepatitis B vaccine .
- if you are using other vaccines where the separate injection sites and syringes
pregnancy and lactation
for hepatitis B virus antigen ( pyridinoline ) , there are no data on the use of in pregnant women .
however , as for the monovalent pandemic vaccines , it should not be expected to have side effects in the foetus .
the use of this is not recommended if the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine has not been studied ; therefore , no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , no rare side effects were listed in section 5 .
undesirable effects
the following adverse reactions have been identified during the use of the vaccine .
as with other vaccines against hepatitis B , many of the vaccine with the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) , lymphadenopathy .
immune system disorders Very rare ( &lt; 1 / 10,000 ) ( &lt; 1 / 10,000 ) , anaphylaxis .
vascular disorders Very rare ( &lt; 1 / 10,000 ) , haemorrhage .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) associated with bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 ) , headache , diarrhoea , abdominal pain .
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) increase , alopecia , urticaria , erythema multiforme , urticaria , eructation
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 ) , WRAPPED , p , myalgia .
very rare ( &lt; 1 / 10,000 ) somnolence , fever , influenza-like symptoms .
elevated liver enzymes ( &lt; 1 / 10,000 ) elevation
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics , ATC code :
the vaccine induced antibodies to the surface antigen against the hepatitis B virus ( phenylpropanolamine ) .
in two clinical studies in the full adolescents and adults , 289 of the vaccinated subjects developed protective levels of antibodies , with geometric means of NCI activators / l .
as with other hepatitis B vaccines , it is not known for this time .
the need for a booster dose of 5.25 is not yet understood , except on the booster dose at 12 months , 1 , 2 .
3 All patients The primary lung disease of the liver is a serious complication of the hepatitis B infection .
studies have shown that the chronic
the vaccine of hepatitis B virus has been evoked as long as it prevents the risk of the liver .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a vial ( Type I glass ) .
not all pack sizes may be marketed .
special precautions for disposal
shake well before use .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
08 / 1 / 04 / 285 / 001 Date of last renewal :
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection in a pre-filled syringe
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
( )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection in a clear , white pre-filled syringe .
clinical PARTICULARS
therapeutic indications
treatment groups can be made based on official guidance .
it may be expected to have the vaccination with reacts via protection against hepatitis D since hepatitis D ( rectum ) do not develop hepatitis B .
posology and method of administration
adults and adolescents ( from 16 years of age ) :
1 dose ( 10 g ) of 1 ml solution for injection should be used .
primary course of vaccination :
the two-dose vaccination course should be at least three injections .
two cycles of vaccination may be recommended :
0 , 1 , 6 injections or two injections at a third month , followed by a third month after the first dose .
0 , 2 , 12 , 12 and 12 months at a dose of 12 months after the first dose .
it is recommended that the vaccine should be administered as one of the regimens .
people receiving the two-dose regimen ( 0 , 1 , 2 months ) should receive a booster dose at 12 months to obtain high levels of antibodies .
remember :
race
the need for a booster dose of complying with the full primary vaccination course has not been established .
however , certain vaccination regimens are currently available on a booster dose recommendation and they should be dispersed .
immunocompromised patients ( e.g. dialysis )
in immunocompromised subjects , additional doses of vaccine should be recommended if the leukocyte counts becomes less than 10 IU / l
carcinogenesis
when used after primary vaccination course are mandatory , bruised of the response after a further dose , and detected after a further three doses .
however , since there is limited data on the safety of hepatitis B vaccine when the number of doses left to the recommended dose , D-penicillamine of subjects receiving a new vaccination regimen is not advisable .
Athletes should be considered for subjects at high risk , following giving the potential risks and benefits of regional adverse reactions .
special recommendations for known exposure or cytostatic for hepatitis B ( e. g. needle stick injury ) :
- H2 weakness as soon as possible after the exposure ( within 24 24 hours ) ,
hours ) .
- The injection of a vaccine of the vaccine should be used within 7 days of exposure .
it can be given at the same time as there may be at the same time as the injection site .
- Within intravascular coagulation is also recommended , with subsequent injections of the vaccine , if the
according to the guidelines in CCR5-tropic Europe and long term .
- In order to clean or shorter persons , additional injections should be used .
be made according to the current schedule .
the exact schedule of the infant to 12 months may be proposed .
method of administration This vaccine should be injected into the intramuscular route .
as with adults , the injection should preferably be supportive .
do not administer intravascularly .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe
special warnings and precautions for use
during the long time period of hepatitis B , there is a possibility that the infection of the vaccination course is not present .
in such cases it may not be the infection of the hepatitis B virus .
some factors that may impair the immune response to hepatitis B vaccines .
these factors include age , unintentional or cancer , your doctor will draw the medicine for the administration of some late-onset conditions .
periodic monitoring should be considered in people who may be at risk of not able to achieve complete seroprotection .
additional doses may be considered in people who respond to or not vaccination .
the vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
as with all injectable vaccines , appropriate medical treatment should always be given immediately , due to anaphylactic reactions occurring after the administration of the vaccine .
this vaccine may contain traces of pus and heparan sulfate and potassium .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
the vaccine may be given :
- with anti-hepatitis B immunoglobulin , a bolus site surface area .
- to avoid a booster or a booster dose of Busilvex or be used during
a separate vaccine against hepatitis B vaccine .
- if you are using other vaccines where the separate injection sites and syringes
pregnancy and lactation
for hepatitis B virus antigen ( pyridinoline ) , there are no data on the use of in pregnant women .
however , as for the monovalent pandemic vaccines , it should not be expected to have side effects in the foetus .
the use of this is not recommended if the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine has not been studied ; therefore , no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , no rare side effects were listed in section 5 .
undesirable effects
the following adverse reactions have been identified during the use of the vaccine .
as with other vaccines against hepatitis B , many of the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) , lymphadenopathy .
immune system disorders Very rare ( &lt; 1 / 10,000 ) ( &lt; 1 / 10,000 ) , anaphylaxis .
vascular disorders Very rare ( &lt; 1 / 10,000 ) , haemorrhage .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) associated with bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 ) , headache , diarrhoea , abdominal pain .
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) increase , alopecia , urticaria , erythema multiforme , urticaria , eructation
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 ) , WRAPPED , p , myalgia .
very rare ( &lt; 1 / 10,000 ) somnolence , fever , influenza-like symptoms .
elevated liver enzymes ( &lt; 1 / 10,000 ) elevation
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics , ATC code :
the vaccine induced antibodies to the surface antigen against the hepatitis B virus ( phenylpropanolamine ) .
in two clinical studies in the full adolescents and adults , 289 of the vaccinated subjects developed protective levels of antibodies , with geometric means of NCI activators / l .
as with other hepatitis B vaccines , it is not known for this time .
the need for a booster dose of 5.25 is not yet understood , except on the booster dose at 12 months , 1 , 2 .
3 All patients The primary lung disease of the liver is a serious complication of the hepatitis B infection .
studies have shown that the chronic
the vaccine of hepatitis B virus has been evoked as long as it prevents the risk of the liver .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a pre-filled syringe ( Type I glass ) , without needles ( chlorobutyl ) .
packs of 1 , 10 , 1 ml suspension for injection in a pre-filled syringe ( Type I glass ) , with 1 needle ( chlorobutyl ) attached .
packs of 1 , 10 , 1 ml suspension for injection in a pre-filled syringe ( glass ) , with 2 gauge needles ( chlorobutyl ) .
not pack packs may be marketed .
special precautions for disposal
shake well before use .
keep the syringe barrel and attach the needle by turning the needle clockwise until it locks into place .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
08 / 1 / 04 / 285 / 001 Date of last renewal :
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
Alcon 40 micrograms / ml suspension for injection Hepatitis B ( rDNA )
qualitative AND QUANTITATIVE COMPOSITION
a dose ( 1 ml ) contains :
( )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
suspension for injection , a slightly opaque , white suspension .
clinical PARTICULARS
therapeutic indications
in the vaccine is indicated for the prevention of active vaccine caused by all types of infection , for adult or dialysis patients .
it may be expected to have the vaccination with reacts via protection against hepatitis D since hepatitis D ( rectum ) do not develop hepatitis B .
posology and method of administration
adult and paediatric patients :
1 .
primary parameter
the following vaccination course should be three injections :
22 , 1 , 6 injections or two injections at a third month , followed by a third month after the first dose .
remember :
a booster dose should be recommended in these subjects if the ANC fails to surface antigen against hepatitis B surface antigen ( phenylpropanolamine ) after leaving is less than 10 IU / l .
as a standard medical standards for administration of hepatitis B vaccines should be respected in haemodialysis patients .
a booster dose should be given when the titre antibody titres returns to 10 IU / l .
special warnings and precautions for hepatitis B ( e. g. needle stick injury ) :
- H2 weakness as soon as possible after the exposure ( within 24 24 hours ) ,
hours ) .
- The injection of a vaccine of the vaccine should be used within 7 days of exposure .
it can be given at the same time as there may be at the same time as the injection site .
- Within intravascular coagulation is also recommended , with subsequent injections of the vaccine , if the
according to the guidelines in CCR5-tropic Europe and long term .
- In the female or select wounds , additional injections should be used .
take it as recommended .
method of administration This vaccine should be injected into the intramuscular route .
injection should be preferably into the deltoid muscle .
do not administer intravascularly .
exceptionally , the vaccine may be administered subcutaneously in patients with thrombocytopenia or bleeding disorders .
see section 6.6 for instructions for preparation .
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- severe
special warnings and precautions for use
during the long time period of hepatitis B , there is a possibility that the infection of the vaccination course is not present .
in such cases it may not be the infection of the hepatitis B virus .
the vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
as with all injectable vaccines , appropriate medical treatment should be available immediately , following administration of the vaccine .
this vaccine may contain traces of pus and heparan sulfate and potassium .
therefore , hypersensitivity reactions may occur .
interaction with other medicinal products and other forms of interaction
the vaccine may be given :
- with anti-hepatitis B immunoglobulin , at the same site will be provided .
- to avoid a booster or a booster dose of Busilvex or be used during
a separate vaccine against hepatitis B vaccine .
- if you are using other vaccines where the separate injection sites and syringes
pregnancy and lactation
for hepatitis B virus antigen ( pyridinoline ) , there are no data on the use of in pregnant women .
however , as for the monovalent pandemic vaccines , it should not be expected to have side effects in the foetus .
the use of this is not recommended if the benefit outweighs the potential risk to the foetus .
caution should be exercised when prescribing to pregnant women .
the effect of this vaccine has not been studied ; therefore , no malformation has been established .
effects on ability to drive and use machines
no studies on the effects on the ability to drive and use machines have been performed .
however , no rare side effects were listed in section 5 .
undesirable effects
the following adverse reactions have been identified during the use of the vaccine .
as with other vaccines against hepatitis B , many of the vaccine has not been established .
blood and lymphatic system disorders Very rare ( &lt; 1 / 10,000 ) , lymphadenopathy .
immune system disorders Very rare ( &lt; 1 / 10,000 ) ( &lt; 1 / 10,000 ) , anaphylaxis .
vascular disorders Very rare ( &lt; 1 / 10,000 ) , haemorrhage .
respiratory , thoracic and mediastinal disorders Very rare ( &lt; 1 / 10,000 ) associated with bronchospasm .
gastrointestinal disorders very rare ( &lt; 1 / 10,000 ) , headache , diarrhoea , abdominal pain .
skin and subcutaneous tissue disorders Very rare ( &lt; 1 / 10,000 ) increase , alopecia , urticaria , erythema multiforme , urticaria , eructation
musculoskeletal and connective tissue disorders Very rare ( &lt; 1 / 10,000 ) , WRAPPED , hypoaesthesia , arthralgia , pain in extremity .
very rare ( &lt; 1 / 10,000 ) somnolence , fever , influenza-like symptoms .
elevated liver enzymes ( &lt; 1 / 10,000 ) elevation
overdose
no case of overdose has been reported .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : antimycotics , ATC code :
the vaccine induced antibodies to the surface antigen against the hepatitis B virus ( phenylpropanolamine ) .
as a standard medical standards for administration of hepatitis B vaccines should be respected in haemodialysis patients .
a booster dose should be given when the titre antibody titres returns to 10 IU / l .
in subjects with impaired antibody function , subsequent use of other hepatitis B vaccines should be considered .
3 All patients The primary lung disease of the liver is a serious complication of the hepatitis B infection .
studies have shown that the chronic
the vaccine of hepatitis B virus has been evoked as long as it prevents the risk of the liver .
pharmacokinetic properties
not applicable .
preclinical safety data
animal reproduction studies have not been conducted with this vaccine .
pharmaceutical PARTICULARS
list of excipients
sodium chloride Water for injections
Incompatibilities
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
Shelf life
3 years .
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
nature and contents of container
1 ml suspension for injection in a vial ( Type I glass ) .
special precautions for disposal
shake well before use .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
manufacturer Sanofi Winthrop Industrie 8 , rue de Champaret F-92654 cedex France
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
08 / 1 / 04 / 285 / 001 Date of last renewal :
date OF REVISION OF THE TEXT
manufacturer ( S ) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
manufacturer ( S ) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer ( s ) of the biological active substance
name and address of the manufacturer ( s ) responsible for batch release
box 581 Internacional , Postbus , PC Haarlem The Netherlands
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription .
the marketing authorisation holder will continue to submit yearly PSURs .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
sulphinpyrazone 5 micrograms / 0.5 ml vial Component of 1 , 10 , 10
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B injection Hepatitis B
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
( meters ) Tartaric acid ( 0.25 circumference )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
10 x 0.5 ml vials .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CA012-0 5 micrograms / 0.5 ml vial
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection Hepatitis B injection Hepatitis B
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
( meters ) Tartaric acid ( 0.25 circumference )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
1 pre-filled syringe with sterile needle protection .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / 0.5 ml suspension for injection Hepatitis B injection Hepatitis B
subcutaneous use
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
multi-organ failure
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
( meters ) Tartaric acid ( 0.25 circumference )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
50 pre-filled syringes with 0.5 ml solution .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
shake the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
5 micrograms / 0.5 ml ( 1 / 100 to 1 / 10 )
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
( meters ) Tartaric acid ( 0.25 circumference )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
10 ml pre-filled syringes with 1 injection needle and 1.2 ml with 1 injection needle ( for each syringe ) .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
multi-organ failure 5 micrograms / 0.5 ml pre-filled syringe with 2 gauge needles
name OF THE MEDICINAL PRODUCT
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 0.5 ml ) contains :
( meters ) Tartaric acid ( 0.25 circumference )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
10 ml pre-filled syringes with 2 ml needle ( for each syringe ) .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / 0.5 ml suspension for injection Hepatitis B injection Hepatitis B
subcutaneous use
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
sulphinpyrazone 10 micrograms / lndonesia vial Bio-Set from 1 , 10 Box of 1 , 10
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection Hepatitis B ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
Wyeth Europa Ltd
( diffuse ) vesicles Application site ( 0.50 CAPSULES )
based on human strain of erythroid cerevisiae ( H5N1 )
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
suspension for injection 1 vial Bioset of 1 ml .
5 ml in 1 ml
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE

name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / ml suspension for injection Hepatitis B ( rDNA )
subcutaneous use
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
multi-organ syringe 10 micrograms / lndonesia pre-filled syringe Note off 1 , 10 x 1 , 10
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
antigen of recombinant hepatitis B virus ( phenylpropanolamine ) Macrogols ( E965 ) phosphooxy ( 0.50 indigo carmine syndrome )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
suspension for injection 1 pre-filled syringe with 1 ml , without needle filled syringe with 1 ml without needle
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
multi-organ syringe 10 micrograms / lndonesia pre-filled syringe with 1 injection needle AFTER from 1 , 10 , 10
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
antigen of recombinant hepatitis B virus ( phenylpropanolamine ) Macrogols ( E965 ) phosphooxy ( 0.50 indigo carmine syndrome )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
10ml
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
sulphinpyrazone 10 micrograms / lndonesia pre-filled syringe with 2 gauge needles Note needle 1 , 10 gauge needle
name OF THE MEDICINAL PRODUCT
5 micrograms / ml suspension for injection in a pre-filled syringe
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
antigen of recombinant hepatitis B virus ( phenylpropanolamine ) Macrogols ( E965 ) phosphooxy ( 0.50 indigo carmine syndrome )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections
pharmaceutical FORM AND CONTENTS
10ml ( 1 ml ) .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use .
read the package leaflet before use .
intramuscular use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE

name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
5 g / ml suspension for injection Hepatitis B ( rDNA )
subcutaneous use
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
J02AX04
name OF THE MEDICINAL PRODUCT
Alcon 40 micrograms / ml suspension for injection Hepatitis B ( rDNA )
statement OF ACTIVE SUBSTANCE ( S )
1 dose ( 1 ml ) contains :
antigen of recombinant hepatitis B virus ( phenylpropanolamine ) Macrogols ( E965 ) phosphooxy ( 0.50 indigo carmine syndrome )
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
list OF EXCIPIENTS
sodium chloride , Postbus and water for injections .
pharmaceutical FORM AND CONTENTS
suspension for injection 1 vial Bioset of 1 ml .
method AND ROUTE ( S ) OF ADMINISTRATION
shake well before use Read the package leaflet before use .
intramuscular use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
special STORAGE CONDITIONS
store in a refrigerator Do not freeze
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BATCH
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE

name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
alkyl 40 g / ml suspension for injection Hepatitis B ( rDNA )
subcutaneous use
method OF ADMINISTRATION
shake well before use
expiry DATE
BATCH NUMBER
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 ml
other
package LEAFLET
package LEAFLET :
information FOR THE USER
5 micrograms / 0.5 ml suspension for injection Hepatitis B ( rDNA )
read all of this leaflet carefully before you start your child starts .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is
before you use programmes 5 micrograms / 0.5 ml 3 .
how to use Avamys 5 micrograms / 0.5 ml 4 .
possible side effects 5 .
how to store Apidra- of 5 micrograms / 0.5 ml
further information
what AMBIRIX 5 micrograms / 0.5 ml AND WHAT IT IS USED FOR
it can be expected to know that the vaccination with reacts will also inhibit hepatitis D since your hepatitis D ( rectum ) do not develop hepatitis B .
this vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
before YOU USE ALDURAZYME
do not use sunlamps 5 micrograms / 0.5 ml :
- if you are allergic ( hypersensitive ) to the hepatitis B surface antigen or any of the other hepatitis B infection ,
other ingredients in methylhydroxybenzoate ( see section 6 ) .
- if your child has a severe infection
using other vaccines :
this vaccine may be administered intravascularly with virus resistant immunoglobulins , provided to use a site site .
this vaccine may need a single or be used by a doctor or pharmacist in the subjects who have received another vaccine for hepatitis B vaccine .
this vaccine may be given in combination with certain other vaccines , including separate injection sites and syringes .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ALDURAZYME
dosage :
each dose for each injection ( 0.5 ml ) is 5 micrograms for children and adolescents ( of up to 15 years ) .
the vaccination schedule should be given at least three injections .
two cycles of vaccination may be recommended :
6 months )
- 3 injections at a dose of 1 year at once the first injection , once every 3 months from the first dose , once a year by the first dose , once every 2 months .
( 0 , 1 , 12 months ) .
the medicinal product for hepatitis B virus are given concomitantly with the first dose of 5.25 and a dose of immunoglobulins that are used concomitantly .
in some vaccination regimens , it is recommended to administer a booster dose .
your doctor or pharmacist will inform you if a booster dose is necessary .
method of Administration :
shake well before use until a white suspension is slightly opaque , slightly opaque , .
as soon as the vaccine has been expelled , the vaccine will be used rapidly and the vial must be withdrawn .
the doctor will normally provide the vaccine in a muscle .
infants and infants should be washed with the preferred part of the thigh .
in children and adolescents , the injection should preferably be supportive .
the vaccine should never be injected into a vein .
exceptionally , this vaccine can be administered subcutaneously in patients with thrombocytopenia ( platelets ) or who are intolerant to the infected haemorrhages .
if you miss a dose of 5 micrograms / 0.5 ml :
if a injection is missed , your doctor will decide when the full dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , syncope3 can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B , many other vaccines and the vaccine has not been established .
7a .
the most common side effects are local reactions at the injection site as pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date which is stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
strength 5 micrograms / 0.5 ml
the active substance is : a
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
the other ingredients are sodium chloride , glycerol , and water for injections .
what CellCept 5 micrograms / 0.5 ml looks like and contents of the pack
each dose contains 0.5 ml suspension for injection in a vial .
packs of 1 and 10 vials without a needle / needle .
packs of 1 vial with syringe and needle .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi Winthrop Industrie Manufacturing ApS , 8 rue Erlanger F-92654 Boulogne-Billancourt , France .
manufacturer responsible for batch release :
Merck Sharp Dohme and AB V. , Waarderweg 39 , 08320 PC Haarlem , 27709 .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
BelgiÃ« / Belgique / Belgien :
Merck Sharp Dohme , IDEA , Inc :
manufacturer Sanofi Winthrop Industrie , Emil Barell Str
161 :
manufacturer Sanofi Winthrop Industrie S. A. Skin , s. France :
Gilead Merck Sharp Dohme , s. your doctor :
Polska MSD Polska Sp. z o. o :
Merck Sharp Dohme Romania S. R. L. :
Merck Sharp Dohme , inovativna zdravila Tel : approx :
Merck Sharp Dohme IDEA , Inc .
manufacturer Sanofi Winthrop Industrie , Bray / :
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
5 micrograms / 0.5 ml suspension for injection in a pre-filled syringe
read all of this leaflet carefully before you start your child starts .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is
before you use programmes 5 micrograms / 0.5 ml 3 .
how to use Avamys 5 micrograms / 0.5 ml 4 .
possible side effects 5 .
how to store Apidra- of 5 micrograms / 0.5 ml
further information
what AMBIRIX 5 micrograms / 0.5 ml AND WHAT IT IS USED FOR
it can be expected to know that the vaccination with reacts will also inhibit hepatitis D since your hepatitis D ( rectum ) do not develop hepatitis B .
this vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .
before YOU USE ALDURAZYME
do not use sunlamps 5 micrograms / 0.5 ml :
- if you are allergic ( hypersensitive ) to the hepatitis B surface antigen or any of the other hepatitis B infection ,
other ingredients in methylhydroxybenzoate ( see section 6 ) .
- if your child has a severe infection
using other vaccines :
this vaccine may be administered intravascularly with virus resistant immunoglobulins , provided to use a site site .
this vaccine may need a single or be used by a doctor or pharmacist in the subjects who have received another vaccine for hepatitis B vaccine .
this vaccine may be given in combination with certain other vaccines , including separate injection sites and syringes .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ALDURAZYME
dosage :
each dose for each injection ( 0.5 ml ) is 5 micrograms for children and adolescents ( of up to 15 years ) .
the vaccination schedule should be given at least three injections .
two cycles of vaccination may be recommended :
6 months )
- 3 injections at a dose of 1 year at once the first injection , once every 3 months from the first dose , once a year by the first dose , once every 2 months .
( 0 , 1 , 12 months ) .
the medicinal product for hepatitis B virus are given concomitantly with the first dose of 5.25 and a dose of immunoglobulins that are used concomitantly .
in some vaccination regimens , it is recommended to administer a booster dose .
your doctor or pharmacist will inform you if a booster dose is necessary .
method of Administration :
shake well before use until a white suspension is slightly opaque , slightly opaque , .
the needle is taken by turning the needle clockwise until it is blocked .
the doctor will normally provide the vaccine in a muscle .
infants and infants should be washed with the preferred part of the thigh .
in children and adolescents , the injection should preferably be supportive .
the vaccine should never be injected into a vein .
exceptionally , this vaccine can be administered subcutaneously in patients with thrombocytopenia ( platelets ) or who are intolerant to the infected haemorrhages .
if you miss a dose of 5 micrograms / 0.5 ml :
if a injection is missed , your doctor will decide when the full dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , syncope3 can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B , many other vaccines and the vaccine has not been established .
7a .
the most common side effects are local reactions at the injection site as pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date which is stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
strength 5 micrograms / 0.5 ml
the active substance is : a
based on the H5N1 strain of Saccharomyces cerevisiae ( H5N1 ) .
the other ingredients are sodium chloride , glycerol , and water for injections .
what CellCept 5 micrograms / 0.5 ml looks like and contents of the pack
each dose contains 0.5 ml suspension for injection in a pre-filled syringe .
packs of 1 , 10 , 20 and 50 pre-filled syringes without needles Component of 1 and 10 pre-filled syringes with 1 or 2 pre-filled syringes .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi Winthrop Industrie Manufacturing ApS , 8 rue Erlanger F-92654 Boulogne-Billancourt , France .
manufacturer responsible for batch release :
Merck Sharp Dohme and AB V. , Waarderweg 39 , 08320 PC Haarlem , 27709 .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
BelgiÃ« / Belgique / Belgien :
Merck Sharp Dohme , IDEA , Inc :
manufacturer Sanofi Winthrop Industrie , Emil Barell Str
161 :
manufacturer Sanofi Winthrop Industrie S. A. Skin , s. France :
Gilead Merck Sharp Dohme , s. your doctor :
Polska MSD Polska Sp. z o. o :
Merck Sharp Dohme Romania S. R. L. :
Merck Sharp Dohme , inovativna zdravila Tel : approx :
Merck Sharp Dohme IDEA , Inc .
manufacturer Sanofi Winthrop Industrie , Bray / :
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
5 micrograms / ml , suspension for injection Hepatitis B ( rDNA )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is
before you use programmes - 10 micrograms / ml 3 .
how to use BYETTA 10 micrograms / ml 4 .
possible side effects 5 .
how to store Apidra- 10 micrograms / ml 6 .
further information
what AMBIRIX 10 micrograms / ml AND WHAT IT IS USED FOR
this vaccine is indicated for the course of the infection caused by all types of hepatitis B virus in adults and adolescents ( from 16 years of age )
it can be expected to know that the vaccination with reacts will also inhibit hepatitis D since your hepatitis D ( rectum ) do not develop hepatitis B .
this vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .

do not use BYETTA 10 micrograms / ml :
- if you are allergic ( hypersensitive ) to recombinant hepatitis B surface , or any of the other ingredients of
of these ) .
- if you have severe febrile infection
take special care with Busilvex 10 micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not an interruption of treatment .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
in rare side effects may impair the ability to drive or use machines .
using other vaccines :
this vaccine may be administered intravascularly with specific immunoglobulins specific hepatitis B immunoglobulin provided to use an additive site .
this vaccine may need a single or be used by a doctor or pharmacist in the subjects who have received another vaccine for hepatitis B vaccine .
this vaccine may be given in combination with other vaccines where separate injection sites and syringes .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE 10 micrograms / ml
dosage :
the recommended dose for each injection ( 1 ml ) is 10 micrograms for adults and adolescents ( from 16 years of age ) .
the vaccination schedule should be given at least three injections .
two cycles of vaccination may be recommended :
6 months )
- 3 injections at a dose of 1 year at once the first injection , once every 3 months from the first dose , once a year by the first dose , once every 2 months .
( 0 , 1 , 12 months ) .
the medicinal product for hepatitis B virus are given concomitantly with the first dose of 5.25 and a dose of immunoglobulins that are used concomitantly .
in some vaccination regimens , it is recommended to administer a booster dose .
your doctor or pharmacist will inform you if a booster dose is necessary .
method of Administration :
shake well before use until a white suspension is slightly opaque , slightly opaque , .
the doctor will normally provide the vaccine in a muscle .
the injection site necroses in adults and adolescents is the muscle on the top of the arms .
the vaccine should never be injected into a vein .
exceptionally , this vaccine can be administered subcutaneously in patients with thrombocytopenia ( platelets ) or in patients with bleeding .
if you miss a dose of 10 micrograms / ml :
if a injection is missed , your doctor will decide when the full dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , syncope3 can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B , many other vaccines and the vaccine has not been established .
7a .
the most common side effects are local reactions at the injection site as pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date which is stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
what analgesic contains 10 micrograms / ml
the active substance is
based on human strain of erythroid cerevisiae ( H5N1 )
the other ingredients are sodium chloride , glycerol , and water for injections .
what CellCept 5 micrograms / 0.5 ml looks like and contents of the pack
each dose contains 1 ml of suspension for injection in a vial .
packs of 1 and 10 vials .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi Winthrop Industrie Manufacturing ApS , 8 rue Erlanger F-92654 Boulogne-Billancourt , France .
manufacturer { release } :
Merck Sharp Dohme and AB V. , Waarderweg 39 , 08320 PC Haarlem , 27709 .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
BelgiÃ« / Belgique / Belgien :
Merck Sharp Dohme , IDEA , Inc :
manufacturer Sanofi Winthrop Industrie , Emil Barell Str
161 :
manufacturer Sanofi Winthrop Industrie S. A. Skin , s. France :
Gilead Merck Sharp Dohme , s. your doctor :
Polska MSD Polska Sp. z o. o :
Merck Sharp Dohme Romania S. R. L. :
Merck Sharp Dohme , inovativna zdravila Tel : approx :
Merck Sharp Dohme IDEA , Inc .
manufacturer Sanofi Winthrop Industrie , Bray / :
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
5 micrograms / ml , suspension for injection in a pre-filled syringe
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is
before you use programmes - 10 micrograms / ml 3 .
how to use BYETTA 10 micrograms / ml 4 .
possible side effects 5 .
how to store Apidra- 10 micrograms / ml 6 .
further information
what AMBIRIX 10 micrograms / ml AND WHAT IT IS USED FOR
this vaccine is indicated for the course of the infection caused by all types of hepatitis B virus in adults and adolescents ( from 16 years of age )
it can be expected to know that the vaccination with reacts will also inhibit hepatitis D since your hepatitis D ( rectum ) do not develop hepatitis B .
this vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .

do not use BYETTA 10 micrograms / ml :
- if you are allergic ( hypersensitive ) to recombinant hepatitis B surface , or any of the other ingredients of
of these ) .
- if you have severe febrile infection
take special care with Busilvex 10 micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not an interruption of treatment .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
in rare side effects may impair the ability to drive or use machines .
using other vaccines :
this vaccine may be administered intravascularly with specific immunoglobulins specific hepatitis B immunoglobulin provided to use an additive site .
this vaccine may need a single or be used by a doctor or pharmacist in the subjects who have received another vaccine for hepatitis B vaccine .
this vaccine may be given in combination with other vaccines where separate injection sites and syringes .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE 10 micrograms / ml
dosage :
the recommended dose for each injection ( 1 ml ) is 10 micrograms for adults and adolescents ( from 16 years of age ) .
the vaccination schedule should be given at least three injections .
two cycles of vaccination may be recommended :
6 months )
- 3 injections at a dose of 1 year at once the first injection , once every 3 months from the first dose , once a year by the first dose , once every 2 months .
( 0 , 1 , 12 months ) .
the medicinal product for hepatitis B virus are given concomitantly with the first dose of 5.25 and a dose of immunoglobulins that are used concomitantly .
in some vaccination regimens , it is recommended to administer a booster dose .
your doctor or pharmacist will inform you if a booster dose is necessary .
method of Administration :
shake well before use until a white suspension is slightly opaque , slightly opaque , .
the needle is taken by turning the needle clockwise until it is blocked .
the doctor will normally provide the vaccine in a muscle .
the injection site necroses in adults and adolescents is the muscle on the top of the arms .
the vaccine should never be injected into a vein .
exceptionally , this vaccine can be administered subcutaneously in patients with thrombocytopenia ( platelets ) or in patients with bleeding .
if you miss a dose of 10 micrograms / ml :
if a injection is missed , your doctor will decide when the full dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , syncope3 can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B , many other vaccines and the vaccine has not been established .
7a .
the most common side effects are local reactions at the injection site as pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date which is stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
what analgesic contains 10 micrograms / ml
the active substance is
based on human strain of erythroid cerevisiae ( H5N1 )
the other ingredients are sodium chloride , glycerol , and water for injections .
what BYETTA looks like and contents of the pack
each dose contains 1 ml of suspension for injection in a pre-filled syringe .
packs of 1 and 10 pre-filled syringes without needles , or 2 gauge needles .
not all pack sizes may be marketed .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi Winthrop Industrie Manufacturing ApS , 8 rue Erlanger F-92654 Boulogne-Billancourt , France .
manufacturer responsible for batch release :
Merck Sharp Dohme and AB V. , Waarderweg 39 , 08320 PC Haarlem , 27709 .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
BelgiÃ« / Belgique / Belgien :
Merck Sharp Dohme , IDEA , Inc :
manufacturer Sanofi Winthrop Industrie , Emil Barell Str
161 :
manufacturer Sanofi Winthrop Industrie S. A. Skin , s. France :
manufacturer Sanofi Winthrop Industrie , s. K K :
Gilead Merck Sharp Dohme , s. your doctor :
Polska MSD Polska Sp. z o. o :
Merck Sharp Dohme Romania S. R. L. :
Merck Sharp Dohme , inovativna zdravila Tel : approx :
Merck Sharp Dohme IDEA , Inc .
manufacturer Sanofi Winthrop Industrie , Bray / :
this leaflet was last approved in
package LEAFLET :
information FOR THE USER
Alcon 40 micrograms / ml , suspension for injection Hepatitis B ( rDNA )
read all of this leaflet carefully before you start receiving this vaccine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what is
before you use programmes only 40 micrograms / ml 3 .
how to use Betaferon 40 micrograms / ml 4 .
possible side effects 5 .
how to store IFL 40 micrograms / ml 6 .
further information
what AMBIRIX 40 micrograms / ml IS AND WHAT IT IS USED FOR
this vaccine is indicated for the vaccination of the fungal infection caused by all types of hepatitis B virus in adults or to dialysis .
it can be expected to know that the vaccination with reacts will also inhibit hepatitis D since your hepatitis D ( rectum ) do not develop hepatitis B .
this vaccine will not prevent infection caused by the hepatitis A virus , hepatitis C or other pathogens known to infect the liver .

do not use sunlamps 40 micrograms / ml :
- if you are allergic ( hypersensitive ) to hepatitis B or any of the other hepatitis B surface .
of these constituents ( see section 4.4 ) .
- if you have severe febrile infection
take special care with CellCept 40 micrograms / ml :
pregnancy and breast-feeding :
caution should be exercised when prescribing to pregnant women .
breast-feeding is not an interruption of treatment .
ask your doctor or pharmacist for advice before taking any medicine .
driving and using machines :
in rare side effects may impair the ability to drive or use machines .
using other vaccines :
this vaccine may be administered intravascularly with specific immunoglobulins specific hepatitis B immunoglobulin provided to use an additive site .
this vaccine may need to be a single or be used .
this vaccine may be given in combination with other vaccines where separate injection sites and syringes .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
how TO USE ALDURAZYME
dosage :
the recommended dose for each injection ( 1 ml ) is 40 micrograms for adult or dialysis patients .
the vaccination schedule should be three injections .
the most common side effect is 2 injections of 3 months , followed by a third month , followed by a third month after the first dose ( 0 , 1 , 6 months ) .
a booster dose should be recommended in these subjects if the leukocyte counts are lower than 10 IU / l .
method of Administration :
shake well before use until a white suspension is slightly opaque , slightly opaque , .
the doctor will normally provide the vaccine in a muscle .
the injection site necroses in adults is the muscle of the arms .
the vaccine should never be injected into a vein .
exceptionally , this vaccine can be administered subcutaneously in patients with thrombocytopenia ( platelets ) or in patients with bleeding .
if you miss a dose of allopurinol 40 micrograms / ml :
if a injection is missed , your doctor will decide when the full dose .
if you have any further questions on the use of this product , ask your doctor or pharmacist .
possible SIDE EFFECTS
like all medicines , syncope3 can cause side effects , although not everybody gets them .
as with other vaccines against hepatitis B , many other vaccines and the vaccine has not been established .
7a .
the most common side effects are local reactions at the injection site as pain , redness and oedema .
if any of the side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor or pharmacist .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date which is stated on the label .
store in a refrigerator ( 2 C 8 C ) .
further INFORMATION
check of 40 micrograms / ml
the active substance is
based on human strain of erythroid cerevisiae ( H5N1 )
the other ingredients are sodium chloride , glycerol , and water for injections .
what Apidra looks like and contents of the pack
each dose contains 1 ml of suspension for injection in a vial .
1 vial .
MARKETING Authorisation Holder and Manufacturer
MARKETING Authorisation Holder :
Sanofi Winthrop Industrie Manufacturing ApS , 8 rue Erlanger F-92654 Boulogne-Billancourt , France .
manufacturer responsible for batch release :
Merck Sharp Dohme and AB V. , Waarderweg 39 , 08320 PC Haarlem , 27709 .
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
BelgiÃ« / Belgique / Belgien :
Merck Sharp Dohme , IDEA , Inc :
manufacturer Sanofi Winthrop Industrie , Emil Barell Str
161 :
manufacturer Sanofi Winthrop Industrie S. A. Skin , s. France :
Gilead Merck Sharp Dohme , s. your doctor :
Polska MSD Polska Sp. z o. o :
Merck Sharp Dohme Romania S. R. L. :
Merck Sharp Dohme , inovativna zdravila Tel : approx :
Merck Sharp Dohme IDEA , Inc .
manufacturer Sanofi Winthrop Industrie , Bray / :
this leaflet was last approved in
M05B CusÃ­ OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
theoretically is a monovalent &apos;vaccine that is related to active substances , causing the infection of the hepatitis B virus at all types of formalin inactivated exposure as this virus .
the active substance in this happening vaccine , vaccine ( recombinant ) hepatitis B vaccine is the virus of the hepatitis B virus ( phenylpropanolamine ) , talc and recombinant .
multi-organ disease is a vaccine that initiates a condition that leads to the immune response and the specific likelihood against the hepatitis B infection caused by the hepatitis B virus .
the benefit of barbiturates are protection against hepatitis B in all the lifetime groups , in the finished product setting .
problems with mock-up
the CHMP has a strong , the CHMP decided that the CHMP concluded that the reporter had a Post-Marketing Surveillance Safety Update Report ( PSUR ) and long-term hepatitis against hepatitis B vaccines against hepatitis B vaccines against hepatitis B against hepatitis B vaccines against hepatitis B against hepatitis B vaccines .
the CHMP builds on whether there is a net response of response to hepatitis B after CYP1A1 .
this variability is to be related to currently untreated species .
the small statements refer to the small extension of the constituents of microtubules , the possible implications for long-term protection against hepatitis B infection and vaccination will following vaccination with this vaccine .
during attempts with the expiry date , the CHMP concluded that the CHMP had developed the decrease of the intermediate application of the recombinant active components contained in 384 and heparan .
the Committee decided that the potential for an
the Committee also indicated that the last study of one year was performed on a year basis .
therefore , data obtained should be paid to this , because they are a single dose ( 5 g ) of the BIO-SET vaccine before this .
he / she should be washed out , unless the vaccine is less troublesome than the vaccine produces in comparison .
the reduction in the decrease in the immunogenicity of several years has not been identified .
a decision to take , which has been considered to be taken with the questions of the quality and a successful clinical response .
the European Commission granted a marketing authorisation valid throughout the European Union ( IC50 ) .
345
the area of the quality of cleavage , there are no malformative or animal metastases to predict the immunogenicity of recombinant human components in humans .
when the patient is being used as pre-specified , but not reinstituted for the safety and efficacy ( immunogenicity ) as pre-specified for the safety and efficacy
however , the following safety
although the the cause of the immunogenicity for most patients within the last 5 years should be allowed .
Lansoprazol showed a better process to increase the immunogenicity of the immunogenicity .
the CHMP measured on the basis of the CHMP guideline on 7 four-week studies and 20.4 , was still ongoing .
these studies have been carried out in various groups at risk of MI , including infants infected with hepatitis B , infants , children and healthy subjects aged 16 to 35 years .
in the day studies on breastfed newborns and heparan , respectively , among the neonate were obtained .
no evidence of impact on the course of short-term or long-term effects have been identified .
in addition , a study of evaluated for the disease against the disease we as we died , including hepatitis B vaccines , and serious viruses .
because of the risk of a relatively high infection of the HIV infection , the possibility of mothers should not breast-feed unless the lowest possible course of the vaccine is included .
as there is no evidence of an increase in the number of acute hepatitis B infection in anticipation of hepatitis B vaccine , because of the EU is a nasal spray , no safety problems can be identified by the CHMP .
the results of all three trials of the medicinal product involved medicinal product authorised with predicted performance and gag-pol polyprotein Training ( FAP ) , different from other patient available .
in new-born infants , a high diagnosis of adolescents and young adults always with high elevation of a high hemoglobin .
therefore , the study results supports the currently available product produces the available antibodies of antibodies in all patient populations only .
the CHMP should be terminated with diazepam on the differential information on the own , to allow the information that makes them at all the procedure , in the procedure .
the SPC and the pleuromutilins involve information from the full day of the product , based on clinical data .
these changes usually disappear , respond to the CHMP rich in their CHMP and its schedule .
in the context of studies , diazepam is committed to affect the sections 4.2 , 4.4 ( reports if needed ) and 5.1 of the SPC :
the CHMP also looked at the full list and clinical information available to simplify .
the CHMP concluded that the use of this vaccine has not been formally studied , irrespective of any of the target for which the vaccine is indicated .
the potential ratios for humans will be reduced to a sympathomimetic level in the conjunctival sac .
there is no information on the health care of health care professionals and location the use of the vaccine in different approval groups .
the CHMP displaced the new information about the medicine information and resolving microtubules to die 20 without other medicines .
folliculitis OF THE SOLUTION AUTHORISATION
taking
the CHMP boosted that the information on the medicine information should be modified to ensure the urethra for the following reasons for the following reasons :
due to the small data available on the low date , the CHMP decided that it was necessary to allow other studies to look out for patients to follow the basal hepatitis B vaccine , with the A protection vaccine .
the use of this vaccine is not recommended until any special risk is achieved .
the potential ratios for humans will be accumulated to a acceptable extent of the vermilion synthetase ;
the CHMP presented that the benefit-risk balance of the OFF versus protection against all injectable infections for the hepatitis B virus , is remaining as a similar risk of exposure to all of the hepatitis B virus , remains similar .
the CHMP recommended that Application be given marketing authorisation , according to Article 5 , 2 , venlafaxine ( i. e. ) ART-naÃ¯ve / 2004 .
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is programmes ?
eighteen vasoconstrictors are a diagnosis test .
it is supplied in a diary containing one tablet which is made up into a solution .
the powder is made from the active substance &apos; ( 45 mg for children or 75 mg for adults ) .
what tables is dropped used for ?
eighteen periods are used in the diagnosis of stomach infection and nail ( the gut of the gut and the gut of the gut - the gut ( the gut of the gut tissue just ) .
hydroxychloroquine is a copy that occurs as a factor
detach 28.1 may be used to test adults , adolescents , and children from 3 to 11 years of age .
it cannot be used in children when prespecified training ( e.g. Entry of an overnight tube ) do not use or have any formal results , or to check that pancytopenia or to check that pancytopenia is not indicated or to test the results .
Multivitamins was primed after specific treatment to support the infection .
how do I test my use ?
detach Addendum is a respiratory centre : samples of air tested were withdrawn from
to test the patient must ensure the patient &apos; s four samples , two prior to sevelamer intake and two after receipt of the anaesthesia .
the patient should consist of at least 6 hours before the test test .
four patients in the presentations of both air 9.0 , i. e. perpendicular or liquid included with ZBP .
the patient receives a high-fat meal ( either 200 ml ) .
by 30 minutes after swallowing the solution , the patient &apos; s New matter .
in children aged between three and 11 years of age , the a high-fat diet should include 100 ml of orange fruit juice .
for information on how to use this process , see the Package Leaflet .
J02AX04
this allows the amounts of white blood sugar may be measured by serial passage technique .
there is no appreciable cap in the air alfa-2a , it may flat up to a 2 in the stomach or pharmacy .
how has been studied ?

all of the patients received 75 mg of urea mg , except in children who are under 45 mg of age who received 45 mg .
in adults was conducted in patients who have received antibiotics to antibiotics for whom the infection .
what benefit has 83.5 shown during the studies ?
in all studies , the test results showed a definitive test pattern were consistent with the exception of the exception of the cases .
what is the risk associated with scars complications ?
there are no known adverse reactions associated with this Ames test .
however , if the patient develops during the screening , the patient should be hospitalised , but not before the expiry date .
why FOR INJECTING 2
the Committee recommended that ventilatory PSURs is marketing authorisation .
other information about launch :
the name / ADDRESS }
the marketing authorisation was renewed on 14 August 2002 and on 14 August 2007 .
the full EPAR for complying will be found here .
this summary was last updated in 09-2007 .
EU Number
Invented name
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
package size
75 mg Rhinitis
powder for oral solution
anus
alkenyl
acuity species
75 mg Rhinitis
powder for oral solution
alkyl SCHEDULE
mg Convulsions
- Clean , Lynce in the countries including a puncture-resistant container
powder for oral solution
oral
acuity species
mg Convulsions
product-specific periods
J02AX04
powder for oral solution
alkyl SCHEDULE
alkenyl
including alcohol fluids
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
mg Ethanol , as
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder for oral solution .
clear , colourless solution .
clinical PARTICULARS
therapeutic indications
4.29 Addendum may be used for in vivo infection of neutropaenic infections methoxypolyethylene Incontinence in the :
- adult
- adolescents that may have stenosing ulcer
this medicinal product is for single use only .
posology and method of administration
this medicinal product must be administered by a healthcare professional under strict medical supervision .
J02AX04
the dose for adults and adolescents from 12 years of age is of 75 mg .
the patient should be on an overnight fast for more than 6 hours , preferably during the day .
the test lasts about 40 minutes .
if the test should not be repeated , it should not be repeated before the day .
Patient-time attempt may manifest negative results .
therefore , it should be considered only after discussing the resolution of 4 weeks and other systemic treatments after the last dose of antibacterial agents .
both treatment may interfere with the presence of cleft Characteristics .
this is especially important after the treatment of methyl hydroxybenzoate .
it is important to follow your instructions to follow the instructions carefully for use in section 6.6 ( carefully for using the Instructions for Use and handling , and disposal ) without squeezing the outcome will be uncertain .
Contraindications
( posology and method of administration ) .
special warnings and precautions for use
there is no indication for a treatment of demyelination .
diagnostic diagnostic with differential mental measures may be necessary for the presence of other urticarial conditions such as ulcer , oesophagitis , inflammation and malignancies .
there are insufficient data to recommend the FVC of the OFF FVC for preventing amputation and patients under 12 years of age .
for children over three years of age , the entry recognises 3 to 11 years is available .
in isolated cases ( rectum ) , the respiratory test could give a positive test results , therefore , other unwanted findings may be required to support the presence of cleft Pointes .
in case of vomiting who should not receive this during pregnancy requiring this cycle , this has to be noted until the foreskin is empty , but not reinstituted ( MUGA and method of administration ) .
interaction with other medicinal products and other forms of interaction
w.1 Addendum may be affected by all products with basiliximab or indomethacin with bandages or indomethacin .
pregnancy and lactation
no special hazard for humans are available in patients with severe renal impairment or lactation .
it is recommended that the leaflet of treatment be taken into account during pregnancy and lactation .
effects on ability to drive and use machines
Sixty-two .
undesirable effects
no known effects .
overdose
no overdose is considered to be fully supplemented with 75 mg of 11.7 .
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : other diagnostic agents , ATC code :
no pharmacological activity was described in the amount of 32 mg propyl parahydroxybenzoate administered with the respiratory assay .
3 - After oral administration , urea layer
in the presence of consolidation arising , D-penicillamine is metabolized by apoptosis chain after the reaction :
hyperventilation revasc .
enzyme
345
carbon dioxide by carbon dioxide .
remember it is extracted as bicarbonate until the gullet and combine it is extracted with expired air .
in the presence of bacterial and rectum , the proportion of the -L-iduronidase recognises / 905 is modified .
the amount of anti-HBs in the samples is determined by serial fat ( pyridinoline ) and related ( baseline ) differences between the
Patient-time is produced in the stomach , only by diaries .
other things that are rarely in the adipocyte , in the aqueous humour .
by self-monitored blood glucose levels , susceptibility to the respiratory biomarkers , in clinical studies with 384 patients , presenting with secondary-progressive accident ( 95 leak :
alkyl sulfonates ( Creatine S-1-15083 :
detach ) , while the in clinical trials with adolescent patients between 12 and 17 years old in the brain decreases with the normal range ( 90 G :
20 Paediatrics :
7a ) .
in the absence of bacterial and perennial , the total amount of urea applied , after gastrointestinal tract will be seen as urea .
ammonia is maintained , as described above , hydrolysis is heat in the metabolism of oblong .
pharmacokinetic properties
glycosylation given mouth , is metabolised to titanium dioxide and ammonia or ornithine in the endogenous cycle of urea .
the increase in LDL-C will be registered .
the absorption of norethindrone are more rapid than the action of cytidine .
as a result , the central nervous system process are the responsibility of the complete process .
there is no significant dose adjustment for patients with CLCR 2 mg urea .
preclinical safety data
there are no fairly recurrence for the use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
do not store above 25 C.
nature and contents of container
frequency
alkyl
rubber stopper ) containing
frequency
CellCept 500 mg powder for oral solution .
butylated methacrylate copolymer or glass Sodium Chloride Injection :
fluctuations
Research and Produtos FarmacÃªuticos , occasional NECESSARY
blister MANUAL
special precautions for disposal and other handling
the method should be done in the presence of an acceptable person .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
it is recommended that you adhere to a rest period .

then pulling any of the 200 ml fruit juice ( 100 dilute ) or 1 g of citric acid in 200 ml water .
measure the content of the powder into a glass vial .
( total volume of water should be approximately 30 ml ) .
7 .
solution should be inspected visually for particulate matter and discolouration prior to administration .
remove the peel-off stickers in the blister pack on the basis of the scientific Safety Update Reports .
tubes with mutants should be guided in the outer carton for the scientific ring .
respiratory samples and 70.5
inter ( seminiferous ) tubes in tubes or 10 ml of 10 ml were analysed by CYP1A1 of mass of fat ( 21.8 ) .
the analysis of the septum / lndonesia in the conjunctival sac of the Marketing Authorisation issued .
Patient-time is retarded related to the respiratory quality .
Athletes of quarter of the fat are such as facilities , stability ( lysine of the reference ) and Ammonaps of the suggested measures &apos; to CA-I .
the primary analysis is required to ensure that the analysis is carried out .
the method for this use is as follows :
preparation of anti-hepatitis Water for Injections
to determine the proportion of the gullet / lndonesia of the mucosae of the mucosae of the mucosae of urine gluconate , wind should be isolated of normal and restart in neurons of the fat .
the system of an automatic preparation for imidazole fat CD34 cells used for the purposes of the solid leukaemic assay is based on fermentation treatment .
it is extracted from the sample bound to Friday or the system of microtubules , which separates each register in one centimetre of microtubules , and we breathe .
in the retina , all deposits are detected by one migraine .
the colour of the dopaminergic fraction , dry of the autoimmune fluid , consists of fat mass .
alanine aminotransferase increased
126 to spontaneous mineral host disease post-transplant , its amino_acid sequence should be tapped , namely , digitalis via adjuvant imaging , V82T and excluded .
these five steps are mandatory in learning of the fat , which is a three parts of three parts :
Immunodepressed formation and mobilisation are given in the limb .
introduction of baseline
.
for the purposes of the respiratory marrow , haemofiltration of the DNA activators from baseline to the reference chain is essential .
this means a reinforced goal at this time , when equivalent to the 1-ml content of the GAGs is taken relative to the pre-selected standard with the accumulated standard .
Alcon
Lansoprazol of the respiratory test is based on administration of urea and Pelvic Floor synthetase , which lasted Day 2 in breath .
the mass of fat should be reached :
post-marketing analyses :
3 years on the same sample during the operation .
safety of a small safety system :

cleft palate / diglycerides of 459 / intracerebral as amended ( 21.8 ) .
Gilead test :
&lt; 200 the amount of
tests for to test are the form of the reference , ( &apos; contributing to the reference ) and Ammonaps .
all of the redistribution of donors should be considered with the following convention :
1 to 10 for samples :
w.1 between 1 and 7 .
spontaneously sufficient if the difference in the percent of the urethra / alveolar mutation / alveolar mutation and 30 minutes is greater than 4 .
the other methods properly may be used by serial interpretation systems .
MARKETING AUTHORISATION HOLDER
HÃ¤lsa SYNTHELABO LIMITED CZ-281 Cernymi lesy Czech Francisco
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
hardening includes :
mg Ethanol , as
pharmaceutical FORM
powder for oral solution .
clear , colourless solution .
clinical PARTICULARS
therapeutic indications
4.29 Addendum may be used for in vivo infection of neutropaenic infections methoxypolyethylene Incontinence in the :
- adult
- adolescents that may have stenosing ulcer
this medicinal product is for single use only .
posology and method of administration
this medicinal product must be administered by a healthcare professional under strict medical supervision .
J02AX04
the dose for patients on the age of 12 years is of 75 mg .
the patient should be on an overnight fast for more than 6 hours , preferably during the day .
the test lasts about 40 minutes .
if the test should not be repeated , it should not be repeated before the day .
Patient-time attempt may manifest negative results .
therefore , it should be considered only after discussing the resolution of 4 weeks and other systemic treatments after the last dose of antibacterial agents .
both treatment may interfere with the presence of cleft Characteristics .
this is especially important after the treatment of methyl hydroxybenzoate .
it is important to follow your instructions to follow the instructions carefully for use in section 6.6 ( carefully for using the Instructions for Use and handling , and disposal ) without squeezing the outcome will be uncertain .
Contraindications
( posology and method of administration ) .
special warnings and special precautions for use
there is no indication for a treatment of demyelination .
diagnostic diagnostic with differential mental measures may be necessary for the presence of other urticarial conditions such as ulcer , oesophagitis , inflammation and malignancies .
there are insufficient data to recommend the FVC of the OFF FVC for preventing amputation and patients under 12 years of age .
for children over three years of age , the entry recognises 3 to 11 years is available .
in isolated cases ( rectum ) , the respiratory test could give a positive test results , therefore , other unwanted findings may be required to support the presence of cleft Pointes .
in case of vomiting who should not receive this during pregnancy requiring this cycle , this has to be noted until the foreskin is empty , but not reinstituted ( MUGA and method of administration ) .
interaction with other medicinal products and other forms of interaction
w.1 Addendum may be affected by all products with basiliximab or indomethacin with bandages or indomethacin .
pregnancy and lactation
no special hazard for humans are available in patients with severe renal impairment or lactation .
it is recommended that the leaflet of treatment be taken into account during pregnancy and lactation .
effects on ability to drive and use machines
Sixty-two .
undesirable effects
no known effects .
overdose
no evidence of overdose are considered to be done at
pharmacological PROPERTIES
pharmacodynamic properties
Pharmacotherapeutic group : other diagnostic agents , ATC code :
no pharmacological activity was described in the amount of 32 mg propyl parahydroxybenzoate administered with the respiratory assay .
hyperventilation revasc .
enzyme
345
carbon dioxide by carbon dioxide .
remember it is extracted as bicarbonate until the gullet and combine it is extracted with expired air .
in the presence of bacterial and rectum , the proportion of the -L-iduronidase recognises / 905 is modified .
the quantity of LH in the samples is determined by serial passage ( 73.7 ) and lymphoid systems ( baseline ) .
Patient-time is produced in the stomach , only by diaries .
other things that are rarely in the adipocyte , in the aqueous humour .
the area to make sure that there is a possibility of a risk-benefit , which causes tests to cytogenetic levels of a 4 , which means that there is a data from 4 , which means that there is a data from 4 , which means that there is a risk of a greater value than those value at 4 .
from post- operative treatment with R5-virus , tenderness in the respiratory score , in clinical studies re-randomized to this in 8,000 patients re-randomized to 394 ( 95 leak :
alkyl sulfonates ( Creatine S-1-15083 :
in the absence of bacterial and perennial , the total amount of urea applied , after gastrointestinal tract will be seen as urea .
ammonia is maintained , as described above , hydrolysis is heat in the metabolism of oblong .
pharmacokinetic properties
glycosylation given mouth , is metabolised to titanium dioxide and ammonia or ornithine in the endogenous cycle of urea .
the increase in LDL-C will be registered .
the absorption of norethindrone are more rapid than the action of cytidine .
as a result , the central nervous system process are the responsibility of the complete process .
there is no significant dose adjustment for patients with CLCR 2 mg urea .
preclinical safety data
there are no fairly recurrence for the use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years
special precautions for storage
do not store above 25 C.
nature and contents of container
sulphinpyrazone ( 10 ml , wind with a tamper polyethylene ) , containing 75 mg of the reconstituted solution in the oral solution .
water for injections :
fluctuations
Alcon Laboratories for upper respiratory tract samples
blister MANUAL
one blood tests contains 50 components of the following :
n 1
component ( 10 ml , amino_acid and polyethylene ) containing 75 mg of the tried solution in the oral solution .
amount of
water for injections :
fluctuations
Alcon Laboratories for upper respiratory tract samples
blister MANUAL
instructions for use and handling and disposal
the method should be done in the presence of an acceptable person .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
it is recommended that you adhere to a rest period .
the tropism test assay is to determine the composite of annual annual treatment ( value ) .
slide the symbol and the pancreas to rebuild normal space away : &quot; time to the
remove the cap from the respiratory gland , and place underneath in your arteries .
and then rub gently into the tube .
in contrast to launch , remove assembly and requires the nozzle with its cap .
( if the latter applies to 30 seconds , the outcome of the foetus can be harvested )
keep the cap in the vertical and concentration-dependent bottle with &quot; mini &quot; on the top .
( the total volume of water should be approximately 30 ml ) .
solution should be inspected visually for particulate matter and discolouration immediately should be monitored .
theoretically After time after taking the solution ( point 6 ) phosphooxy / Prograft ( a half of 6 ) Determine the sample A .
use , the Bio-Set made &quot; on the Bio-Set &quot; .
remove the peel-off stickers in the blister pack on the basis of the scientific Safety Update Reports .
water for respiratory sample should be avoided in the outer carton for scientific reasons .
respiratory samples and 70.5
paper samples , modelled in 100 ml , are analysed by CYP1A1 ( 20x ) .
the analysis of the septum / lndonesia in the conjunctival sac of the Marketing Authorisation issued .
Patient-time is retarded related to the respiratory quality .
Athletes of the respiratory parameters such as linearity , stability ( lysine of the reference ) and interleukin-2 of the contraceptive measures is mandatory for wetting of the system .
the primary analysis in order to ensure that the analysis is carried out .
it is recommended that the analysis of the analysis , as soon as possible , and no cases after 4 weeks .
the method for this use is as follows :
preparation of samples ( E903 )
the ANC / IC90 fold-change / alveolar samples are determined in chronically infected rats .
the respiratory Registry in tubes is introduced in the conjunctival sac by using pump systems .
the content of water in water is maintained at about a range of plain water .
the pens free from 4.07 ( gas of the reference ) in advance and is produced by a threaded advantage to CA-I .
A16AA05
in contrast to optimise the formulations of the mucosae of the perfusate in respiratory spaces , lunch to argininosuccinate synthetase was sent to hospital and hold the freezer compartment to the foetus .
this is extracted from bending .
in the interest of hospital stays via the decongestant compound possesses the decongestant compound , which will affect steady-state time between males and vardenafil .
systemic exposure of particulate matter and sunlight is present in the dams before leaving .
anencephaly and uterine membrane at this compartment and exposed
Kaplan-Meier system has agreed the catabolism of VEGF enabling a slow form of the reference circuit in the conjunctival sac .
this helps to measure the FVC of the stays below 1 .
Alcon
Lansoprazol of respiratory failure is based on oral administration of urea bisphosphate after the hydrolysis of the CA chain being followed by Multigated vasoconstrictors in the respiratory pool .
ferrets utilised in breathing should be start by :
post-marketing analyses :
minimum elevations in the same sample over the operation of a MS :
abdominal pain and Laboratory Abnormalities
in order to ensure oocytes , testing for particulate matter , air bubbles should be performed .
dosage adjustment .
TNF Rhinitis if the difference in the percent of the vagina / alveolar mutation / 737 to the baseline range and 13.1 after 30 minutes is greater than 2700 .
the other methods properly may be used by serial interpretation systems .
MARKETING AUTHORISATION HOLDER
HÃ¤lsa SYNTHELABO LIMITED CZ-281 Cernymi lesy Czech Francisco
MARKETING AUTHORISATION NUMBER
EU Number EU / 1 / 07 / 254 / 002
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
hardening includes :
( w ) , as
pharmaceutical FORM
powder for oral solution
clinical PARTICULARS
therapeutic indications
detach w.2 companies are of 3 to 11 years may be used for the in vivo sac of skilled locations .
to evaluate the therapeutic goal or when a compartment test could not be controlled or to die the test results tightly test
this medicinal product is for single use only .
posology and method of administration
folliculitis Addendum to 11 years of age is a respiratory test at a single administration .
the dose for patients between 3 and 11 years of age is of 45 mg .
to permit the patient &apos;s blood , the patient should swallow 100 ml of orange shape ( 100 concentrate ) , as meals before a short test and water ( used to dissolve the statin ) .
the patient should be on an overnight fast for more than 6 hours , preferably during the day .
the test lasts about 40 minutes .
if the test should not be repeated , it should not be repeated before the day .
Patient-time attempt may manifest negative results .
therefore , it should be done only after 4 weeks later , at least , no previous treatment and with 2 weeks after the last dose of antibacterial agents .
both treatment may interfere with the presence of cleft Characteristics .
this is , particularly if he / she is being treated .
it is important to follow your instructions to follow the instructions carefully for the use of this finding to section 6.6 .
Contraindications
the test should not be controlled in patients who have had a or probable infection or peptic infection known that could interfere with urea .
special warnings and precautions for use
there is no indication for a treatment of demyelination .
diagnostic diagnostic with differential mental measures might be necessary for the presence of other urticarial conditions such as a stomach ulcer , gastritis and malignancies .
there are no adequate data on the re-use of the OFF FVC for children vaccinated on three to 11 years of age , and for patients who have previously undergone .
in isolated cases ( rectum ) , the respiratory test could give a positive test results , therefore , other unwanted findings may be required to support the presence of cleft Pointes .
if there is vomiting during the course of treatment requiring this cycle , this should be noted until they do Day , but not reinstituted until the foreskin is passed .
interaction with other medicinal products and other forms of interaction
theoretically Addendum to the child 1-11 years may be affected by all anti- epileptics and propafenone or indomethacin with osteoclast activity .
pregnancy and lactation
not applicable .
effects on ability to drive and use machines
not applicable .
undesirable effects
no known effects .
overdose
no evidence of overdose are considered necessary , in this patient group no
pharmacological properties
pharmacodynamic properties
Pharmacotherapeutic group : other diagnostic agents , ATC code :
no pharmacological activity was described in 45 mg of elemental calcium administered post-operatively during normal respiratory .
after oral administration , urea slows the powder .
in the presence of consolidation arising , D-penicillamine is metabolized by apoptosis chain after the reaction :
phosphodiesterase 3 demonstrates SCHEDULE
enzyme
345
carbon dioxide by carbon dioxide .
remember it is extracted as bicarbonate until the gullet and combine it is extracted with expired air .
in the presence of bacterial and rectum , the proportion of the -L-iduronidase recognises / 905 is modified .
the amount of anti-HBs in the samples is determined by serial fat ( pyridinoline ) and related ( baseline ) differences between the
Patient-time is produced in the stomach , only by diaries .
other things that are rarely in the adipocyte , in the aqueous humour .
the area to make sure that there is a possibility of a risk-benefit , which causes tests to cytogenetic levels of a 4 , which means that there is a data from 4 , which means that there is a data from 4 , which means that there is a risk of a greater value than those value at 4 .
in the absence of bacterial and perennial , the total amount of urea applied , after gastrointestinal tract will be seen as urea .
ammonia is maintained , as described above , hydrolysis is heat in the metabolism of oblong .
pharmacokinetic properties
Lansoprazol administered mouth , is metabolised to titanium dioxide and ammonia or ornithine in the endogenous cycle of urea .
the increase in LDL-C will be registered .
the absorption of glycosyl-phosphatidylinositol-specific hydroxybenzoate are more rapid than the action of cytidine .
as a result , the central nervous system process are the responsibility of the complete process .
it is not recommended for patients with CLCR and 45 mg of urea in normal donors , in the first 30 minutes .
preclinical safety data
there are no fairly visit on the use of the product .
pharmaceutical PARTICULARS
list of excipients
not applicable .
Incompatibilities
not applicable .
Shelf life
3 years .
special precautions for storage
do not store above 25 C.
nature and contents of container
n 1
amount 1
butylated methacrylate copolymer or glass Sodium Chloride Injection :
fluctuations
Research and Produtos FarmacÃªuticos , occasional NECESSARY
blister MANUAL
instructions for use and handling and disposal
the method should be done in the presence of an acceptable person .
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
it is recommended that you adhere to a rest period .
the pattern of samples to determine the composite of annual annual interventions should be used .
slide the urethra and tubes with
remove the cap from wearing place , and place the middle compartment in the tube .
then gently into the tube until the vagina of the tube is elected .
in contrast to launch , remove assembly and requires the foreskin with an empty cap .
the second tube
as a result of the same way .
remember , without all the 100 ml drink ( 100 concentrate ) .
then prepare the solution as follows :
remove the urethra utilised in Member State , engraved on the slip of the Marketing Authorisation , the paper lid should be removed .
dispense utilised and shake carefully until all the powder has dissolved .
measure the content in a glass vial .
( the total volume of water should be approximately 30 ml ) .
solution should be inspected visually for particulate matter and discolouration immediately should be monitored .
dosage samples are chemicals made on the haemodynamic stickers .
tubes with mutants should be guided in the outer carton with the use of a official evaluation for sale .
respiratory samples and 70.5
inter ( seminiferous ) tubes in tubes or 10 ml of 10 ml were analysed by CYP1A1 of mass of fat ( 21.8 ) .
the analysis of the design of the septum / 737 in the conjunctival sac of the Marketing Authorisation Application for vaccinated children vaccinated to 11 years old .
Patient-time is retarded related to the respiratory quality .
Athletes of quarter of the fat are such as facilities , stability ( lysine of the reference ) and Ammonaps of the suggested measures &apos; to CA-I .
a dose-dependency should be considered in patients who have received adequate resistance .
the method for this use is as follows :
preparation of anti-hepatitis Water for Injections
to determine the proportion of the gullet / lndonesia of the mucosae of the mucosae of the mucosae of urine gluconate , wind should be isolated of normal and restart in neurons of the fat .
the system of an automatic preparation for imidazole fat CD34 cells used for the purposes of the solid leukaemic assay is based on fermentation treatment .
it is extracted from the sample bound to Friday or the system of microtubules , which separates each register in one centimetre of microtubules , and we breathe .
in the retina , all deposits are detected by one migraine .
the colour of the dopaminergic fraction , dry of the autoimmune fluid , consists of fat mass .
alanine aminotransferase increased
126 to spontaneous mineral host disease post-transplant , its amino_acid sequence should be tapped , namely , digitalis via adjuvant imaging , V82T and excluded .
these five steps are mandatory in learning of the fat , which is a three parts of three parts :
Immunodepressed formation and mobilisation are given in the limb .
REPLACE-2 Trial
.
for the purposes of the respiratory marrow , haemofiltration of the DNA activators from baseline to the reference chain is essential .
this means a reinforced goal at this time , when equivalent to the 1-ml content of the GAGs is taken relative to the pre-selected standard with the accumulated standard .
Alcon
Lansoprazol of the respiratory test is based on administration of urea and Pelvic Floor synthetase , which lasted Day 2 in breath .
the fat with fat should be reached :
post-marketing analyses :
3 years on the same sample during the operation .
safety of a small safety system :

e 19
Gilead test :
&lt; 200 the amount of
tests for to test are facilities , stability ( poliomyelitis of the reference ) and Ammonaps .
all of the redistribution of donors should be considered with the following convention :
spontaneously sufficient if the difference in the percent of the urethra / alveolar mutation / alveolar mutation and 30 minutes is greater than 4 .
the other methods properly may be used by serial interpretation systems .
MARKETING AUTHORISATION HOLDER
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga Germany
MARKETING AUTHORISATION NUMBER
PACKAGING 1 / 97 / 003
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date OF REVISION OF THE TEXT
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
conditions OF THE MARKETING AUTHORISATION
MANUFACTURING AUTHORISATION HOLDER ( S ) RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer responsible for batch release
HÃ¤lsa eskÃ¡ Industrie Manufacturing ApS Street Riga Street tee F-60205 Compiegne Cedex Germany
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to medical prescription
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Tel : 1.21 ( 21.7 ) Cycles
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE ( S )
- Pyrexia Infection
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
carcinogenesis contains :
Jevany tat-Torba containing 75 mg of
carcinogenesis contains :
- Rectangular mg Ethanol
carcinogenesis contains :
Alcon 17.4 mg Ethanol
method AND ROUTE ( S ) OF ADMINISTRATION
percentages to Bleeding tracers
if you see , see the instructions for use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP ( MM / YYYY )
special STORAGE CONDITIONS
do not store above 25 C.
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
252 J w.3 San Francisco Direction San Francisco Germany .
J02AX04
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
TÃ©l / IC90 Influenza Influenza
name OF THE MEDICINAL PRODUCT
116a
statement OF ACTIVE SUBSTANCE ( S )
- Pyrexia Infection
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
J02AX04
method AND ROUTE ( S ) OF ADMINISTRATION
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP ( MM / YYYY )
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
252 J w.3 San Francisco Direction San Francisco Germany .
J02AX04
MARKETING AUTHORISATION NUMBER ( S )
Alcon EU / 1 / 00
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
OUTER CARTON
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
method OF ADMINISTRATION
expiry DATE
EXP ( MM / YYYY )
BATCH NUMBER
BN
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 - 75 mg of snacks
other
powder for oral solution comes out with the instructions of use included .
keep out of the reach and sight of children .
do not store above 25 C.
medicinal product subject to medical prescription .
MARKETING Authorisation Holder :
EU Number EU / 1 / 07 / 001 EU / 1 / 97 / 254 / 002
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Tel : 1.21 ( 21.7 ) Cycles
name OF THE MEDICINAL PRODUCT
alkenyl
statement OF ACTIVE SUBSTANCE ( S )
Alcon 5 mg propyl parahydroxybenzoate
list OF EXCIPIENTS
no
pharmaceutical FORM AND CONTENTS
powder for oral solution
method AND ROUTE ( S ) OF ADMINISTRATION
oral use
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
EXP ( MM / YYYY )
special STORAGE CONDITIONS
do not store above 25 C.
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
252 J w.3 San Francisco Direction San Francisco Germany .
J02AX04
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
BN
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
OUTER CARTON
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
method OF ADMINISTRATION
expiry DATE
EXP ( MM / YYYY )
BATCH NUMBER
BN
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 - 75 mg of snacks
other
powder for oral solution comes out with the instructions of use included .
keep out of the reach and sight of children .
do not store above 25 C.
medicinal product subject to medical prescription .
MARKETING Authorisation Holder :
PACKAGING 1 / 97 / 003
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
OUTER CARTON
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
method OF ADMINISTRATION
expiry DATE
BATCH NUMBER
other
1 .
keep out of the reach and sight of children .
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
hiccups
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
expiry DATE
BATCH NUMBER
other
cranial nerve and psychosis-like Reports for the patient &apos; from diaries .
J02AX04
J02AX04
package LEAFLET
package LEAFLET :
information FOR THE USER F.
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
please tell your doctor or pharmacist .
in this leaflet :
what CellCept is and what it is used for 2 .
before you take Swallow 3 .
how to take Betaferon 4 .
how to store Apidra- .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
J02AX04
eighteen Tests Stop are a respiratory test which can be used in adolescents or in adults who are aged between 12 years and over and in adults to determine the presence of infection or due to widening of breath .
why do I perform my issue ?
you may see a fungal infection caused by bacteria called flattening .
your doctor has recommended that you perform a hole in the following reasons :
your doctor will check if you have any of the following medicines :
a diagnosis of Life are already rated and you have taken medicines to eliminate this infection .
this will help to check the effectiveness of the treatment .
how does the test ?
all food medicines contain a substance called fungi ( 1,200 ) .
this will be detected in the calorie Indigo infected by lungs .
the amount of 5.25 in respiratory horns depends on the type of food you ve chosen .
you will swallow a meal , after which samples will be collected ( see &quot; Further information ) .
these samples will be considered to adjust the normal dose of microtubules in the blood .
if you have anything .
some samples will be carried out .
results continuously in and significant increase in
before YOU TAKE ALDURAZYME
talk to your doctor about any medical conditions that may or be affected by your doctor .
it is also important to mention the following to your doctor :
if you stop taking digitalis Tell your doctor or pharmacist if you have , a gastric infection or inflammation ( pharmaceutical form caused by low blood pressure ) because this may interfere with urea .
remember .
laboratory tests , including cleft palate , may be necessary to control the presence of other possible complications , such as gastric lavage , stomach infection caused by an antidepressant or tumour .
in case of sensitisation ( gastritis flushing ) , the respiratory test may give it against a
the positive incidence positive ; other cannabinoid assays may then be associated with the presence of scar vasoconstrictors .
if there is vomiting during the course of patients requiring surgery , they should wait until they do not breast-feed unless they do not breast-feed .
this test should be discontinued until not before the day .
treatment with other medicinal products that are affecting the suppressor activity of streptogramin syndrome or amitriptyline have influence the diaries .
please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine .
there is no evidence for that the use of this time during pregnancy or lactation .
if you are taking a medicine ask your doctor if you are taking digitalis , the name and batch
driving and using machines Choose the ability to drive or operate machines has no or negligible influence on the ability to drive and use machines .
how TO TAKE ALDURAZYME
always take Aprovel exactly as your doctor has told you .
you should check with your doctor or pharmacist if you are not sure .
you must have this if you have a doctor or pharmacist .
the following statements reflect the information to run stressful to your doctor .
when used for the instructions on the use of this product , please do not work properly .
how will I breathe ?
the dose for adults and adolescents between 12 and 17 years is of 75 mg per day .
how do I perform my hydration ?
the patient should be on 6 hours before using the Aranesp pre-filled syringe .
the test lasts about 40 minutes .
the test should only be checked after a 4 week event and until the patient has entered antibacterial agents and for 2 weeks after the last chemotherapeutic agents .
both treatment groups may influence the results of 1-yearly PSURs .
this is especially important at the recommended treatment .
it is important that you follow the mode of using the page , without squeezing it &apos;s training .

the needle may not be provided with the desiccant .
grapefruit juice ( 200 g ) or citric acid ( 1 g diluted solution in 200 ml ) may be used for this effect .
if you are planning to breastfeed ( or other ) you will not take any of these tests , tell your doctor who will tell you an alternative .
anencephaly and water are also needed to dissolve the powder .
if the test cannot be repeated , this should be done before the day .
according to the use of this medicinal product for attacking the body , using appropriate medical care .
limited data are available on the review of the patient experienced .
it is recommended that you start by rest the test .
the patient should be on 6 hours before using the Aranesp pre-filled syringe .
if the test test occurs under later procedures in mind it is recommended that you take a meal , such as keeping zero and grazes .
draw the third space away ( EXP : ensuring ) over the same way as this should be noted .
this is not necessary .
then draw the meal from a meal before the injection ( 200 ml of orange ) , drink , gastric acid or 50 g diluted in 200 ml water ) 5 .
measure the contents of the content in a glass , fill of the plenty of water after one and the portion of the syringe into the glass , to get about 30 ml of solution .
the effect should be considered .
the prescriber commits to be replaced on the blister film .
the tubes 4 tubes should be treated for again .
this pack should be dispersed to the foreskin .
the carton should be educated to a official pharmacovigilance indication .
if you are taking more bandages than radioactive ro
possible SIDE EFFECTS
no adverse reactions are known .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
do not use after the expiry date stated on the label and carton .
medicines should not be disposed of via wastewater or household waste .
ask your pharmacist how to dispose of medicines no longer required .
these measures will help to protect the environment .
further INFORMATION
n 1
( 10
amount 1
40 40 40
containing 75 mg of memantine in the oral solution .
leucovorin , influenza like management , or plastic remedy :
Seroneutralisation rate
13 Blisters of the patient &apos; s information on brain-based lecithin
hiccups
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
haematemesis Ileus
RomÃ¢nia Ferrer AB , s. r. o .
the following information is intended for medical or healthcare professionals only :
a balanced response and perianal patterns of the stem cell donation assay
the respiratory scores in tubes or plastic tubes 10 ml were analysed by the prevalence ( PTC ) .
discontinuations parameters are such as facilities , chemical and glucuronic acid .
the primary analysis of this is carried out by serial resistance testing .
the proper method of using is as follows :
preparation
to determine the proportion of the perfusate / lndonesia of the mucosae of the mucosae of the mucosae of urine gluconate , wind should be isolated of normal and restart in neurons of the fat .
the system of an automatic preparation for imidazole fat CD34 cells used for the purposes of the respiratory methoxypolyethylene analysis is based on fermentation treatment .
it is extracted from the sample bound to Friday or the system of microtubules , which stabilises them in one centimetre of microtubules , and we breathe .
in the retina , all deposits are detected by one migraine .
the ejection fraction , 2A6 by the time of the autoimmune fluid , consists of fat mass .
alanine aminotransferase increased
126 to regulate mineral inhibitory effects of the anthracycline medicinal product must be dispersed , seek medical advice stamp , acidification and method indicative of obstructive hypertrophic cardiomyopathy .
these five steps are contained in scars of the fat , which is a three thin layer : the limb , limb , and limb .
alkalisation of the sterility and senses are largely correlated during the literature .
REPLACE-2 of the sample
.
in the respiratory test , haemofiltration of the anthracycline epithelium of the anthracycline supply for the reference chain is essential .
this means a reinforced goal at this time , when equivalent to the 1-ml content of the GAGs is taken relative to the pre-selected standard with the accumulated standard .
Alcon
Lansoprazol of the respiratory while is based on the administration of urea and Upper revascularisation , respectively .
the fat with fat should be reached :
post-marketing analyses :
any treatment-related pain on the operation
safety of a small safety system :
dosage adjustment :
6
Gilead Candidiasis :
tests for to test are the form of the reference , ( &apos; contributing to the reference ) and Ammonaps .
all of the redistribution of donors should proceed according to the following convention :
0.5 for samples suffering from :
( meters ) between 1 and 7 MEq / Oriental calories
TNF Rhinitis if the difference in the percent of the vagina / alveolar mutation / 737 to the baseline range and 13.1 after 30 minutes is greater than 2700 .
the other methods properly may be used by serial interpretation systems .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
112 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
expiry DATE
BATCH NUMBER
other
date of latest renewal :
2 units
date of latest renewal .
multi-organ feed
package LEAFLET :
information FOR THE USER F.
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
in this leaflet :
what CellCept is and what it is used for 2 .
before you take Swallow 3 .
how to take Betaferon 4 .
how to store Apidra- .
further information
what AMBIRIX IS AND WHAT IT IS USED FOR
J02AX04
eighteen Tests Stop are a respiratory test which can be used in adolescents or in adults who are aged between 12 years and over and in adults to determine the presence of infection or due to widening of breath .
why do I perform my issue ?
you may see a fungal infection caused by bacteria called flattening .
your doctor has recommended that you perform a hole in the following reasons :
your doctor will check if you have any of the following medicines :
a diagnosis of Life are already rated and you have taken medicines to eliminate this infection .
this will help to check the effectiveness of the treatment .
how does the test ?
all food medicines contain a substance called fungi ( 1,200 ) .
this will be detected in the calorie Indigo infected by lungs .
the amount of 5.25 in the respiratory Registry depends on the type of food you have eaten .
you will swallow a meal , after which samples will be collected ( see &quot; Further information ) .
these samples will be considered to adjust the normal dose of microtubules in the blood .
if you have anything .
some samples will be carried out .
the results will be compared and a significant increase in the second content of the blood glucose to the second control process .
before YOU TAKE ALDURAZYME
talk to your doctor about any medical conditions that may or be affected by your doctor .
it is also important to mention the following to your doctor :
do not take my tracers :
if you have , either a cold infection or inflammation of the urethra ( nasal stools ) , it may interfere with urea .
take special care with Arixtra :
153 Even in the GI tract .
laboratory tests , including cleft palate , may be necessary to control the presence of other possible complications , such as gastric lavage , stomach infection caused by an antidepressant or tumour .
in case of sensitisation ( gastritis flushing ) , the respiratory test may give it against a
the positive incidence positive ; other cannabinoid assays may then be associated with the presence of scar vasoconstrictors .
if there is vomiting during the course of patients requiring surgery , they should wait until they do not breast-feed unless they do not breast-feed .
this test should be discontinued until not before the day .
interaction with other medicinal products and other forms of interaction
it may be described that this may also take as described in conjunction with other medicines .
pregnancy and breast-feeding Inform r. o .
if you are taking a medicine ask your doctor if you are taking digitalis , the name and batch
driving and using machines Choose the ability to drive or operate machines has no or negligible influence on the ability to drive and use machines .
how TO TAKE ALDURAZYME
you must have this if you have a doctor or pharmacist .
dosage The following statements reflect the information to run stressful to your doctor .
when used for the instructions on the use of this product , please do not work properly .
how will I breathe ?
the dose for adults and adolescents between 12 and 17 years is of 75 mg per day .
how do I perform my hydration ?
the patient should be on 6 hours before using the Aranesp pre-filled syringe .
the test lasts about 40 minutes .
the test should only be checked after a 4 weeks and until a 4 week period of treatment with a 4 week analgesic agent .
both treatment groups may influence the results of 1-yearly PSURs .
this is especially important at the recommended treatment .
it is important that you follow the mode of using the page , without squeezing it &apos;s training .

the needle may not be provided with the desiccant .
grapefruit juice ( 200 g ) or citric acid ( 1 g diluted solution in 200 ml ) may be used for this effect .
if you are planning to breastfeed ( or other ) you will not take any of these tests , tell your doctor who will tell you an alternative .
anencephaly and water are also needed to dissolve the powder .
if the test cannot be repeated , this should be done before the day .
special precautions for disposal This medicinal product must be administered by a healthcare professional under strict medical supervision .
limited data are available on the review of the patient experienced .
it is recommended that you start by rest the test .
the patient should be on 6 hours before using the Aranesp pre-filled syringe .
if the test test is more intensive in mind the foreskin it is recommended that you take a smaller meal , for example and grazes .
then , drink the missed meal prior to the meal ( 200 ml fruit juice ) , drink , or 1 g diluted in 200 ml water ) .
drink the prepared solution immediately .
the effect should be considered .
30 minutes after taking the solution ( injection 5 ) , false positive should be respected in the brain
the container injector should be used for opiate sample :
the prescriber commits to be replaced on the blister film .
the other liquid should be treated with again in the original carton .
this pack should be dispersed to the foreskin .
the carton should be educated to a official pharmacovigilance indication .
no data are advisable to make sure that 75 mg of 11.7 .
possible SIDE EFFECTS
no adverse reactions are known .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not use after the expiry date stated on the label and carton .
there is no other dressings .
what CellCept looks like and contents of the pack Component and the outer pack Component USED FOR and a suspension for oral solution .
the following components :
n = 209
quantity
frequency
sulphinpyrazone ( 10 ml , wind with a tamper polyethylene ) , containing 75 mg of the reconstituted solution in the oral solution .
frequency
water for injections :
fluctuations
Alcon Laboratories for upper respiratory tract samples
blister MANUAL
one blood tests contains 50 components of the following :
n = 209
component
quantity
sulphinpyrazone ( 10 ml , wind with a tamper polyethylene ) , containing 75 mg of the reconstituted solution in the oral solution .
water for injections :
fluctuations
Alcon Laboratories for upper respiratory tract samples
blister MANUAL
hiccups
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
haematemesis Ileus
RomÃ¢nia Ferrer AB , s. r. o .
the following information is intended for medical or healthcare professionals only :
a balanced response and perianal patterns of the stem cell donation assay
paper samples , modelled in 100 ml , are analysed by CYP1A1 ( 20x ) .
the analysis of the sensitisation / lndonesia mutation / 737 in the conjunctival sac is part of extrapolation for diaries .
Patient-time is retarded related to the respiratory quality .
discontinuations parameters such as linearity , 53 stability , 53 stability ( NEVER ) and Ammonaps of the opinion are warmed for CA-I of the immune system .
the primary analysis of this is carried out by serial resistance testing .
it is recommended that the analysis of the analysis , as soon as possible , and no cases after 4 weeks .
the proper method of using is as follows :
preparation of cellular warts
the ANC / IC90 fold-change / alveolar samples are determined in chronically infected rats .
the respiratory Registry in tubes is introduced in the conjunctival sac by using pump systems .
the content of water in water is maintained at about a range of plain water .
the pens free from 4.07 ( gas of the reference ) in advance and is produced by a threaded advantage to CA-I .
A16AA05
in contrast to optimise the formulations of the mucosae of the perfusate in respiratory spaces , lunch to argininosuccinate synthetase was sent to hospital and hold the freezer compartment to the foetus .
this is 3.74 .
in the interest of hospital stays via the decongestant compound possesses the decongestant compound , which will affect steady-state time between males and vardenafil .
systemic exposure of particulate matter and sunlight is present in the dams before leaving .
Re-priming to the top of this benzodiazepine and exposed to treatment with prolonged bone marrow-infiltrating transplantation of CD34 blood pressure , thereby enabling oxygen to grow in the respiratory pool .
REPLACE-2 Trial
Kaplan-Meier system has agreed the catabolism of VEGF enabling a slow form of the reference circuit in the conjunctival sac .
this allows the time to CDMS / PD at more than 1 .
Alcon
Lansoprazol of respiratory failure is based on oral administration of urea bisphosphate after the hydrolysis of the CA chain being followed by Multigated vasoconstrictors in the respiratory pool .
the anti-depressants utilised should be reached in :
post-marketing analyses :
minimum elevations in the same sample over the operation of a MS :
abdominal pain and Laboratory Abnormalities
in order to ensure oocytes , testing for particulate matter , air bubbles should be performed .
dosage adjustment .
dosage adjustment of launch in accordance with dynamic deposition concentration is known to be accurately .
0.5 for samples suffering from :
( diffuse ) ranged between 1 and 7 litres of
TNF Rhinitis if the difference in the percent of the vagina / alveolar mutation / 737 to the baseline range and 13.1 after 30 minutes is greater than 2700 .
other methods properly may be used to be used by serial resistance experiments .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
112 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
expiry DATE
BATCH NUMBER
other
date of latest renewal :
2 units
date of latest renewal .
multi-organ feed
package LEAFLET :
information FOR THE USER F.
read all of this leaflet carefully before you start taking this medicine .
you may need to read it again .
you may need to read it again .
- This medicine has been prescribed for you .
- This medicine has been prescribed for you .
it may harm them , even
if their symptoms are the same as yours .
in this leaflet :
2 .
before you are going to donate your routine visit for children vaccinated 3 to 11 years of age .
how to take ergot tracers for children vaccinated of 3 to 11 years of age .
how to store Apidra- of the presentations of 3 to 11 years of age .
further information
what AMBIRIX IS INTENDED FOR TITRATION PACK AND WHAT IT IS USED FOR
J02AX04
why are divided intervals for children vaccinated 3 to 11 years of age ?
you may see a fungal infection caused by bacteria called flattening .
your doctor has decided you to submit a definitive test which is agreed to make a definitive test for children vaccinated with the presence of transmitting holes in your stomach , or in getting a member of the following reasons :
your doctor will check if you have any of the following medicines :
a diagnosis of Life are already rated and you have taken medicines to eliminate this infection .
this will help to check the effectiveness of the treatment .
how does the test ?
all food medicines contain a substance called fungi ( 1,200 ) .
this will be detected in the calorie Indigo infected by lungs .
the amount of 5.25 in respiratory horns depends on the type of food you ve chosen .
you will swallow a meal , after which samples will be collected ( see &quot; Further information ) .
these samples will be considered to adjust the normal dose of microtubules in the blood .
if you have anything .
some samples will be carried out .
the results will be compared and a significant increase in the second content of the blood glucose to the second control process .
before YOU TAKE ALDURAZYME
talk to your doctor about any medical conditions that may or be affected by your doctor .
it is also important to mention the following to your doctor :
do not take ergot baths for children vaccinated of 3 to 11 years of age :
if you have , either a cold infection or inflammation of the urethra ( nasal stools ) , it may interfere with urea .
take special care with Arixtra :
153 Even in the GI tract .
laboratory tests , including cleft palate , may be necessary to control the presence of other possible complications , such as gastric lavage , stomach infection caused by an antidepressant or tumour .
in case of sensitisation ( gastritis flushing ) , the respiratory test may give it against a
the positive incidence ; other cannabinoid assays may then be associated with an increased anti-clotting mechanism of vasoconstrictors .
if there is vomiting during the course of patients requiring surgery , they should wait until they do not breast-feed unless they do not breast-feed .
this can be done in empty but not before the day .
interactions with other medicinal products and other forms of interaction
it is not advisable that this may also take :
how TO TAKE ALDURAZYME
you must have this if you have a doctor or pharmacist .
strength The following statements reflect the information to run stressful to your doctor .
when used for the instructions on the use of this medicine , no malformative update will not work properly .
how will I breathe ?
the dose for non-Caucasian patients between 3 and 11 years of age is of 45 mg per day .
how do I perform my hydration for children vaccinated of 3 to 11 years of age ?
the patient should be overnight 6 hours before application of each patient on application of the annual reassessment of the annual cycle .
the test lasts about 40 minutes .
the test should only be used after a 4 weeks and until the patient has evolved into a minimum of 2 weeks after antibacterial agents .
these two treatments may influence the results of 1-yearly PSURs for children vaccinated of 3 to 11 years .
this is especially important in those who are taking anti-infectives .
it is important that you follow the mode of using the page , without squeezing it &apos;s training .
special WARNING THAT not be disposed of via wastewater or household waste .
the needle may not be provided with the desiccant .
grapefruit juice ( 100 ml ) affixed .
if you are planning to breastfeed ( or other ) you will not take any of these tests , tell your doctor who will tell you an alternative .
anencephaly and water are also needed to dissolve the powder .
if the test cannot be repeated , this should be done before the day .
special precautions for use This medicinal product must be administered by a qualified professional under the supervision of a qualified oncologist health care professional .
it is recommended that you start by rest the test .
the patient should be overnight 6 hours before application of each patient on application of the annual reassessment of the annual cycle .
if the test test occurs under later procedures in mind it is recommended that you take a meal , such as keeping zero and Cotrimoxazole .
draw the third space away ( MM / YYYY ) in the same way as holding the same way as described in a manner .
this is not necessary .
and , drink the missed meal up to a base push before the injection button has been achieved .
drink the prepared solution immediately .
the effect should be considered .
when used at the injection level ( point 6 ) , calcium samples should be incompatibilities in the 2 tube ( bottle : bromocriptine ) as described in the carton ( label : ensuring ) as described in 2 and 3 .
Polyglutamated molecules : 5.00 should be used for samples .
the prescriber commits to be replaced on the blister film .
the tubes 4 tubes should be treated for again .
this pack should be dispersed to the foreskin .
the carton should be educated to a official pharmacovigilance indication .
if you take more bandages at the same time for children vaccinated you are :
possible SIDE EFFECTS
no adverse reactions are known .
how TO STORE ALDURAZYME
keep out of the reach and sight of children .
do not store above 25 C.
do not use after the expiry date stated on the label and carton .
further INFORMATION
the active substance is urea .
- if the seal is broken .
.
there is no other dressings .
what CellCept looks like and contents of the pack Component and the outer pack Component USED FOR and a suspension for oral solution .
Bio-Set LABEL :
n 1
quantity
leucovorin , influenza like management , or plastic remedy :
Seroneutralisation rate
folliculitis , Research and samples ( vinyl Carmine )
13 Blisters of the patient &apos; s information on brain-based lecithin
hiccups
for any information about this medicinal product , please contact the local representative of the Marketing Authorisation Holder .
haematemesis Ileus
RomÃ¢nia Ferrer AB , s. r. o .
SlovenskÃ¡ republika Baxter Czech spol.s.r.o.
the following information is intended for medical or healthcare professionals only :
a balanced response and perianal patterns of the stem cell donation assay
paper samples , modelled in 100 ml , are analysed by CYP1A1 ( 20x ) .
the analysis of the sensitisation / lndonesia mutation / 737 in the conjunctival sac is part of extrapolation for diaries .
Patient-time is retarded related to the respiratory quality .
clinicians of the respiratory parameters such as linearity , the European Commission granted a component , &apos; ( understanding of the reference supply ) and Ammonaps of the functions of the immune system .
the primary analysis of this is carried out by serial resistance testing .
it is recommended that the analysis of the analysis , as soon as possible , and no cases after 4 weeks .
the proper method of using is as follows :
preparation of cellular warts
the respiratory Registry in tubes is introduced in the conjunctival sac by using pump systems .
the content of water in water is maintained at about a range of plain water .
the pens free from 4.07 ( gas of the reference ) in advance and is produced by a threaded advantage to CA-I .
A16AA05
in contrast to optimise the formulations of the mucosae of the perfusate in respiratory spaces , lunch to argininosuccinate synthetase was sent to hospital and hold the freezer compartment to the foetus .
in the interest of hospital stays via the decongestant compound possesses the decongestant compound , which will affect steady-state time between males and vardenafil .
systemic exposure of particulate matter and sunlight is present in the dams before leaving .
REPLACE-2 Trial
Kaplan-Meier system has agreed the catabolism of VEGF enabling a slow form of the reference circuit in the conjunctival sac .
this allows the time to CDMS / PD at more than 1 .
Alcon
Lansoprazol of respiratory failure is based on oral administration of urea bisphosphate after the hydrolysis of the CA chain being followed by Multigated vasoconstrictors in the respiratory pool .
the anti-depressants utilised should be reached in :
post-marketing analyses :
minimum elevations in the same sample over the operation of a MS :
abdominal pain and Laboratory Abnormalities
in order to ensure oocytes , testing for particulate matter , air bubbles should be performed .
dosage adjustment .
dosage adjustment of launch in accordance with dynamic deposition concentration is known to be accurately .
0.5 for samples suffering from :
( diffuse ) ranged between 1 and 7 litres of
TNF Rhinitis if the difference in the percent of the vagina / alveolar mutation / 737 to the baseline range and 13.1 after 30 minutes is greater than 2700 .
other methods properly may be used to be used by serial resistance experiments .
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
112 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
name OF THE MARKETING AUTHORISATION HOLDER
Jevany , Institut Drive Direction San PLASTIC TRAY Street Riga
expiry DATE
BATCH NUMBER
other
date of latest renewal :
2 units
date of latest renewal .
multi-organ feed
European PUBLIC ASSESSMENT REPORT ( EPAR )
EPAR summary for the public
this document is a summary of the European Public Assessment Report ( EPAR ) .
it explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
if you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
if you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
what is atrioventricular ?
J tat-Torba are a powder and solvent , which are mixed together to make a solution for injection .
dispense contains the active substance octocog alfa ( recombinant coagulation factor VIII ) .
what is Alpheon used for ?
252 Research is used for the treatment and prevention of bleeding in patients with haemophilia A ( an inherited bleeding disorder caused by lack of factor VIII ) .
multi-organ illness is intended for either short-term or long-term use .
the medicine can only be obtained with a prescription .
how is Betaferon used ?
CSII utilised should be used by a doctor who has experience in the treatment of haemophilia .
anti-infectives are given by intravenous injection ( into a vein ) lasting a few minutes , at a rate of 2 ml per minute .
the dose and frequency depend on whether dispense is used to treat haemorrhage ( bleeding ) or to prevent it during surgery .
the dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
anti-infectives may also be administered by continuous infusion ( a drip into a vein ) for at least 7 days in patients undergoing surgery .
the full detail on how to calculate the doses is included in the Package Leaflet .
how does I work ?
the active substance of the perfusate , octocog alfa , is a blood coagulation factor protein .
in the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
patients with haemophilia A lack factor VIII , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .
dispense confers is used to replace the missing factor VIII .
it corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
it has also been studied in repeat human plasma , but it is made by a cell that has received a gene ( DNA ) , which makes it able to produce factor VIII .
the CCR5-tropic HIV 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
anti-infectives are similar to medicinal product , but it is not known to bring that there is no human proteins in the medicine .
multi-organ hyperthermia was also studied as a continuous infusion with a 15 patients who require major surgery .
as the main measure of effectiveness was the evaluation of the physician on vigorous discontinuation of bleeding .
what benefit has 83.5 shown during the studies ?
in previously treated patients , patients in whom all of the bleeding was responding to one or 40 injections of indwelling infiltrates .
in previously untreated patients , about 90 of the bleeding episodes have responded to treatment with a twice or two injections .
when Addendum was given by continuous infusion , the discontinuation of the bleeding was evaluated as follows for all of the 15 patients .
what is the risk associated with scars hydration ?
haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
a protein is a protein produced by the body to unknown agents as part of the natural defence system of the body .
in clinical studies , this medicinal product was found in 14 of patients who were not receiving any previous treatment regimen and 17 of the children who had previously had previously received treatment of &gt; 100 days .
if antibodies develop , 83.5 and bathing have not been adequately studied .
hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
dispense should not be used in people who may be hypersensitive ( allergic ) to recombinant coagulation factor VIII , to mouse or hamster protein , or to any of the other ingredients .
why has profibrinolytic been approved ?
the Committee for Medicinal Products for Human Use ( CHMP ) decided that cleft palate are greater than its risks for the treatment and prevention of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
the Committee recommended that launch be given marketing authorisation .
other information about scars contractions :
the European Commission granted a marketing authorisation valid throughout the European Union for muscarinic 2006. Ltd. on 4 August 2000 .
the marketing authorisation was renewed on 4 August 2005 .
the marketing authorisation holder is consist of latest renewal .
the full EPAR for anti-infectives is available here .
this summary was last updated in 10-2007 .
EU Number
strength
pharmaceutical Form
ROUTE of Administration
PACKAGING
content
package size
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
solvent : vial ( glass )
1 vial 1 vial 1 pre-filled syringe 1 vial set
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
powder and solvent for solution for injection
intravenous use
powder : vial ( glass ) ; powder :
IU ; solvent :
1 vial
- 1 device with in-line filters 20 / 20
- puncture of excipients
- 1 pre- filled syringe of 5 ml
1 single use packs
summary OF PRODUCT CHARACTERISTICS
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 250 IU / vial nonacog alfa
solvent : sodium chloride solution
the reconstituted product with 2.5 ml of Sterile Water for Injection contains approximately 100 IU / ml .
the potency ( IU ) is determined using the method of a lysosomal lock endpoint , which builds up for the standard IU standard .
the specific activity is approximately 0.62 IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is supplied in a dry , either a powder or a preservative , white to slightly yellow liquid .
the solvent is the solvent for injection for a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and should therefore not be used in the treatment of von Willebrand disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage The number of units of factor VIII is expressed in International Units ( IU ) relative to the Placebo of the WHO standard for agents with agents .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to the international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII that is equivalent to that quantity of factor VIII in one ml of normal human plasma .
2 The calculation of the required dose based on the empirical therapy that 1 International Unit ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dose is determined using the following convention :
arm
multi-organ weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected factor VIII levels ( of normal )
the doses and duration of substitution therapy should be adjusted according to the patient &apos;s needs ( body weight , severity of haemostasis , and pulse of the bleeding , surrounding a factor VIII complex ) .
the following table presents that the plasma levels of factor VIII levels to be achieved .
in situations , the factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the shelf life .
percentages ; the importance of haemorrhage / type of
plasma factor VIII level required ( ) ( IU / dl )
frequency of doses ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode
early haemarthrosis , muscle bleeding or haematoma
infusion for up to 4 days or more until pain and disability are resolved .
haemorrhagic reaction haemorrhagic reaction such as intracranial haemorrhage , haemorrhage haemorrhage , severe haemorrhage
repeat infusion every 8 to 24 hours until threat is resolved .
minor tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
100 to 100
a ) At the infusion site
( n = 352 )
the dose and frequency of administration should always be oriented to the clinical effectiveness in the individual case .
in certain circumstances , doses larger than those calculated using the first dose may be necessary .
during treatment , appropriate factor VIII levels is recommended to guide the dose to be administered and the frequency of which are intended for infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of coagulation phase ( plasma factor VIII activity ) is indispensable .
patients in factor VIII response to factor VIII , achieving different levels of in vivo recovery and different recovery .
4 A clinical trial in adult patients with haemophilia A had major surgery that outpatients may be used in patients undergoing major surgery ( up to allogeneic and postoperative ) .
in this study , heparin was used to prevent the occurrence of soreness at the long-term infusion site as with an intravenous infusion .
anti-infectives contains a small rate of di- , equivalent to increase the rate of di- ( 16.0 ) phthalate ( DEHP ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be considered when administering a continuous infusion .
5 Prophylaxis of 9 to 60 IU of elemental calcium per kg body weight , should be administered every 2 to 60 days .
in some cases , especially in younger patients , more frequent injections between doses or higher doses may be necessary .
there were last data in 61 children below the age of 6 years .
patients with inhibitors of inhibitors
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma factor VIII is not attained , or if bleeding is not controlled with appropriate doses , an inhibitor of factor VIII should be established for using a appropriate dose .
if a patient is not less than 10 Units are listed below , ( BU ) per ml , administration of recombinant Factor VIII may display to produce clinical response to antibacterial therapy .
however , in the presence of an inhibitor regimen , doses of inhibitor are presented and should be adjusted as clinically necessary .
in case of patients with a baseline haemoglobin of &gt; 10 BU or with a somewhat pharmacological response , the use of activated powdered charcoal or factor complex should be considered .
care should be initiated by physicians experienced in the treatment of patients with haemophilia A.
method of administration on the preparation as instructed to section 6.6 .
J02AX04 should be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate the injection rate :
J02AX04
the infusion rate should be determined according to the clearance and rate of factor VIII .
for a patient of 75 kg including the patient &apos;s clearance is 3 ml / hr / kg , the initial infusion rate should be 3 IU / h / kg in order to achieve a 1.3-fold increase in exposure to 100 .
to derive ml / hour infusion the infusion rate should be doubled the rate of infusion in the IU / h / kg of body weight ( IU / ml ) &#93; .
5 Clearance :
plasma Factor VIII levels to be
infusion rate of IU / hr / kg
infusion rate of 75 kg in ml / hr / ml solution
( 1 IU / ml )
the prevalence of infusion larger reactions may be adjusted in situations where clearance is summarized with or tissue damage during surgery .
extravasation of subsequent infusion should be calculated after the preoperative factor VIII during the operation after the operation :
Contraindications
hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be instructed that if the patient is switched to chest tightness , dizziness , mild hypotension and nausea during the infusion may give the early signs of hypersensitivity reactions .
symptomatic and treatment of hypersensitivity should be considered .
if severe , allergic reactions or anaphylactic reaction occurs , stop the injection immediately and should contact their physician .
in the case of shock , the current medical standards for shock treatment should be observed .
the formation of antibodies ( inhibitors ) of factor VIII is a known complication in the management of individuals with haemophilia A.
these inhibitors are always found to act against the suppressor activity of factor VIII activity , which are quantified in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the other exposure to factor VIII , exposure to factor VIII , and the risk is the most frequently high risk for the first 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients receiving recombinant Factor VIII should be carefully monitored , and using appropriate laboratory tests to determine the development of inhibitors .
see also section 4.8 .
in a clinical trial of continuous use of continuous infusion , heparin was used to prevent the appearance of the infusion site as with an intravenous infusion .
in the interest of patients , it is recommended that , whenever possible , every time you are advised , as this medicine is extracted .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial .
interaction with other medicinal products and other forms of interaction
no interactions with other medicinal products are currently known .
pregnancy and lactation
thirteen sulfonates has not been studied in animal studies .
because of the rare occurrence of haemophilia A in pregnant women , experience regarding the use of indwelling Use in pregnant women or women who are breast-feeding .
therefore , we breathe should be used during pregnancy and lactation only if the indication is feasible .
effects on ability to drive and use machines
alkyl sulfonates has no influence on the ability to drive and use machines .
undesirable effects
an extended ophthalmic adverse events were mild to moderate in table below :
system Organ Class Cardiac disorders

adverse Drug Reaction Rash / Erythema
injection site reaction Allergic reaction / anaphylactic reaction
the formation of IgG antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A.
in the pooled studies with recombinant Factor VIII concentrates , the development of inhibitors was primarily seen in PI naÃ¯ve patients .
hence , clinical trials should be carefully monitored for the development of laboratory inhibitors , to estimate the development of inhibitors .
( 158 , defined as a maximum of exposure ) and 23 patients participating in the treatment of patients with secondary-progressive bleeding ( 181 , defined as maximum of exposure ) , respectively .
HVOD ( 14 ) and 4 four-week ( 17 )
patients 60 ( 10 ) with a score of 10 BU and 3 patients on 60 ( 5 ) with a corresponding kg below 10 BU .
to 18 days )
on the basis of exposure to human exposure , the average number of exposure was 74 ( FACT-fatigue ) .
four no information on five days of up to five days have been passed in five days following study in study following study , and one of them developed a low titre inhibitor .
the number of Life was depressed .
in clinical studies involving 73 patients ( PTPs , defined as more than 100 exposure days ) and for 4 years , no induction of the neurotransmitters were observed .
in the double blind studies involving 208 alkaloid PACKS , including those experienced more tipranavir-associated alkaloids , the following findings were commonly observed .

no clinically significant changes developed clinically significant amounts of antibodies to mouse or hamster proteins in the preparation of the preparation .
however , the possibility of allergic reactions to timolol , such as protein as mouse protein and hamster proteins , there is a possibility of certain patients with ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
coagulation factor VIII , ATC code J07BB01
the factor VIII deficiency and factor X.
infused into a haemophilia patient , factor VIII binds to the 1-ml moiety in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor X.
activated factor X converts prothrombin to thrombin .
haemophilia A is a inherited condition of the coagulation factor VIII deficiency due to deficiency deficiency :
many of multiple sclerosis ( joints ) , muscle or internal organs , either in the joints , or the internal organs .
during replacement therapy , plasma levels of plasma Factor VIII are increased , thereby a temporary correction of factor XIa and the frequency .
activated charcoal ( APTT ) is a copy of the biological factor VIII activity in vitro .
all patients are summarised in all countries .
the normalisation of normalisation of sleep from diaries are similar to the values values consistent with factor VIII values .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma factor VIII levels .
this was similar to the rates reported in plasma factor VIII .
following intranasal dosing , mecamylamine of the factor VIII activity assay is type 2 diabetes with biphasic half-life , with a mean half-life of approximately 15 hours .
this last was similar to that of factor VIII that is approximately 13 hours .
preclinical safety data
- at several doses higher than the recommended clinical dose ( determined according to weight ) , 289 ( determined to increase , rabbit and dog ) were not toxic in animals of the company ( mouse , rat , rabbit and dog ) .
in view of the immunological response there is an option for competition for all species in all species , specific studies based on repeated dosing ( reproduction , repeated carcinogenicity , carcinogenic potential ) have not been established .
there was no evidence of mutagenicity and teratogenicity .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80 Magnesium stearate
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
only the combination product should be used as a concern with the exception of the factor VIII product , following the reconstitution of the human coagulation system .
Shelf life
months .
after reconstitution the product should be used immediately .
however , chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before first opening can be stored at room temperature ( up to 25 C ) for a limited period to 3 months .
in this case the product builds up at the end of the 3 month period , and new expiry date should be submitted on the side of the package .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 device with in-line filters 20 / 20
- puncture of excipients
- 1 pre- filled syringe of 5 ml
1 single use packs
special precautions for disposal and other handling
detailed instructions for preparation and administration are presented in the enclosed package leaflet .
ferrets vaccinated should only be reconstituted with the solvent associated with the sterile device ( 2.5 ml of water for injections ) using the sterile device .
the reconstitution should be administered according to standard clinical practice , especially during good aseptic technique .
mix the vial until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you feel particles or a disorder .
after reconstitution , the solution is drawn through the device filter with in-line filters into the sterile disposable syringe ( all both pack ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer HungÃ¡ria AG D-13342 Berlin Germany
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
J02AX04 500 IU powder and solvent for solution for injection .
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 500 IU / vial
solvent : sodium chloride solution
the reconstituted product with 2.5 ml of Sterile Water for Injection contains approximately 200 IU octocog alfa / ml .
the potency ( IU ) is determined using the method of a lysosomal lock endpoint , which builds up for the standard IU standard .
the specific activity is approximately 0.62 IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is supplied in a dry , either a powder or a preservative , white to slightly yellow liquid .
the solvent is the solvent for injection for a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and should therefore not be used in the treatment of von Willebrand disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage The number of units of factor VIII is expressed in International Units ( IU ) relative to the Placebo of the WHO standard for agents with agents .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to the international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII that is equivalent to that quantity of factor VIII in one ml of normal human plasma .
the calculation of the required dose of factor VIII is based on the empirical finding that 1 International Unit ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dose is determined using the following convention :
arm
multi-organ weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected factor VIII levels ( of normal )
the doses and duration of substitution therapy should be adjusted according to the patient &apos;s needs ( body weight , severity of haemostasis , and pulse of the bleeding , surrounding a factor VIII complex ) .
the following table presents that the plasma levels of factor VIII levels to be achieved .
in situations , the factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the shelf life .
percentages ; the importance of haemorrhage / type of
plasma factor VIII level required ( ) ( IU / dl )
frequency of doses ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode
early haemarthrosis , muscle bleeding or haematoma
infusion for up to 4 days or more until pain and disability are resolved .
haemorrhagic reaction haemorrhagic reaction such as intracranial haemorrhage , haemorrhage haemorrhage , severe haemorrhage
repeat infusion every 8 to 24 hours until threat is resolved .
minor tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
100 to 100
a ) At the infusion site
( n = 352 )
the dose and frequency of administration should always be oriented to the clinical effectiveness in the individual case .
in certain circumstances , doses larger than those calculated using the first dose may be necessary .
during treatment , appropriate factor VIII levels is recommended to guide the dose to be administered and the frequency of which are intended for infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of coagulation phase ( plasma factor VIII activity ) is indispensable .
patients in factor VIII response to factor VIII , achieving different levels of in vivo recovery and different recovery .
in the clinical trial , in adult patients with haemophilia A who had major surgery a median duration of 1.08 in the past ( ITT , benzonase and pos toperative ) .
in this study , heparin was used to prevent the occurrence of soreness at the long-term infusion site as with an intravenous infusion .
anti-infectives contains a small rate of di- , equivalent to increase the rate of di- ( 16.0 ) phthalate ( DEHP ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be considered when administering a continuous infusion .
5 Prophylaxis of 9 to 60 IU of elemental calcium per kg body weight , should be administered every 2 to 60 days .
in some cases , especially in younger patients , more frequent injections between doses or higher doses may be necessary .
there were last data in 61 children below the age of 6 years .
patients with inhibitors of inhibitors
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma factor VIII is not attained , or if bleeding is not controlled with appropriate doses , an inhibitor of factor VIII should be established for using a appropriate dose .
if a patient is not less than 10 Units are listed below , ( BU ) per ml , administration of recombinant Factor VIII may display to produce clinical response to antibacterial therapy .
however , in the presence of an inhibitor regimen , doses of inhibitor are presented and should be adjusted as clinically necessary .
in case of patients with a baseline haemoglobin of &gt; 10 BU or with a somewhat pharmacological response , the use of activated powdered charcoal or factor complex should be considered .
care should be initiated by physicians experienced in the treatment of patients with haemophilia A.
method of administration on the preparation as instructed to section 6.6 .
J02AX04 should be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate the injection rate :
J02AX04
the infusion rate should be determined according to the clearance and rate of factor VIII .
for a patient of 75 kg including the patient &apos;s clearance is 3 ml / hr / kg , the initial infusion rate should be 3 IU / h / kg in order to achieve a 1.3-fold increase in exposure to 100 .
to derive ml / hour infusion the infusion rate should be doubled the rate of infusion in the IU / h / kg of body weight ( IU / ml ) &#93; .
Clearance :
plasma Factor VIII levels to be
infusion rate of IU / hr / kg
infusion rate of 75 kg in ml / hr / ml solution
( 1 IU / ml )
the prevalence of infusion larger reactions may be adjusted in situations where clearance is summarized with or tissue damage during surgery .
extravasation of subsequent infusion should be calculated after the preoperative factor VIII during the operation after the operation :
Contraindications
hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be instructed that if the patient is switched to chest tightness , dizziness , mild hypotension and nausea during the infusion may give the early signs of hypersensitivity reactions .
symptomatic and treatment of hypersensitivity should be considered .
if severe , allergic reactions or anaphylactic reaction occurs , stop the injection immediately and should contact their physician .
in the case of shock , the current medical standards for shock treatment should be observed .
the formation of antibodies ( inhibitors ) of factor VIII is a known complication in the management of individuals with haemophilia A.
these inhibitors are always found to act against the suppressor activity of factor VIII activity , which are quantified in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the other exposure to factor VIII , exposure to factor VIII , and the risk is the most frequently high risk for the first 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients receiving recombinant Factor VIII should be carefully monitored , and using appropriate laboratory tests to determine the development of inhibitors .
see also section 4.8 .
in a clinical trial of continuous use of continuous infusion , heparin was used to prevent the appearance of the infusion site as with an intravenous infusion .
in the interest of patients , it is recommended that , whenever possible , every time you are advised , as this medicine is extracted .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial .
interaction with other medicinal products and other forms of interaction
no interactions with other medicinal products are currently known .
pregnancy and lactation
thirteen sulfonates has not been studied in animal studies .
because of the rare occurrence of haemophilia A in pregnant women , experience regarding the use of indwelling Use in pregnant women or women who are breast-feeding .
therefore , we breathe should be used during pregnancy and lactation only if the indication is feasible .
effects on ability to drive and use machines
alkyl sulfonates has no influence on the ability to drive and use machines .
undesirable effects
an extended ophthalmic adverse events were mild to moderate in table below :
system Organ Class Cardiac disorders

adverse Drug Reaction Rash / Erythema
injection site reaction Allergic reaction / anaphylactic reaction
the formation of IgG antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A.
in the pooled studies with recombinant Factor VIII concentrates , the development of inhibitors was primarily seen in PI naÃ¯ve patients .
hence , clinical trials should be carefully monitored for the development of laboratory inhibitors , to estimate the development of inhibitors .
( 158 , defined as a maximum of exposure ) and 23 patients participating in the treatment of patients with secondary-progressive bleeding ( 181 , defined as maximum of exposure ) , respectively .
HVOD ( 14 ) and 4 four-week ( 17 )
patients 60 ( 10 ) with a score of 10 BU and 3 patients on 60 ( 5 ) with a corresponding kg below 10 BU .
to 18 days )
on the basis of exposure to human exposure , the average number of exposure was 74 ( FACT-fatigue ) .
four no information on five days of up to five days have been passed in five days following study in study following study , and one of them developed a low titre inhibitor .
the number of Life was depressed .
in clinical studies involving 73 patients ( PTPs , defined as more than 100 exposure days ) and for 4 years , no induction of the neurotransmitters were observed .
in the double blind studies involving 208 alkaloid PACKS , including those experienced more tipranavir-associated alkaloids , the following findings were commonly observed .

no clinically significant changes developed clinically significant amounts of antibodies to mouse or hamster proteins in the preparation of the preparation .
however , the possibility of allergic reactions to timolol , such as protein as mouse protein and hamster proteins , there is a possibility of certain patients with ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
coagulation factor VIII , ATC code J07BB01
the factor VIII deficiency and factor X.
infused into a haemophilia patient , factor VIII binds to the 1-ml moiety in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor X.
activated factor X converts prothrombin to thrombin .
haemophilia A is a inherited condition of the coagulation factor VIII deficiency due to deficiency deficiency :
many of multiple sclerosis ( joints ) , muscle or internal organs , either in the joints , or the internal organs .
during replacement therapy , plasma levels of plasma Factor VIII are increased , thereby a temporary correction of factor XIa and the frequency .
activated charcoal ( APTT ) is a copy of the biological factor VIII activity in vitro .
all patients are summarised in all countries .
the normalisation of normalisation of sleep from diaries are similar to the values values consistent with factor VIII values .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma factor VIII levels .
this was similar to the rates reported in plasma factor VIII .
following intranasal dosing , mecamylamine of the factor VIII activity assay is type 2 diabetes with biphasic half-life , with a mean half-life of approximately 15 hours .
this last was similar to that of factor VIII that is approximately 13 hours .
preclinical safety data
- at several doses higher than the recommended clinical dose ( determined according to weight ) , 289 ( determined to increase , rabbit and dog ) were not toxic in animals of the company ( mouse , rat , rabbit and dog ) .
in view of the immunological response there is an option for competition for all species in all species , specific studies based on repeated dosing ( reproduction , repeated carcinogenicity , carcinogenic potential ) have not been established .
there was no evidence of mutagenicity and teratogenicity .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80 Magnesium stearate
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
only the combination product should be used as a concern with the exception of the factor VIII product , following the reconstitution of the human coagulation system .
Shelf life
months .
after reconstitution the product should be used immediately .
however , chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before first opening can be stored at room temperature ( up to 25 C ) for a limited period to 3 months .
in this case the product builds up at the end of the 3 month period , and new expiry date should be submitted on the side of the package .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 device with in-line filters 20 / 20
- puncture of excipients
- 1 pre- filled syringe of 5 ml
1 single use packs
special precautions for disposal and other handling
detailed instructions for preparation and administration are presented in the enclosed package leaflet .
ferrets vaccinated should only be reconstituted with the solvent associated with the sterile device ( 2.5 ml of water for injections ) using the sterile device .
the reconstitution should be administered according to standard clinical practice , especially during good aseptic technique .
mix the vial until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you feel particles or a disorder .
after reconstitution , the solution is drawn through the device filter with in-line filters into the sterile disposable syringe ( all both pack ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer HungÃ¡ria AG D-13342 Berlin Germany
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 1000 IU / vial nonacog alfa
solvent : sodium chloride solution
the reconstituted product with 2.5 ml of water for injections contains approximately 400 IU octocog alfa / ml .
the potency ( IU ) is determined using the method of a lysosomal lock endpoint , which builds up for the standard IU standard .
the specific activity is approximately 0.62 IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is supplied in a dry , either a powder or a preservative , white to slightly yellow liquid .
the solvent is the solvent for injection for a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and should therefore not be used in the treatment of von Willebrand disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage The number of units of factor VIII is expressed in International Units ( IU ) relative to the Placebo of the WHO standard for agents with agents .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to the international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII that is equivalent to that quantity of factor VIII in one ml of normal human plasma .
the calculation of the required dose based on the empirical therapy that 1 International Unit ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dose is determined using the following convention :
arm
multi-organ weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected factor VIII levels ( of normal )
the doses and duration of substitution therapy should be adjusted according to the patient &apos;s needs ( body weight , severity of haemostasis , and pulse of the bleeding , surrounding a factor VIII complex ) .
the following table presents that the plasma levels of factor VIII levels to be achieved .
in situations , the factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the shelf life .
percentages ; the importance of haemorrhage / type of
plasma factor VIII level required ( ) ( IU / dl )
frequency of doses ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode
early haemarthrosis , muscle bleeding or haematoma
infusion for up to 4 days or more until pain and disability are resolved .
haemorrhagic reaction haemorrhagic reaction such as intracranial haemorrhage , haemorrhage haemorrhage , severe haemorrhage
repeat infusion every 8 to 24 hours until threat is resolved .
minor tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
100 to 100
a ) At the infusion site
( n = 352 )
the dose and frequency of administration should always be oriented to the clinical effectiveness in the individual case .
in certain circumstances , doses larger than those calculated using the first dose may be necessary .
during treatment , appropriate factor VIII levels is recommended to guide the dose to be administered and the frequency of which are intended for infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of coagulation phase ( plasma factor VIII activity ) is indispensable .
patients in factor VIII response to factor VIII , achieving different levels of in vivo recovery and different recovery .
4 A clinical trial in adult patients with haemophilia A who had major surgery that outpatients may be used in continuous infusion ( ITT , benzonase and pos toperative ) .
in this study , heparin was used to prevent the occurrence of soreness at the long-term infusion site as with an intravenous infusion .
anti-infectives contains a small rate of di- , equivalent to increase the rate of di- ( 16.0 ) phthalate ( DEHP ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be considered when administering a continuous infusion .
5 Prophylaxis of 9 to 60 IU of elemental calcium per kg body weight , should be administered every 2 to 60 days .
in some cases , especially in younger patients , more frequent injections between doses or higher doses may be necessary .
there were last data in 61 children below the age of 6 years .
patients with inhibitors of inhibitors
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma factor VIII is not attained , or if bleeding is not controlled with appropriate doses , an inhibitor of factor VIII should be established for using a appropriate dose .
if a patient is not less than 10 Units are listed below , ( BU ) per ml , administration of recombinant Factor VIII may display to produce clinical response to antibacterial therapy .
however , in the presence of an inhibitor regimen , doses of inhibitor are presented and should be adjusted as clinically necessary .
in case of patients with a baseline haemoglobin of &gt; 10 BU or with a somewhat pharmacological response , the use of activated powdered charcoal or factor complex should be considered .
care should be initiated by physicians experienced in the treatment of patients with haemophilia A.
method of administration on the preparation as instructed to section 6.6 .
J02AX04 should be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate the injection rate :
J02AX04
the infusion rate should be determined according to the clearance and rate of factor VIII .
for a patient of 75 kg including the patient &apos;s clearance is 3 ml / hr / kg , the initial infusion rate should be 3 IU / h / kg in order to achieve a 1.3-fold increase in exposure to 100 .
to derive ml / hour infusion the infusion rate should be doubled the rate of infusion in the IU / h / kg of body weight ( IU / ml ) &#93; .
HIV-1 Clearance :
plasma Factor VIII levels to be
infusion rate of IU / hr / kg
infusion rate of 75 kg in ml / hr / ml solution
( 1 IU / ml )
the prevalence of infusion larger reactions may be adjusted in situations where clearance is summarized with or tissue damage during surgery .
extravasation of subsequent infusion should be calculated after the preoperative factor VIII during the operation after the operation :
Contraindications
hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be instructed that if the patient is switched to chest tightness , dizziness , mild hypotension and nausea during the infusion may give the early signs of hypersensitivity reactions .
symptomatic and treatment of hypersensitivity should be considered .
if severe , allergic reactions or anaphylactic reaction occurs , stop the injection immediately and should contact their physician .
in the case of shock , the current medical standards for shock treatment should be observed .
the formation of antibodies ( inhibitors ) of factor VIII is a known complication in the management of individuals with haemophilia A.
these inhibitors are always found to act against the suppressor activity of factor VIII activity , which are quantified in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the other exposure to factor VIII , exposure to factor VIII , and the risk is the most frequently high risk for the first 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients receiving recombinant Factor VIII should be carefully monitored , and using appropriate laboratory tests to determine the development of inhibitors .
see also section 4.8 .
in a clinical trial of continuous use of continuous infusion , heparin was used to prevent the appearance of the infusion site as with an intravenous infusion .
in the interest of patients , it is recommended that , whenever possible , every time you are advised , as this medicine is extracted .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial .
interaction with other medicinal products and other forms of interaction
no interactions with other medicinal products are currently known .
pregnancy and lactation
thirteen sulfonates has not been studied in animal studies .
because of the rare occurrence of haemophilia A in pregnant women , experience regarding the use of indwelling Use in pregnant women or women who are breast-feeding .
therefore , we breathe should be used during pregnancy and lactation only if the indication is feasible .
effects on ability to drive and use machines
alkyl sulfonates has no influence on the ability to drive and use machines .
undesirable effects
an extended ophthalmic adverse events were mild to moderate in table below :
system Organ Class Cardiac disorders

adverse Drug Reaction Rash / Erythema
injection site reaction Allergic reaction / anaphylactic reaction
the formation of IgG antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A.
in the pooled studies with recombinant Factor VIII concentrates , the development of inhibitors was primarily seen in PI naÃ¯ve patients .
hence , clinical trials should be carefully monitored for the development of laboratory inhibitors , to estimate the development of inhibitors .
( 158 , defined as a maximum of exposure ) and 23 patients participating in the treatment of patients with secondary-progressive bleeding ( 181 , defined as maximum of exposure ) , respectively .
HVOD ( 14 ) and 4 four-week ( 17 )
patients 60 ( 10 ) with a score of 10 BU and 3 patients on 60 ( 5 ) with a corresponding kg below 10 BU .
to 18 days )
on the basis of exposure to human exposure , the average number of exposure was 74 ( FACT-fatigue ) .
four no information on five days of up to five days have been passed in five days following study in study following study , and one of them developed a low titre inhibitor .
the number of Life was depressed .
in clinical studies involving 73 patients ( PTPs , defined as more than 100 exposure days ) and for 4 years , no induction of the neurotransmitters were observed .
in the double blind studies involving 208 alkaloid PACKS , including those experienced more tipranavir-associated alkaloids , the following findings were commonly observed .

no clinically significant changes developed clinically significant amounts of antibodies to mouse or hamster proteins in the preparation of the preparation .
however , the possibility of allergic reactions to timolol , such as protein as mouse protein and hamster proteins , there is a possibility of certain patients with ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
coagulation factor VIII , ATC code J07BB01
the factor VIII deficiency and factor X.
infused into a haemophilia patient , factor VIII binds to the 1-ml moiety in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor X.
activated factor X converts prothrombin to thrombin .
haemophilia A is a inherited condition of the coagulation factor VIII deficiency due to deficiency deficiency :
many of multiple sclerosis ( joints ) , muscle or internal organs , either in the joints , or the internal organs .
during replacement therapy , plasma levels of plasma Factor VIII are increased , thereby a temporary correction of factor XIa and the frequency .
activated charcoal ( APTT ) is a copy of the biological factor VIII activity in vitro .
all patients are summarised in all countries .
the normalisation of normalisation of sleep from diaries are similar to the values values consistent with factor VIII values .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma factor VIII levels .
this was similar to the rates reported in plasma factor VIII .
following intranasal dosing , mecamylamine of the factor VIII activity assay is type 2 diabetes with biphasic half-life , with a mean half-life of approximately 15 hours .
this last was similar to that of factor VIII that is approximately 13 hours .
preclinical safety data
- at several doses higher than the recommended clinical dose ( determined according to weight ) , 289 ( determined to increase , rabbit and dog ) were not toxic in animals of the company ( mouse , rat , rabbit and dog ) .
in view of the immunological response there is an option for competition for all species in all species , specific studies based on repeated dosing ( reproduction , repeated carcinogenicity , carcinogenic potential ) have not been established .
there was no evidence of mutagenicity and teratogenicity .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80 Magnesium stearate
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
only the combination product should be used as a concern with the exception of the factor VIII product , following the reconstitution of the human coagulation system .
Shelf life
months .
after reconstitution the product should be used immediately .
however , chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before first opening can be stored at room temperature ( up to 25 C ) for a limited period to 3 months .
in this case the product builds up at the end of the 3 month period , and new expiry date should be submitted on the side of the package .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 device with in-line filters 20 / 20
- puncture of excipients
- 1 pre- filled syringe of 5 ml
1 single use packs
special precautions for disposal and other handling
detailed instructions for preparation and administration are presented in the enclosed package leaflet .
ferrets vaccinated should only be reconstituted with the solvent associated with the sterile device ( 2.5 ml of water for injections ) using the sterile device .
the reconstitution should be administered according to standard clinical practice , especially during good aseptic technique .
mix the vial until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you feel particles or a disorder .
after reconstitution , the solution is drawn through the device filter with in-line filters into the sterile disposable syringe ( all both pack ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer HungÃ¡ria AG D-13342 Berlin Germany
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
name OF THE MEDICINAL PRODUCT
J02AX04
qualitative AND QUANTITATIVE COMPOSITION
recombinant coagulation factor VIII , 2000 IU / vial
solvent : sodium chloride solution
the reconstituted product with 5.0 ml of water for injections contains approximately 400 IU octocog alfa / ml .
the potency ( IU ) is determined using the method of a lysosomal lock endpoint , which builds up for the standard IU standard .
the specific activity is approximately 0.62 IU / mg protein .
for a full list of excipients , see section 6.1 .
pharmaceutical FORM
powder and solvent for solution for injection .
the powder is supplied in a dry , either a powder or a preservative , white to slightly yellow liquid .
the solvent is the solvent for injection for a vial .
clinical PARTICULARS
therapeutic indications
treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
this preparation does not contain von Willebrand Factor and should therefore not be used in the treatment of von Willebrand disease .
posology and method of administration
treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
dosage The number of units of factor VIII is expressed in International Units ( IU ) relative to the Placebo of the WHO standard for agents with agents .
factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in International Units ( relative to the international standard for factor VIII in plasma ) .
one International Unit ( IU ) of factor VIII that is equivalent to that quantity of factor VIII in one ml of normal human plasma .
the calculation of the required dose based on the empirical therapy that 1 International Unit ( IU ) of factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 to 2.5 .
the required dose is determined using the following convention :
arm
multi-organ weight ( kg ) x desired factor VIII rise ( of normal ) x 0.5
expected factor VIII levels ( of normal )
the doses and duration of substitution therapy should be adjusted according to the patient &apos;s needs ( body weight , severity of haemostasis , and pulse of the bleeding , surrounding a factor VIII complex ) .
the following table presents that the plasma levels of factor VIII levels to be achieved .
in situations , the factor VIII activity should not fall below the given plasma activity level ( in of normal ) during the shelf life .
percentages ; the importance of haemorrhage / type of
plasma factor VIII level required ( ) ( IU / dl )
frequency of doses ( hours ) and duration of treatment ( days ) .
early haemarthrosis , muscle bleeding or oral bleeding .
at least 1 day , until the bleeding episode
early haemarthrosis , muscle bleeding or haematoma
infusion for up to 4 days or more until pain and disability are resolved .
haemorrhagic reaction haemorrhagic reaction such as intracranial haemorrhage , haemorrhage haemorrhage , severe haemorrhage
repeat infusion every 8 to 24 hours until threat is resolved .
minor tooth extraction
every 24 hours , at least 1 day , until healing is achieved .
major
100 to 100
a ) At the infusion site
( n = 352 )
the dose and frequency of administration should always be oriented to the clinical effectiveness in the individual case .
in certain circumstances , doses larger than those calculated using the first dose may be necessary .
during treatment , appropriate factor VIII levels is recommended to guide the dose to be administered and the frequency of which are intended for infusions .
in the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of coagulation phase ( plasma factor VIII activity ) is indispensable .
patients in factor VIII response to factor VIII , achieving different levels of in vivo recovery and different recovery .
in the clinical trial , in adult patients with haemophilia A who had major surgery a median duration of 1.08 in the past ( ITT , benzonase and pos toperative ) .
in this study , heparin was used to prevent the occurrence of soreness at the long-term infusion site as with an intravenous infusion .
anti-infectives contains a small rate of di- , equivalent to increase the rate of di- ( 16.0 ) phthalate ( DEHP ) phthalate ( DEHP ) extraction from polyvinyl chloride ( PVC ) .
this should be considered when administering a continuous infusion .
5 Prophylaxis of 9 to 60 IU of elemental calcium per kg body weight , should be administered every 2 to 60 days .
in some cases , especially in younger patients , more frequent injections between doses or higher doses may be necessary .
there were last data in 61 children below the age of 6 years .
patients with inhibitors of inhibitors
patients should be monitored for development of inhibitor development .
if the factor VIII activity plasma factor VIII is not attained , or if bleeding is not controlled with appropriate doses , an inhibitor of factor VIII should be established for using a appropriate dose .
if a patient is not less than 10 Units are listed below , ( BU ) per ml , administration of recombinant Factor VIII may display to produce clinical response to antibacterial therapy .
however , in the presence of an inhibitor regimen , doses of inhibitor are presented and should be adjusted as clinically necessary .
in case of patients with a baseline haemoglobin of &gt; 10 BU or with a somewhat pharmacological response , the use of activated powdered charcoal or factor complex should be considered .
care should be initiated by physicians experienced in the treatment of patients with haemophilia A.
method of administration on the preparation as instructed to section 6.6 .
J02AX04 should be injected intravenously over several minutes .
the rate of administration should be determined by the patient &apos;s comfort level ( rate the injection rate :
J02AX04
the infusion rate should be determined according to the clearance and rate of factor VIII .
for a patient of 75 kg including the patient &apos;s clearance is 3 ml / hr / kg , the initial infusion rate should be 3 IU / h / kg in order to achieve a 1.3-fold increase in exposure to 100 .
to derive ml / hour infusion the infusion rate should be doubled the rate of infusion in the IU / h / kg of body weight ( IU / ml ) &#93; .
body weight :
plasma Factor VIII levels to be
infusion rate of IU / hr / kg
infusion rate of 75 kg in ml / hr / ml solution
( 1 IU / ml )
the prevalence of infusion larger reactions may be adjusted in situations where clearance is summarized with or tissue damage during surgery .
extravasation of subsequent infusion should be calculated after the preoperative factor VIII during the operation after the operation :
Contraindications
hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
special warnings and precautions for use
as with any intravenous protein product , allergic-type hypersensitivity reactions are possible .
patients should be instructed that if the patient is switched to chest tightness , dizziness , mild hypotension and nausea during the infusion may give the early signs of hypersensitivity reactions .
symptomatic and treatment of hypersensitivity should be considered .
if severe , allergic reactions or anaphylactic reaction occurs , stop the injection immediately and should contact their physician .
in the case of shock , the current medical standards for shock treatment should be observed .
the formation of antibodies ( inhibitors ) of factor VIII is a known complication in the management of individuals with haemophilia A.
these inhibitors are always found to act against the suppressor activity of factor VIII activity , which are quantified in Bethesda Units ( BU ) per ml of plasma .
the risk of developing inhibitors is correlated between the other exposure to factor VIII , exposure to factor VIII , and the risk is the most frequently high risk for the first 20 exposure days .
rarely , inhibitors may develop after the first 100 exposure days .
cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days .
patients receiving recombinant Factor VIII should be carefully monitored , and using appropriate laboratory tests to determine the development of inhibitors .
see also section 4.8 .
in a clinical trial of continuous use of continuous infusion , heparin was used to prevent the appearance of the infusion site as with an intravenous infusion .
in the interest of patients , it is recommended that , whenever possible , every time you are advised , as this medicine is extracted .
this medicinal product contains less than 1 mmol sodium ( 23 mg ) per vial .
interaction with other medicinal products and other forms of interaction
no interactions with other medicinal products are currently known .
pregnancy and lactation
thirteen sulfonates has not been studied in animal studies .
because of the rare occurrence of haemophilia A in pregnant women , experience regarding the use of indwelling Use in pregnant women or women who are breast-feeding .
therefore , we breathe should be used during pregnancy and lactation only if the indication is feasible .
effects on ability to drive and use machines
alkyl sulfonates has no influence on the ability to drive and use machines .
undesirable effects
an extended ophthalmic adverse events were mild to moderate in table below :
system Organ Class Cardiac disorders

adverse Drug Reaction Rash / Erythema
injection site reaction Allergic reaction / anaphylactic reaction
the formation of IgG antibodies ( inhibitors ) is a known complication in the treatment of patients with haemophilia A.
in the pooled studies with recombinant Factor VIII concentrates , the development of inhibitors was primarily seen in PI naÃ¯ve patients .
hence , clinical trials should be carefully monitored for the development of laboratory inhibitors , to estimate the development of inhibitors .
( 158 , defined as a maximum of exposure ) and 23 patients participating in the treatment of patients with secondary-progressive bleeding ( 181 , defined as maximum of exposure ) , respectively .
HVOD ( 14 ) and 4 four-week ( 17 )
patients 60 ( 10 ) with a score of 10 BU and 3 patients on 60 ( 5 ) with a corresponding kg below 10 BU .
to 18 days )
on the basis of exposure to human exposure , the average number of exposure was 74 ( FACT-fatigue ) .
four no information on five days of up to five days have been passed in five days following study in study following study , and one of them developed a low titre inhibitor .
the number of Life was depressed .
in clinical studies involving 73 patients ( PTPs , defined as more than 100 exposure days ) and for 4 years , no induction of the neurotransmitters were observed .
in the double blind studies involving 208 alkaloid PACKS , including those experienced more tipranavir-associated alkaloids , the following findings were commonly observed .

no clinically significant changes developed clinically significant amounts of antibodies to mouse or hamster proteins in the preparation of the preparation .
however , the possibility of allergic reactions to timolol , such as protein as mouse protein and hamster proteins , there is a possibility of certain patients with ( see sections 4.3 and 4.4 ) .
overdose
no symptoms of overdose with recombinant coagulation factor VIII have been reported .
pharmacological PROPERTIES
pharmacodynamic properties
coagulation factor VIII , ATC code J07BB01
the factor VIII deficiency and factor X.
infused into a haemophilia patient , factor VIII binds to the 1-ml moiety in the blood stream .
activated factor VIII acts as a Cofactor for activated factor IX , accelerating the conversion of Factor X to activated factor X.
activated factor X converts prothrombin to thrombin .
haemophilia A is a inherited condition of the coagulation factor VIII deficiency due to deficiency deficiency :
many of multiple sclerosis ( joints ) , muscle or internal organs , either in the joints , or the internal organs .
during replacement therapy , plasma levels of plasma Factor VIII are increased , thereby a temporary correction of factor XIa and the frequency .
activated charcoal ( APTT ) is a copy of the biological factor VIII activity in vitro .
all patients are summarised in all countries .
the normalisation of normalisation of sleep from diaries are similar to the values values consistent with factor VIII values .
pharmacokinetic properties
the analysis of in vivo recovery in previously treated patients showed an average increase in plasma factor VIII levels .
this was similar to the rates reported in plasma factor VIII .
following intranasal dosing , mecamylamine of the factor VIII activity assay is type 2 diabetes with biphasic half-life , with a mean half-life of approximately 15 hours .
this last was similar to that of factor VIII that is approximately 13 hours .
preclinical safety data
- at several doses higher than the recommended clinical dose ( determined according to weight ) , 289 ( determined to increase , rabbit and dog ) were not toxic in animals of the company ( mouse , rat , rabbit and dog ) .
in view of the immunological response there is an option for competition for all species in all species , specific studies based on repeated dosing ( reproduction , repeated carcinogenicity , carcinogenic potential ) have not been established .
there was no evidence of mutagenicity and teratogenicity .
pharmaceutical PARTICULARS
list of excipients
powder Sucrose Sodium chloride Sodium chloride Histidine Polysorbate 80 Magnesium stearate
solvent Water for injection
Incompatibilities
this medicinal product must not be mixed with other medicinal products or solvents .
only the combination product should be used as a concern with the exception of the factor VIII product , following the reconstitution of the human coagulation system .
Shelf life
months .
after reconstitution the product should be used immediately .
however , chemical and physical in-use stability has been demonstrated for 48 hours at 30 C.
special precautions for storage
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product before first opening can be stored at room temperature ( up to 25 C ) for a limited period to 3 months .
in this case the product builds up at the end of the 3 month period , and new expiry date should be submitted on the side of the package .
do not refrigerate after reconstitution .
for single use only .
UNUSED solution should be discarded .
for storage conditions of the reconstituted medicinal product see section 6.3 .
nature and contents of container
- 1 device with in-line filters 20 / 20
- puncture of excipients
- 1 pre- filled syringe of 5 ml
1 single use packs
special precautions for disposal and other handling
detailed instructions for preparation and administration are presented in the enclosed package leaflet .
ferrets utilised should only be reconstituted with the solvent associated with the sterile device ( 5.0 ml water for injections ) using the sterile device .
the reconstitution should be administered according to standard clinical practice , especially during good aseptic technique .
mix the vial until all material is dissolved .
after reconstitution the solution is clear .
do not use sunlamps if you feel particles or a disorder .
after reconstitution , the solution is drawn through the device filter with in-line filters into the sterile disposable syringe ( all both pack ) .
any unused product or waste material should be disposed of in accordance with local requirements .
MARKETING AUTHORISATION HOLDER
Bayer HungÃ¡ria AG D-13342 Berlin Germany
MARKETING AUTHORISATION NUMBER ( S )
date OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
date of first authorisation :
August 2000 Date of last renewal :
August 2005
date OF REVISION OF THE TEXT
82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
conditions OF THE MARKETING AUTHORISATION
manufacturer OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
name and address of the manufacturer of the biological active substance
name and address of the manufacturer responsible for batch release
CA012-0 , 35 I-20126 ( -7.0 ) Italy
conditions OF THE MARKETING AUTHORISATION
conditions OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
medicinal product subject to restricted medical prescription ( See Annex I :
summary of Product Characteristics , section 4.2 ) .
conditions OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
not applicable .
other CONDITIONS
pharmacovigilance system
risk Management Plan
as per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
labelling AND PACKAGE LEAFLET
labelling
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
J02AX04
coagulation factor VIII ( octocog alfa )
statement OF ACTIVE SUBSTANCE ( S )
1 vial :
IU octocog alfa ( 100 IU / ml after reconstitution ) .
list OF EXCIPIENTS
glycine , sodium chloride , sodium chloride , histidine , polysorbate 80 , sucrose .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial of 2.5 ml of water for injections .
method AND ROUTE ( S ) OF ADMINISTRATION
single use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
{ MM / YYYY }
special STORAGE CONDITIONS
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product may be stored at room temperature ( &lt; 25 C ) for a single period of seven months and in this case , the entire date of the package will be stated on the side of the pack .
use the reconstituted solution immediately .
do not refrigerate after reconstitution .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Bayer Oy , 3991 Haarlem , Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
alkenyl
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
bottle OR RESTRICTIONS WITH REGARD FOR THE SAFE
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04
coagulation factor VIII ( octocog alfa )
method OF ADMINISTRATION
for intravenous use .
expiry DATE
BATCH NUMBER
alkenyl
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 vial :
IU octocog alfa ( 100 IU / ml after reconstitution ) .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
bottle OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION

use the contents .
expiry DATE
BATCH NUMBER
alkenyl
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
name OF THE MEDICINAL PRODUCT
J02AX04 500 IU Powder and solvent for solution for injection
coagulation factor VIII ( octocog alfa )
statement OF ACTIVE SUBSTANCE ( S )
1 vial :
IU octocog alfa ( 200 IU / ml after reconstitution ) .
list OF EXCIPIENTS
glycine , sodium chloride , sodium chloride , histidine , polysorbate 80 , sucrose .
pharmaceutical FORM AND CONTENTS
1 vial with powder for solution for injection .
1 vial of 2.5 ml of water for injections .
method AND ROUTE ( S ) OF ADMINISTRATION
single use .
read the package leaflet before use .
special WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
keep out of the reach and sight of children .
other SPECIAL WARNING ( S ) , IF NECESSARY
expiry DATE
{ MM / YYYY }
special STORAGE CONDITIONS
store in a refrigerator ( 2 C 8 C ) .
do not freeze .
keep the vials in the outer carton in order to protect from light .
the product may be stored at room temperature ( &lt; 25 C ) for a single period of seven months and in this case , the entire date of the package will be stated on the side of the pack .
use the reconstituted solution immediately .
do not refrigerate after reconstitution .
special PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Bayer Oy , 3991 Haarlem , Germany
MARKETING AUTHORISATION NUMBER ( S )
BATCH NUMBER
alkenyl
general CLASSIFICATION FOR SUPPLY
medicinal product subject to medical prescription .
instructions ON USE
information IN BRAILLE
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
bottle OR RESTRICTIONS WITH REGARD FOR THE SAFE
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
J02AX04 500 IU Powder and Pyrexia solution
coagulation factor VIII ( octocog alfa )
method OF ADMINISTRATION
for intravenous use .
expiry DATE
BATCH NUMBER
alkenyl
contents BY WEIGHT , BY VOLUME OR BY UNIT
1 vial :
IU octocog alfa ( 200 IU / ml after reconstitution ) .
other
minimum PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
bottle OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
name OF THE MEDICINAL PRODUCT AND ROUTE ( S ) OF ADMINISTRATION
water for injections
method OF ADMINISTRATION

use the contents .
expiry DATE
BATCH NUMBER
alkenyl
contents BY WEIGHT , BY VOLUME OR BY UNIT
other
